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Abstract 
Genetic and functional studies of osteoarthritis susceptibility at COL11A1 and GDF5 
Osteoarthritis (OA) is the most common musculoskeletal disease and is characterised by joint 
pain and dysfunction resulting from the progressive focal loss of the articular cartilage of the 
joint.  It is a multifactorial disease arising from the interplay between genetic and 
environmental risk factors, with a continuous distribution between the two extremes of 
predominantly genetic and predominantly environmental.  Whilst several environmental risk 
factors for the disease are known, including body mass index (BMI), injury and occupation, 
known genetic risk factors are less well understood.  Two major strategies have been 
employed in order to identify genetic factors conferring OA susceptibility: the investigation of 
candidate genes, which are principally chosen on the basis that the proteins that they code for 
are known to have a role in joint formation and maintenance, and genome wide association 
scans (GWASs), which search agnostically for disease associated polymorphic DNA variants.  
Within this thesis I report research on two genes highlighted using both strategies, although 
each is a compelling candidate. I report on the investigation of the functional effects of 
common polymorphism within COL11A1, which harbours a single nucleotide polymorphism 
(SNP) that showed evidence of association to OA via the arcOGEN GWAS. I also report on the 
search for and analysis of rare variants of GDF5, a gene previously discovered as harbouring 
OA susceptibility by candidate gene studies.  I tested for an allelic expression imbalance (AEI) 
of COL11A1 using RNA from patient cartilage but I did not detect a correlation between 
genotype at the GWAS OA associated SNP rs2615977 and the expression of the gene.  I did 
however discover that genotype at a second polymorphism within COL11A1, rs1676486, did 
correlate with COL11A1 AEI.  rs1676486 has previously been reported to be associated with 
lumbar disc herniation. However, my analysis of the arcOGEN dataset revealed that this SNP is 
not associated with OA.  To identify rare variants in GDF5 that could impact upon OA 
susceptibility I sequenced the protein coding region of the gene, its untranslated regions, 
exon-intron boundaries and its proximal promoter in 962 OA cases and controls.  Six novel and 
very rare variants with minor allele frequencies (MAFs) of ≤0.0006 were discovered and I 
confirmed the existence of known variants with common MAFs.  The absence of variants with 
intermediate MAFs implies that the gene may have been subjected to a genetic bottleneck.  
One rare variant, within the proximal promoter of GDF5, was carried forward for functional 
analysis using luciferase reporter assays.  I discovered that the novel A-allele of this variant 
increased the expression of the reporter plasmid relative to its common C-allele. I also 
demonstrated that this A-allele is able to counteract the reduced gene expression mediated by 
the T allele of the previously reported OA associated GDF5 SNP rs143383. I subsequently 
performed electrophoretic mobility shift assays (EMSAs) and identified the transcriptional 
activator/repressor YY1 as the trans-acting factor binding differentially to the alleles of the 
variant.  Overall, this thesis demonstrates that the OA association to COL11A1 identified by 
GWAS is not caused by AEI of that gene within the articular cartilage of OA patients, and that 
the deep sequencing of current OA susceptibility loci to identify novel risk alleles is also a 
means to identify mechanisms to counteract the effects of susceptibility alleles that are 
already known. 
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Chapter 1: Introduction 
1.1 Osteoarthritis 
Osteoarthritis (OA) is the most common musculoskeletal disease, affecting a large 
proportion of people above the age of 65, regardless of ethnicity, sex or geographic location 
(1, 2).  Buckwalter 2004 (2) claim that in some populations more than 75% and as high as 90% 
of over 65s have OA in one or more of their joints.  The economic cost of OA has been difficult 
to attribute, as traditionally OA has been grouped with other joint diseases or even with all 
musculoskeletal diseases as a whole.  The economic burden of OA to the United States has 
been estimated at $60 billion per year and in terms of working disability was second only to 
ischemic heart disease in men over the age 50 years (2).  In the United States a total of half a 
million joint replacements occur per year, and it has been estimated that every 90 seconds a 
joint is replaced in Europe as a consequence of OA (1).  With the incidence of the disease 
predicted to double by 2020 the economic and social burden of OA will continue to escalate. 
OA has commonly been considered a disease of the articular cartilage, a smooth 
frictionless material that covers the ends of bones in synovial joints.  It has however been 
suggested that OA in actual fact is a disease of the entire synovial joint organ, affecting 
synovium, menisci, ligaments and subchondral bone (3, 4).  Characterised by joint pain and 
dysfunction, due to the progressive loss of articular cartilage, the joint undergoes remodelling 
by attempting to repair the cartilage, forming new bone in the joint margins (osteophytes), 
and the thickening of the subchondral bone (sclerosis) (Figure 1.1) (3).  It can affect any 
synovial joint; however it is common in the hand, foot, spine, and especially the knee and hip 
joints.  Primary OA rarely manifests in the ankle, wrist, elbow or shoulder, whereas these joints 
are common sites for secondary - or post-traumatic - OA.  Age is the most predominant risk 
factor of OA although genetic predisposition, obesity, female gender, increased bone density 
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and joint laxity are all recognised factors (2), racial and ethnic differences also exist with a 
higher incidence of knee OA in black and Chinese people (5).  As yet there is no cure for OA, 
with only analgesics or anti-inflammatory drugs available to palliate until disease progression 
necessitates a joint replacement (1).  One method of assessing OA progression is 
radiographically, with a classification scale known as the Kellgren-Lawrence grading system (6).  
As only bone shows up on an x-ray, the area of the joint between the bones, where the 
articular cartilage lies, shows up as a space.  As cartilage is lost the bones share an increased 
proximity and so a reduction in this joint space implies a reduction in articular cartilage.  The 
Kellgren-Lawrence grading system has four grades ranging from Grade I: unlikely joint space 
narrowing and possible osteophytes; Grade II: possible joint space narrowing and small 
osteophytes; Grade III: definite joint space narrowing, mild sclerosis (hardening of the bones), 
possible deformation of the end of the bones, and multiple osteophytes; Grade IV: severe joint 
space narrowing, sclerosis and deformation of the end of the bones, and multiple large 
osteophytes. 
 
Figure 1.1 Diagram depicting the structure of the knee and the changes which occur in an 
osteoarthritic joint.  Figure taken from Osteoarthritis, Hunter & Felson, 2006. Reference (3) 
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1.2 The synovial joint 
 A joint is the connection of two structural skeletal elements, and most of the joints in 
the body are synovial joints.  Unlike fibrous or cartilaginous joints, synovial joints are made up 
of a collection of varied tissue types which include, or may include depending upon the site of 
the joint; articular cartilage, subchondral bone, ligament, tendon, synovium, synovial fluid, 
synovial membrane, fat pad and menisci all housed within a fibrous capsule (7).  It is this 
intricate multi-tissue makeup that has led to the concept of the synovial joint being regarded 
as an organ, with disease affecting one tissue perpetuating into downstream effects upon 
other tissues within the joint organ (7). 
Articular cartilage is a milky white, shiny, specialised material that acts as a smooth, 
slick, firm surface which allows low friction articulation of a joint and also cushions mechanical 
forces exerting between bones under load (1, 8–10).  The thickness, cell density and matrix 
composition varies both within a joint and between joints but the overall task carried out 
remains constant, and at only a few millimetres thick at most, its ability to resist compression 
and distribute loading is a property that is ubiquitously devoid in any synthetic material (10).  
Cartilage is almost unique in the fact that it is maintained by only a single cell type – the 
chondrocyte – a highly differentiated and solitary cell (2).  The chondrocyte surrounds itself 
with an extracellular matrix (ECM) and forms no cell-to-cell contacts, the cartilage is avascular 
and aneural and as a result chondrocytes depend largely on anaerobic metabolism (7, 10).  
Nutrients required by the chondrocytes for their matrix production and maintenance must 
diffuse through the synovial tissue and synovial fluid as well as through the ECM, restricting 
the size and charge of materials available to the chondrocyte.  Although being the sole cell 
type found within cartilage, the chondrocyte contributes an almost negligible volume to the 
tissue, only approximately 1 per cent (10). 
 The ECM is made up of a highly ordered framework of macromolecules and water 
which provide cartilage with its aforementioned properties.  The macromolecules of the ECM 
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can be placed into two groups; collagenous and non-collagenous (9).  The main collagenous 
component is type II collagen, with types VI, IX, X and XI also being present in lower abundance 
(9, 10).  These collagens form a structured meshwork which gives the tissue cohesiveness and 
allows the entrapment of proteoglycans, the non-collagenous components of the ECM.  
Proteoglycans are a protein core with one or more glycosaminoglycan chains (long unbranched 
polysaccharides consisting of repeating disaccharides that contain an amino sugar) (10).  The 
disaccharides contain negatively charged sulphate groups, resulting in long chains with 
negative charge and thus repelling any like charged molecules while attracting positively 
charged molecules.  The proteoglycans are classified as large aggregating proteoglycan 
monomers, and small proteoglycans (10).  Aggrecan molecules fill most of the space between 
the collagen networks, accounting for 90% of the proteoglycan mass.  When a joint is under 
load, water is expelled from the cartilage as it is compressed.  It is the hydrophilic properties of 
aggrecan monomers which draw water back into the matrix allowing cartilage to recover its 
shape and function (11).   
 The cartilage itself comprises of four layers, or zones: superficial, middle, deep and 
calcified (11) (Figure 1.2).  The superficial zone, which is closest to the joint space, has the 
chondrocytes orientated with the collagen fibrils.  Moving down into the middle zone, the 
chondrocytes become larger, rounder and like the fibrils more distributed throughout the 
ECM.  The deep zone houses chondrocytes arranged in columns perpendicular to the surface, 
mirroring the collagen fibrils which extend down through the tide line – which separates the 
deep and calcified zones – into the calcified zone where they aid the anchoring of the cartilage 
to the subchondral bone (8, 11).   
The synovial capsule, in tandem with ligaments, set the parameters of flexibility of the 
joint and ensure mechanical stability (12).  The synovial membrane is made up of synoviocytes, 
which play a critical role in nourishing the chondrocytes.  They also remove degraded ECM 
material from the synovial space (12).  Synoviocytes are responsible for maintaining 
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homeostasis within the joint by producing hyaluronic acid and lubricin, which acts as a 
lubricant between opposing cartilage surfaces (12, 13).  The synovial fluid is the predominant 
medium through which nutrients, metabolites and oxygen diffuse from the synoviocytes to the 
chondrocytes embedded within the articular cartilage.  
 
 
Figure 1.2 Schematic diagram depicting the four zones of articular cartilage.  Percentage 
values show how much each zone contributes to the overall thickness of articular cartilage.  
Thin fibres represent the orientation of the collagen fibrils through the zones and small dots 
represent the distribution of chondrocytes.  Image adapted from Orthoteers.org (14). 
 
1.3 Bone growth 
Other than the skull, endochondral ossification occurs in all parts of the skeleton, 
where cartilage is replaced by bone.  This cartilaginous skeleton is formed during development 
when embryonic mesenchymal cells condense and differentiate into chondrocytes which go on 
to produce and secrete the components of the ECM (15).  These chondrocytes proliferate and 
go on to expand the cartilaginous skeleton.  An interzone forms as mesenchymal cells 
condense to form chondrocytes and it is this interzone which dictates the location of the joint 
space (16).  Growth/differentiation factor 5 (GDF5) is believed to be expressed firstly 
throughout the mesenchymal condensations, stimulating chondrogenic differentiation and 
Superficial (10-20%) 
Middle (40-60%) 
Deep (30%) 
Calcified 
Tide mark 
Articular surface 
Zone
Subchondral 
bone 
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then later in development its expression becomes limited to the interzone, where it can 
promote apoptosis, segmentation of skeletal precursors, articular cartilage differentiation and 
tendon and ligament development (17).  Loss of GDF5 function in mice results in a broader 
expansion of the interzone and its markers, but also of Gdf5 expression itself, indicating that 
Gdf5 regulates its own expression.  The interzones’ normal expansion can be partially restored 
by the addition of exogenous GDF5 (17). 
Following the formation of the interzone, a process of cavitation and morphogenesis 
takes place where the opposing limb ends form interlocking structures (18).  Following this, 
endochondral ossification occurs whereby chondrocytes firstly proliferate, secreting ECM 
around themselves.  They then undergo hypertrophy, growing in size, arranged in columns that 
run parallel to the length of the limb, while down regulating the synthesis of type II collagen 
and initiating the expression of non-fibrillar type X collagen, a specific marker of hypertrophic 
chondrocytes.  They also express matrix metalloproteinase 13, a collagenase capable of 
degrading type II collagen within the ECM.  During late hypertrophy, the chondrocytes deposit 
vesicles into the matrix containing mainly calcium and phosphate allowing for mineralisation to 
occur.  Finally ossification occurs by the vascular invasion of osteoblasts and osteoclasts.  The 
ossification process occurs during development in the primary centre of ossification in the limb 
but also in the secondary centre of ossification, with the growth plate sandwiched between 
the two centres.  Ossification at the growth plate continues to occur during adolescence 
allowing for further bone growth, it is here that all stages of endochondral ossification can be 
seen at once (Figure 1.3) (15). 
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Figure 1.3 The tibial growth plate from a three week old mouse.  All stages of endochondral 
ossification can be seen here as chondrocytes proliferate and then become hypertrophic 
before undergoing cell death and ossification.  Figure adapted from Mackie et al., 2011, 
reference (15). 
 
1.4 Osteoarthritis pathobiology 
 Osteoarthritis arises from the destruction and failure of the articular cartilage 
extracellular matrix.  An imbalance between applied mechanical stress, such as loading, and 
both the physical and chemical ability of the articular cartilage to resist this stress is generally 
the cause of primary OA, especially in the large load bearing joints (12).  The disease is 
however not restricted to articular cartilage and should be considered as both a failure and a 
disease of the whole joint organ, not just the articular cartilage.  All connective tissues, 
associated muscle groups and the nerve network along with the central nervous system may 
all have a role in the disease (4).  With the primary symptom of OA being pain, the central 
nervous system is a key component, and indeed a therapeutic target and the characterisation 
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of the joint as an organ is significant not only for physiology but also for joint pathology (12).  A 
study looking into pain thresholds and inflammatory responses found that, in a small cohort of 
26 OA patients and 33 age- and sex-matched controls, OA patients have a lower threshold to 
experimental pressure stimuli, and that as a result of this pain they have increased 
inflammatory responses to these stimuli (19).  While the investigators commented on the large 
intra-individual variation within their small test groups, they concentrated on this as an 
inability to identify biomarkers but failed to touch on the fact that not only is there variation of 
pain thresholds between OA patients and healthy controls but there is a large variation 
between OA patients themselves.  The investigators recorded a standard deviation of 43% in 
the pain threshold of leg pressure of their OA patients, but failed to highlight this (19). 
 As mentioned earlier, the synovial capsule, notably the synovial membrane, is a key 
structure in the homeostasis of the articular cartilage and of the joint as a whole.  Taking this 
into account, it is understandable that this tissue can play a crucial role in disease progression, 
if not inception.  The joint capsule, in tandem with the ligaments dictates the mechanical 
stability and flexibility of the joint.  A feature of the disease in many late stage OA patients is 
reduced joint flexibility and therefore patient mobility.  After pain, joint stiffening is the biggest 
concern for OA sufferers and capsular fibrosis is a major cause of this (12).  Significant synovial 
pathology is associated with all cases of OA, both early and advanced (20, 21).  This supports a 
possible link between the synovial reaction and the clinical symptoms of OA.  However, 
whether these alterations are involved in disease initiation or merely progression is unknown, 
but an effect on the latter is accepted.  The turnover of normal articular cartilage matrix 
produces molecular “detritus” and for example under wear and tear of a joint fragments of 
cartilage and bone may be sheared off and end up in the synovial membrane, when these 
“detritus” levels exceed physiological levels, the synoviocytes undergo activation and 
proliferation with a subsequent synovial hyperplasia in order to clear the synovial fluid of these 
fragments.  An increase in the number of type A synoviocytes, which like macrophages are 
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phagocytic, occurs in the synovial lining.  This reaction is described as the initial event in 
osteoarthritic synoviopathy (12). 
 The subchondral bone is also important in the pathology of OA, although whether 
changes (such as sclerosis) to the tissue occur before changes to the articular cartilage or after 
the biomechanical attributes of cartilage have diminished is unclear (22).  The formation of 
osteophytes – or osteochondrophytes – at the joint space margins is a clear indicator of OA.  
However there are contradictory opinions as to whether osteophytes are adaptive to cartilage 
degradation, by redistributing mechanical stresses away from damaged cartilage, or involved 
in cartilage destruction with some studies suggesting osteophyte formation positively 
correlates with cartilage destruction (1).  At present there is no evidence that the removal of 
osteophytes slows or accelerates OA disease progression and pain (1).  
 Cartilage changes from its smooth, firm, milky white and glassy appearance to a soft, 
brown or yellowish appearance in OA, with a rough surface in early disease progression.  
Fibrillation and matrix loss occur in late stages until eventually the cartilage is worn through to 
the subchondral bone (12).  The uncovering of the bone is due to a partnership of enzymatic 
degradation and mechanical wear of the cartilage.  This causes the destruction of the collagen 
network and the depletion of the proteoglycan components of the matrix.  Aggrecan loss, and 
its negative charge with it, is a distinctive marker of early stage cartilage degradation.  
However, collagen levels, which provide the rigidity of the matrix, remain constant until late 
disease stages (23).  Even though the collagen levels remain relatively constant, it is the 
loosening of the network which is the hallmark of cartilage failure.  This sparks a chicken and 
egg scenario; does the loss of proteoglycan or the loosening of the collagen network 
contribute to cartilage degradation?  Either way a vicious cycle ensues with each criteria 
affecting the other.  The most marked degradation occurs in the superficial zone and proximal 
to the chondrocytes, where there are enhanced levels of metalloproteinases responsible for 
matrix degradation.  The chondrocytes undergo cell death or proliferate to compensate for 
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those which have undergone apoptosis.  Their phenotype changes drastically as the gene 
expression profile alters from that of healthy cartilage (12).  The osteoarthritic chondrocyte 
population become vastly heterogeneous and zonal population changes arise.  Osteoarthritic 
chondrocytes mimic those of foetal cartilage whereby type II collagen is up-regulated in 
relation to aggrecan expression, in order to manufacture new matrix (24).  This is in stark 
contrast to normal mature cartilage where chondrocytes maintain a homeostasis by preserving 
matrix composition, primarily with regards to proteoglycan turnover and not type II collagen 
turnover (12).   However, even in some late stage osteoarthritic cartilage, some chondrocytes 
remain anabolically active and still transcribe aggrecan and type II collagen mRNA (25), which 
supports the idea that chondrocytes in osteoarthritic cartilage are heterogeneous and that OA 
affects distinct populations or zones of chondrocytes rather than the global articular cartilage 
population.  In early stage OA, key phenotypic changes occur in the superficial zone.  
Chondrocytes express genes which do not fit into the expression profile of normal 
chondrocytes.  They express enzymes, cytokines and growth factors all involved in the 
degradation of the ECM.  This may be due to epigenetic changes such as the demethylation of 
metalloproteinase genes (26).  This phenotypic alteration propagates from the superficial zone 
down through the mid and deep zones, as more and more chondrocytes become degenerative 
(12).  The ability to therapeutically halt such propagation would certainly been welcomed. 
 A classic feature of cell senescence, and the aging process, is that of the shortening of 
the telomeres, which has been exhibited in chondrocytes (27).  However, due to the 
chondrocytes low replication rate it is unlikely that the cause of this telomere shortening is due 
to any form of replicative senescence (28).  Instead telomere shortening in chondrocytes is 
more likely due to stress-induced senescence caused by oxidative damage and inflammation 
(29, 30).  Cell senescence is not just the halting of cell replication but can also result in the 
alteration of gene expression and cellular phenotype.  This phenotype is known as the 
senescent secretory phenotype (31) and is characterised by the increases in cytokines such as 
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IL-1, Matrix Metalloproteinases (MMPs) and growth factors.  The expression of MMPs along 
with cytokines such as IL-1 is elevated in OA cartilage and this senescent secretory phenotype 
may link the ageing process directly with the onset and progression of OA (28). 
 Another age related change within cartilage is the accumulation of reactive oxygen 
species (ROS) such as super oxide and hydrogen peroxide which are normally controlled by 
anti-oxidants (32, 33).  Evidence shows that levels of these anti-oxidants are lower in aged 
cartilage (34) and that of OA cartilage (35).  The depletion of one anti-oxidant in particular – 
superoxide dismutase 2 – has been shown to lead to oxidative damage and mitochondrial 
dysfunction (36).  This will have a negative effect on normal cell function and this oxidative 
stress as a result of aging can further push chondrocytes into a senescent phenotype and 
prompt the progression of OA (37). 
1.5 The role of genetics in osteoarthritis 
1.5.1 Epidemiological studies/Twin studies 
 Osteoarthritis is as multifactorial disease manifesting from the interplay of both 
genetic and environmental components, with a continuous distribution between the two 
extremes of predominantly genetic and predominantly environmental (38).  The participation 
of genetic factors was first observed by Stecher & Hersh in the 1940s where they studied 
almost 70,000 adults and the heritability of hand OA (39).  They observed a two to threefold 
increased risk of OA in the mothers and sisters of cases with hand OA.  This study lay the 
foundations for expanded studies which began to suggest a multifactorial pattern of 
inheritance rather than a single gene defect with Mendelian inheritance (11).  However this 
familial clustering with suggestion of genetic determinants had its detractors.  An argument 
could be levelled that these families not only shared genetic material but also shared 
environments, implying that genetic factors had little or no role (11, 38).   
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A way of circumventing these criticisms is twin studies, where measures of the 
concordance of disease in monozygotic (MZ) and dizygotic (DZ) twins allows the separation of 
genetic factors and shared environmental factors (40).  This also removed the potential 
confounder of age, which is the predominant risk factor for OA.  Twin studies allow for 
quantification of genetic and environmental contributions due to MZ twins sharing the entirety 
of their genomes, such that any differences in disease concordance between them is 
environmental in origin.  DZ twins however share half their genomes, on average, with each 
other and for that reason differences in disease concordance between these twins is the result 
of an interaction between both genetic and environmental factors (40).  Tim Spector along 
with a number of colleagues has over the last 15 years looked into the heritability of OA at 
various sites through disease concordance in female MZ and DZ twins.  Firstly, they assessed 
hand and knee OA both radiographically and clinical knee pain.  They found that both in terms 
of a radiographic diagnosis and as a presence of joint pain that incidence was higher in MZ 
twins than in DZ twins.  They estimated that the genetic factors accounting for radiographic OA 
of the hand and knee in women is between 39% and 65% (41).   
In the year 2000, Spector and colleagues focused on joint space narrowing in hip OA 
using twin studies and found that the heritability was approximately 60% at this site (42).  They 
also used twins to examine the genetic contribution to both cervical and lumbar spine disc 
degradation using magnetic resonance imaging.  They found that the heritability of spinal disc 
degeneration was 73% at the cervical curve and 74% at the lumbar curve (43).  Taken together 
these findings suggest that genetic factors account for approximately half of the variation in 
the heritability of OA, but individually they suggest that OA may not be a generalised disease 
affecting all joints in exactly the same manner.  A study testing whether shared genetic 
influences were affecting hand, knee and hip OA in MZ and DZ twins, again involving Tim 
Spector, was performed in 2009.  They looked at, and compared, three sites within the hand 
(the distal interphalangeal joint, the proximal interphalangeal joint and the carpometacarpal 
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joints) along with the hip and the knee and found that the only genetic overlap present within 
OA was in the joints of the hand, predominantly in the two interphalangeal joint sites they 
tested (44).  The investigators were unable to find evidence of a ‘generalised OA’ phenotype 
where common genetic factors were attributing to OA at multiple sites, and hypothesised that 
this could predominantly be due to differences in joint morphology.  They detected an overlap 
within the joints of the hand, which due to their close proximity share similar mechanical 
stresses and traumas, with the greatest overlap being recorded between the distal and 
proximal interphalangeal joints which share the greatest morphology amongst of all the joints 
they tested.  The large joints – the knee and hip joints – although they are subjected to similar 
stresses and loads, deal with these in differing ways as one is a hinge joint (although there is 
some lateral rotation during flexion) and the other is a ball joint. 
Classification of OA in genetic studies is a cause for debate, with many investigators 
classifying OA by radiographic changes, which have been shown to have weak association with 
progressive symptomatic OA (38).  Other studies have defined the phenotype as progressive 
OA requiring a total hip/knee replacement (THR/TKR) (38).  However, this classification also 
stimulates debate as it selects for individuals with late stage disease who were willing to 
undergo major surgery to alleviate their pain and their mobility issues, and these factors may 
depend a great deal on varied pain thresholds as well as on varied confidence in medical 
procedures (45).  In 2011, Kerkhof et al. attempted to redress the variation in definition of the 
OA phenotype by proposing a standardisation and a clear definition of what criteria were used 
when patients were recruited (46).  For example, they suggest that instead of stating “patients 
had OA with a Kellgren/Lawrence scale of ≥2” the exact physical condition of the joint should 
be reported such as “at least two moderate definite osteophytes and possible joint space 
narrowing at the tibio-femeral joint”. 
 Despite the problems in defining the phenotypes of OA as well as the initiating and 
progressive molecular elements, there have been numerous successes in identifying 
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susceptibility loci involved in OA by using candidate-gene studies, genome-wide linkage scans, 
and genome-wide association studies (9, 11, 47, 48). 
1.5.2 The candidate gene approach  
Candidate-gene studies in OA initially stemmed from a hypothesis-driven investigation 
of genes known to be mutated in rare diseases in which secondary OA forms a phenotypic 
component of a single gene defect disease, such as an osteochondrodysplasia (40).  These 
rare, monogenic disorders, with high penetrance and autosomal dominance, highlighted genes 
that may also be involved in OA, with the assumption being that common DNA variants in the 
gene rather than highly penetrant rare mutations predispose an individual to primary OA (49, 
50).  Genes investigated included COL2A1, COL1A1, COL9A1, COL11A2, CMP (cartilage matrix 
protein), VDR (vitamin D receptor), ERS1 (estrogen receptor α), IGF-1 (insulin-like growth 
factor 1), ACAN (aggrecan) and TGFB1 (transforming growth factor-β 1) (50).  Candidates were 
tested by association analysis with most results being negative or inconclusive due to the small 
cohort sizes used, with any compelling results suggesting that only a small proportion of OA 
heritability could be attributed to polymorphism at these genes (49). 
A Japanese group chose to test as a candidate gene ASPN for association to OA on the 
basis that its encoded protein can bind transforming growth factor β (TGF-β), blocking the 
growth factor’s interaction with its receptor and modulating TGF-β induced chondrogenesis 
(51).  ASPN was shown to be abundant in the articular cartilage of OA patients but was not 
abundant in unaffected individuals.  They found a triplet repeat coding for a stretch of aspartic 
acid (D) residues in ASPN asporin to be associated with OA.  The group found 10 alleles for this 
D-repeat, ranging from 10-19 aspartic acid residues.  They found the D14 allele was associated 
with both hip- and knee-OA.  Additionally, they identified that the D13 allele, coding for one 
less aspartic acid residue than the OA associated D14 allele, was elevated in their control 
group, suggesting that not only had they found an OA-susceptibility allele but also an OA-
protective allele.  They demonstrated that asporin is able to inhibit TGF-β signalling which then 
16 
 
reduces the expression of type II collagen and aggrecan encoding genes, both of which are the 
fundamental macromolecules of cartilage ECM.  When interrogating the functionality of the 
aspartic acid repeat alleles they noted that the OA-associated D14 allele was the strongest 
inhibitor of TGF-β signalling of all the D-repeat alleles and significantly less than the D13 
encoded asporin (51).   
Their data suggests that both a susceptibility allele and a protective allele exist 
amongst many neutral alleles all at the same locus.  Those carrying the D14 OA associated 
allele produce less type II collagen and aggrecan than those carrying the neutral D-alleles, 
possibly allowing for a looser collagen network which permits the progression of OA, and those 
carrying the D13 allele produce more type II collagen and aggrecan presumably creating 
articular cartilage with a greater structural integrity. 
Another candidate gene in which a reproducible association was found was GDF5, 
which codes for growth/differentiation factor 5 (52).  GDF5, is a member of the transforming 
growth factor-β (TGF-β) superfamily of secreted proteins, and due to its pivotal role in joint 
formation, rare mutations in GDF5 cause several skeletal dysplasias, including type C 
brachydactyly and angel-shaped phalangoepiphyseal dysplasia (52).  The OA association was to 
the T-allele of a SNP, rs143383, found in the 5ʹ UTR of GDF5.  Miyamoto and colleagues 
demonstrated that this T-allele correlates with a reduction in GDF5 expression relative to that 
of the C-allele.  These findings in an Asian population were replicated in a Caucasian 
population by Southam and colleagues (53).  Further functional studies were performed which 
indicated that rs143383 was in of itself the functional cause of the association (54).  Further 
association studies have demonstrated that the OA association to the T-allele of rs143383 is 
one of the most robust associations to OA across multiple populations (55–57). 
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1.5.3 Linkage analysis 
There has been some great success stories in the candidate gene approach to OA 
susceptibility, such as with ASPN and GDF5, as well as complex diseases as a whole, but there 
is no doubt that the number of candidate gene investigations that returned a result of no 
association far, far outweigh the success stories.  The selection of candidates is hampered by 
our incomplete understanding of the OA disease process, which potentially leaves many 
causative factors over-looked (11).  Genome-wide linkage scans aim to scrutinize the genome 
agnostically, with no prior bias to current understanding.  They aim to highlight areas of the 
genome that co-segregate with the disease phenotype, in closely related individuals.  These 
studies are also hampered by the late onset of OA, which makes it difficult to include the 
parents of affected individuals in the linkage studies (58).  To compensate for the difficulties in 
recruiting the parents of affected individuals, linkage analysis is often carried out with affected 
sibling pairs (ASPs), using microsatellites or variable number tandem repeat (VNTRs) 
polymorphisms as genetic markers. 
A genome-wide linkage scan in the UK that defined the OA phenotype as that which 
required a total joint replacement at the hip or knee, studied families with at least one ASP 
(59).  This study was enhanced by stratification of the ASPs by sex and by joint and more 
susceptibility loci were identified, one region (2q23-2q32), once further investigated through 
analysis of genes within the interval demonstrated association to females with hip OA to a 
functional non-synonymous SNP within the FRZB gene (60).  FRZB encodes for secreted 
frizzled-related protein 3 (sFRP3) which acts as an antagonist to the Wnt signalling pathway 
demonstrating a role in both chondrogenesis and osteogenesis (61).  Wnt activity allows for β-
catenin to initiate transcription, Loughlin and colleagues suggested that non-synonymous 
mutation within sFRP3 reduces its ability to antagonise Wnt, therefore reducing the efficacy of 
the Wnt signalling pathway (60).  The subsequent aberrant gene expression could lead to 
structurally compromised articular cartilage laid down during development that manifests as 
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hip OA when mechanically challenged during adult life of females. (60).  Another study 
demonstrated that the FRZB non-synonymous mutation was associated to hip OA and also in 
knee OA (62).  However, when FRZB was assessed for an allelic expression imbalance (AEI) less 
than a quarter of individuals tested exhibited an imbalance in allelic output (63).  Of these 
individuals tested, the fold difference between allelic expressions was an average of 1.19 
suggesting that cis-acting regulatory elements within FRZB were not influencing the 
development of OA.  When a large scale meta-analysis was performed the association to the 
two polymorphisms within FRZB was not replicated (56), demonstrating the need for large 
sample sizes to avoid false positives.  A hypothesis that the OA associated alleles within FRZB 
are correlated with hip morphology has been tested in two studies with conflicting results, 
with one study finding no correlation (64) and a more recent study finding a correlation (65). 
One robust association to OA susceptibility is that of DIO2, encoding the type II 
iodothyronine deiodinase (D2) enzyme which is able to activate thyroid signalling in growth 
plate cartilage (55).    Investigators used a genome-wide linkage scan on affected sibling pairs 
allowing them to identify linkage on chromosome 14q32.11, and subsequent association 
analysis of SNPs in that region allowed them to identify an association between OA and the C-
allele of rs225014 in DIO2.  A further investigation reported that there is an increased level of 
D2 enzyme in OA cartilage compared to healthy cartilage by using immunohistochemistry (67).  
Further to this, they also reported that the C-allele of rs225014 correlates with an increased 
expression of DIO2 relative to that of the T-allele of rs225014.  As yet it is unknown if it is 
rs225014 or another polymorphism in LD with it that is the functional cause of this association. 
1.5.4 Genome-wide association scans (GWASs) 
Genome-wide linkage scans have provided broad genomic intervals that have been 
able to be examined further in a similar manner to candidate approaches but they have been 
succeeded by a more comprehensive, powerful and higher resolution study in genome-wide 
association scans.   
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 Since the completion of the human genome project and the conception of the 
International HapMap Project (68), the latter investigating patterns and correlations of SNPs 
and providing linkage disequilibrium (LD) data, a vast number of SNPs have been discovered 
and catalogued.  A GWAS compares the frequencies of SNPs within a cohort of affected 
individuals and a cohort of controls (either free of disease or representative of the population 
as a whole).  By exploiting LD, the number of SNPs that need to be studied is a fraction of the 
total number of SNPs in the human genome.  The drawback of this however is that once an 
associated SNP is discovered all polymorphisms which are in LD with the tagging SNP (tagSNP) 
must be interrogated, which may be many if the associated SNP resides in an area of high LD. 
GWASs have been applied to many common complex diseases, with type 1 diabetes 
having benefited from over 40 loci being associated with the disease.  However, many of these 
associated loci are still to be fine mapped to identify the functional variant within the LD block, 
with only a hand full of genes so far being pinpointed (69).  In 2007 The Wellcome Trust Case 
Control Consortium performed a GWAS which genotyped half a million SNPs in approximately 
2 000 patients each from seven common complex diseases (bipolar disorder, coronary artery 
disease, Crohn’s disease, hypertension, rheumatoid arthritis, type 1 diabetes and type 2 
diabetes) and a shared set of approximately 3 000 controls (70).  They uncovered 24 
association signals across the seven diseases with a significance of p<5x10-7, and a further 58 
loci with p-values between 10-5 and 10-7.  They demonstrated that the power of a GWAS 
depends upon the effect sizes being uncovered and the sample sizes used.  Should one 
perform a GWAS with a smaller sample size, one should employ a more stringent p-value (ie. a 
lower p-value threshold) which is exactly the opposite of what many investigators of smaller 
GWASs implement. 
 Early GWASs in the OA field were underpowered due to small sample sizes and/or low 
numbers of cases and controls.  In 2006, a GWAS was performed using 25 494 SNPs to look for 
association in 335 female knee OA patients and 335 controls (71).  This study genotyped only 
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5% of the number of SNPs that the latest OA GWAS to be published.  The association they 
uncovered failed to replicate in subsequent studies (72, 73). In 2008 a GWAS testing >100 000 
SNPs on knee OA patients and controls was performed (74).  Despite the increased number of 
SNPs genotyped, the numbers were still low with only 357 knee OA cases and 285 controls 
tested.  Following replication of signals this climbed to 1534 knee OA cases and 2620 controls.  
They detected an association to a SNP proximal to PTGS2 and demonstrated it to be expressed 
in articular chondrocytes from OA patients.  The investigators performed AEI analysis on 
compound heterozygotes of the associated SNP and a transcript SNP within PTGS2 and found 
the OA associated allele correlated with reduced expression in only two out of the six patients 
tested. 
In 2010 a GWAS was performed on a cohort from the Netherlands and reported an 
association to knee and/or hand OA at a locus on 7q22 (75).  By genotyping over half a million 
SNPs in 1 341 OA cases and 3 496 controls, with associated SNPs undergoing replication in 
some 14 938 OA cases and approximately 39 000 controls, this was the first GWAS looking for 
OA susceptibility loci with reasonably high power than the studies which went before it.  A 
further investigation using additional cohorts confirmed this association to 7q22 (76).  The 
most significant associations within the 7q22 locus lay in a 500 kb LD block containing six 
genes: PRKAR2B, encoding protein kinase-cAMP-dependent-regulatory-type II-β; HBP1, 
encoding HMG-box transcription factor 1; COG5, encoding component of oligomeric Golgi 
complex 5; GPR22, encoding G protein-coupled receptor 22; DUS4L, encoding dihydrouridine 
synthase 4-like; and BCAP29, encoding B cell receptor-associated protein 29.  Due to the high 
LD of this 500 kb block the causal factor of the association could lie within any of these six 
genes.  Raine and colleagues investigated the expression of the six genes in OA and disease-
free cartilage (77).  They found that five of the six genes (the exception being GPR22) were 
expressed at a lower level in OA cartilage than that of disease free origin, and that the carriage 
of the OA-associated alleles from the Dutch GWAS correlated with significantly reduced HBP1 
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expression.  HBP1 has been implicated in the Wnt-signalling pathway, suppressing Wnt-β-
catenin-regulated growth (78) and as in the case of FRZB – mentioned earlier – this could 
impinge upon the integrity of the articular cartilage laid down. 
 A Japanese group performed a GWAS in early 2010 on 899 knee OA patients diagnosed 
via radiography and 3 396 controls from the Japanese population.  They tested over half a 
million SNPs between cases and controls after replication and found two SNPs with a genome-
wide significant (p≤5.0X10-8) association to disease within a 340 kb region of the human 
leukocyte antigen (HLA) class II locus on chromosome 6 region 6p21.31 (79).  The genes within 
this region are involved in the body’s immune response and an association supports the 
concept that OA should not be considered as a non-inflammatory disease. 
In late 2007, the Arthritis Research Campaign (now known as Arthritis Research UK) 
announced plans to fund a large well powered GWAS to identify OA susceptibility loci.  This 
undertaking was named arcOGEN, standing for Arthritis Research Campaign Osteoarthritis 
Genetics.  The arcOGEN GWAS was headed by 16 principal investigators from centres across 
the UK (80).  Of the 7 410 unrelated OA patients, 80% of them were selected due to having 
end-stage OA requiring a total joint replacement of the knee or hip.  The 11 009 controls used 
were either population-based, or OA-free controls.  Population-based controls came from 
various sources such as the Type 1 Diabetes Genetics Consortium and the Wellcome Trust Case 
Control Consortium, whereas the OA-free controls stemmed from the TwinsUK cohort which 
used twins to study the heritability and genetics of age-related diseases (80, 81).  One signal, 
that although did not reach genome-wide significance, showed a suggestive association to OA 
at stage 1 of the arcOGEN GWAS and remained significant following replication.  That signal 
was to the T-allele of rs2615977, which resides on chromosome 1p21 within intron 31 of 
COL11A1 (p=1.2x10-5) (82).  Again, while not genome-wide significant, an association within a 
gene coding for part of a cartilage collagen gains increased attention due to its critical role in 
cartilage.  The potential significance of this gene to human disease is heightened due to a 
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discovery that another polymorphism within COL11A1 is associated with lumbar disc 
herniation in the spine (83).  Type XI mutations, including those in COL11A1, typically affecting 
highly conserved glycine residues preventing the correct formation of the heterotrimer, are 
found in certain forms of Stickler syndrome, a rare and Mendelian disorder of severe OA that 
presents during adolescence (84, 85).  Patients with Stickler syndrome also have abnormalities 
with their spine, including a narrowing of the intervertebral disc, further highlighting type XI 
collagen’s critical role (83). 
The most promising signals from the full arcOGEN study were replicated in up to 7 473 
cases and 42 938 controls stemming from other European cohorts from Iceland, Estonia, the 
Netherlands and the UK.  The arcOGEN GWAS identified five loci that associated with disease 
at genome-wide significance (p≤5.0X10-8) (Table 1.1) (80). 
A key reason for the use of GWASs to identify factors contributing to disease aetiology 
is their agnostic and global nature.  With the exact causes of OA unknown, then the use of 
techniques such as expression profiling would depend upon the cell types used.  We know that 
the articular cartilage is primarily affected in OA but it would be naive to assume that the 
chondrocyte is the only cell that is the cause of OA.  There is evidence that pathways identified 
by GWASs can be used as targets for therapies.  In 2009, a GWAS reported an association 
between the IL12/IL23 pathway and Crohn’s disease (86), treatment with anti-IL-12 p40 
monoclonal antibody has a therapeutic effect upon the deregulation of T-helper 1 cells which 
underlies Crohn’s disease (87). 
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Table 1.1 Signals from the arcOGEN GWAS which reached genome-wide significance 
following replication. * denotes the same signal due to an r2=1 value. TJR = Total Joint 
Replacement, THR = Total Hip Replacement.  Data taken from Table 2 of reference (80). 
 
Signal Chromosome Nearest gene(s) Stratum Odds ratio p value 
rs6976* 3 GLT8D1 TJR 1.12 7.24x10-11 
rs1177* 3 GNL3 TJR 1.12 1.25x10-10 
rs4836732 9 ASTN2 THR-female 1.20 6.11x10-10 
rs9350591 6 FILIP1; SENP6 Hip 1.18 2.42x10-09 
rs10492367 12 KLHDC5; PTHLH Hip 1.14 1.48x10-08 
rs835487 12 CHST11 THR 1.13 1.64x10-08 
 
1.6 Investigating osteoarthritis associated genes 
 Once OA associated genes have been identified these genes need to be investigated in 
detail to assess how polymorphism at the genes influences OA development.  Important 
considerations include the effect on exon splicing, allelic expression imbalance (AEI) or the 
discovery of rare variants.  Cis-regulatory elements play a major role in the total transcriptional 
output of the human genome, with functional cis-regulatory sites estimated to be 
heterozygous in over 40% of all genes in an average individual (88).  Functional variants in 
regulatory regions, rather than coding regions, of a gene are difficult to elucidate from solely 
nucleotide sequences.  The location of regulatory elements can reside as much as 1 Mb either 
side of the transcription unit, many of which may be within introns of neighbouring, 
biologically unrelated genes and alternative promoters or exons can confound this issue (89) 
however, a GWAS carried out to look for association to vitamin A deficiency, found a SNP 8 kb 
upsteam of the key enzyme that converts β-carotene to vitamin A, β-carotene 15,15ʹ-
monoxygenase (BCMO1) in what is likely to be an enhancer element (90).  Cis-regulatory 
elements can be context specific and enhance expression in one cell type and repress 
expression in another (91, 92).  It is the spatiotemporal characteristics of cis-regulatory 
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elements which make nucleotide sequence analysis inadequate without functional 
investigation both in vitro and in vivo.   
 In vitro studies can use luciferase reporter plasmids transfected into cell lines, and 
luciferase activity can infer the activity of cis-regulatory elements when allelic variants are 
tested.  In vivo, one can measure the allelic output, via mRNA levels, in order to quantify the 
extent of a particular cis-regulatory element.  By doing this, one would assume that in the 
absence of any cis-regulatory polymorphism the transcriptional output of an autosomal gene 
would yield a ratio of 1:1.  Should any AEI be detected within an individual, the implication 
would be that that individual is heterozygous at a cis-regulatory site which impinges upon 
transcription or mRNA stability.  Each allele represents an internal control against changes in 
trans-acting factors and environmental factors, as each assay is performed within an individual 
and not between individuals (93). 
1.7 The missing heritability in OA and complex disease 
 The heritability of radiographic OA has been estimated at around 50% (94), but 
as yet we only have several OA-associated loci all with small increments in risk, with the GDF5 
SNP rs143383 being one of the most robust associations to disease but with an odds ratio of 
1.15 (56).  This leads to question as to where the remaining ‘missing’ heritability lies.  This is 
true for many complex diseases and traits, human height for example is estimated to have 
heritability of around 80%, and has more than 40 associated loci being identified, but this only 
amounts to only 5% of the phenotypic variance observed (95).  One criticism of many early 
GWASs, into a number of complex diseases, is that imprecise phenotyping, coupled with 
inadequate control groups reduced the effect sizes but still enabled the identification of 
disease/trait associated variants (96).  Some structural variations such as inversions, 
translocations, microsatellite repeats, insertions and complex rearrangements have been 
identified in rare Mendelian conditions but these types of variations have been largely 
unexplored in complex diseases and traits.  GWASs have shown that complex disease cannot 
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be explained by common variants with moderate effects (Figure 1.4), however they are still 
able to show us where rare or structural variants are likely to cluster (96).  
The detection of rare causal variants is not possible using common tagSNPs in a GWAS 
as the weak correlations between the rare and common SNPs leave the study under-powered 
(97).  It has been hypothesised that slightly deleterious SNPs in genes implicated in disease 
pathways are mainly responsible for the inter-individual variation in susceptibility (98).  These 
SNPs have lower minor allele frequencies (MAFs) than common variants (which have MAFs of 
1% or more), but they have higher MAFs than clearly deleterious SNPs (which have MAFs of 
0.1% or less).  Deleterious SNPs are in large numbers in the genome, with the rare allele 
disrupting gene function and dramatically increasing susceptibility.  However their actions are 
not strong enough to be eradicated from the population (98, 99).   
 
 
Figure 1.4 Genetic variants by allele frequency and genetic effect. Most emphasis on 
susceptibility allele discovery has concentrated on those between the dotted lines. Figure 
adapted from (96). 
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 The discovery of rare variants can be achieved by resequencing of candidate genes in a 
cohort of both cases and controls.  If variants are expected to be slightly deleterious then they 
should be elevated in cases, where if they were protective they should be elevated in controls.  
For this reason it is important to resequence both groups, and not resequence cases and then 
merely genotype controls (97). 
1.8 Growth/differentiation factor 5 
Growth/differentiation factor 5 (GDF5), also known as cartilage derived morphogenic 
protein-1, is member of the GDF-subgroup of the bone morphogenetic protein (BMP) family 
(100), with the BMP family itself being a subfamily of the transforming growth factor β (TGFβ) 
superfamily of secreted proteins (47), which in a pro-anabolic process, assist joint homeostasis 
(53).  GDF5’s main role is the induction of chondrogenesis and the patterning of joints (100), 
with GDF5 being expressed during development and in adulthood.  GDF5 is active in all 
synovial joint tissues, being involved in tendon and ligament formation (101), as well as in the 
maintenance and repair of bone and cartilage (102).  GDF5 is located on a 4.88 kb stretch of 
chromosome 20q11.2 and has a 5ʹ UTR, a 3ʹ UTR and 2 exons either side of an intronic 
sequence, giving a 2-383 bp transcript.  According to the Ensembl database 
(www.ensembl.org), there is a hypothetical transcript that codes for an extended 5ʹ UTR, 
creating 2,572 bp mRNA, however, there is no current experimental evidence to support the 
existence of this transcript. 
GDF5 binds to membrane bound serine-threonine receptors, which upon ligand 
binding, transduce their signals via the SMAD signalling pathway, inducing the transcription of 
genes such as aggrecan and COL2A1 (Figure 1.5) (103).  GDF5 interacts with two forms of type I 
BMP receptor; BMPR-IA and BMPR-IB, although shows a higher affinity to BMPR-IB (104).  Null 
mutations within the Bmpr-1b gene lead to viable mice carrying defects in bone and joint 
formation, mirroring those seen in Gdf5 knock-outs (105) but Bmpr-1a knock-outs die in early 
embryogenesis (106).  However, when a conditional knock-out of Bmpr-1a is introduced to 
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circumvent the embryonic leathality under the control of a GDF5-Cre driver mice are viable but 
with age and physical challenge articular cartilage quickly wears, producing an OA-like 
phenotype which indicates this receptor is key for cartilage homeostasis and repair (103, 104).  
It is therefore plausible to suggest that despite a lower binding affinity for GDF5, it is BMPR-1A 
that should command greater attention in OA research.  Wild-type GDF5 has a binding affinity 
for BMPR-IB 12-fold greater than that for BMPR-IA but by mutating Arg57 to an alanine the 
binding affinities become identical, indicating that the Arg57 of GDF5 that is the determinant 
for the binding specificity of BMPR-1B (107).   
 
 
 
Figure 1.5 GDF5 signalling pathway. The GDF5 homodimer binds to its membrane bound 
receptor BMPR1A or BMPR1B (The higher affinity BMPR1B is shown). Upon binding and the 
localisation of the receptor complex, phosphorylation of SMADs 1/5/8 occurs which enables 
the recruitment of SMAD4. This SMAD complex then enters the nucleus and initiates the 
transcription of genes such as COL2A1, ACAN and COL10A1. The binding of the GDF5 
homodimer to Noggin inhibits GDF5 from binding to its receptor complex. Figure adapted from 
(108). 
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A number of rare diseases are caused by penetrant mutations in GDF5, including 
brachydactyly type C (specific pattern of shortened fingers and toes) caused by one of five 
mutations (ΔG121, insertionG206, ΔG759, Arg301STOP and Arg438Cys), brachydactyly type A2 
(shortened index finger and second toe), as well as Grebe and Hunter-Thompson type 
chondrodysplasias (caused by Cys400Tyr and a 22 base pair fame shifting insertion 
respectively) both of which are caused by mutation of the cysteine knot in the mature form of 
GDF5 (100).  Other diseases include: DuPan (dwarfism or absence of bones within the limbs, 
bilateral absence of the fibula); angle-shaped phalangeopiphyseal dysplasia (short stature, hip 
dysplasia, severe bilateral vertical talus (rocker-bottom feet), premature vertebral end-plates); 
proximal symphalangism (ankylosis of proximal interphalangeal joints, fusion of carpal and 
tarsal bones, conductive deafness due to congenital ankylosis of the stapes) and multiple 
synoptosis syndrome 2 (Many skeletal abnormalities such as tarsal-carpal fusion, humeroradial 
synostosis, brachydactyly, proximal symphalangism, broad hemicylindrical nose and vertebral 
fusion) (109).  GDF5 is synthesised as a 501 amino acid precursor protein, which then 
undergoes proteolytic cleavage at residue 381, releasing the mature, active, 120 amino acid C-
terminal protein of GDF5 (100).  It is this proteolytic cleavage which is the defining factor in 
rendering GDF5 active (100).  Cleavage occurs at a conserved R(R/K)RR (RXXR) sequence. 
GDF5 was discovered in the brachypodism (bp) mouse, where a spontaneous mutation 
within the gene results in the absence of proximal interphalangeal joints, joint fusions in the 
ankle and wrist and bone abnormalities associated with dislocations with the mutation causing 
loss of function of GDF5 (110).  Due to the homozygote brachypodism mouse (Gdf5Bp-J/Bp-J) 
exhibiting such a severe developmental phenotype, one group bred the haploinsufficient 
(Gdf5Bp-J/+) mouse where the phenotype shows no difference from that of the wildtype (111).  
Here, the investigators showed that when challenged by use of collagenase induced arthritis, 
the Gdf5Bp-J/+ mouse demonstrated increased OA-like changes in the contralateral knee due to 
increased loading, and a higher degree of synovial hyperplasia when these mice were 
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challenged on a treadmill.  Analysis of the homozygote Gdf5Bp-J/Bp-J mouse revealed that the 
Achilles tendons of these GDF5 insufficient mice are structurally weaker and pervade increased 
laxity in the joint, correlating with the phenotype of both chondrodysplasias Grebe and 
Hunter–Thompson in humans which is characterised by both joint laxity and dislocation (111, 
112).   
Miyamoto et al. sequenced the two exons of GDF5 in 239 Japanese cases with 
symptomatic hip OA validated by radiography, and in 256 Japanese controls (52).  Three 
common GDF5 SNPs were identified and these were tested for association with hip OA.  The 
three SNPs were found to be associated and this was confirmed in an independent case-
control cohort of 761 cases and 728 controls.  After combing the cohorts, Miyamoto and 
colleagues found that the strongest association (p = 1.8 x 10-13) was with a SNP in the 5ʹ UTR 
(rs143383, T/C) with the associated T-allele being present in 84% of cases and 74% of controls, 
with an odds ratio (OR) of 1.79 (95% CI 1.53-2.09).  This SNP was also associated with knee OA 
in Japanese and Han Chinese populations (52). 
When Southam et al. tested for association of rs143383 in Europeans, they genotyped the SNP 
in UK and Spanish knee/hip/hand OA cases (n = 2 487) and age matched controls (n = 2 047) 
and like the Asian study, the T-allele was elevated in OA cases (53).  Whereas, Miyamoto et al. 
had used luciferase reporter assays to demonstrate that the T-allele of rs143383 led to 
reduced expression of GDF5,  Southam et al. carried out an AEI analysis using RNA extracted 
from the articular cartilage of OA patients who were heterozygous for rs143383.  An average 
12% reduction in expression of the T-allele was observed, relative to the C-allele.  From a 
molecular genetics perspective, comparisons can be made between the bp mouse and the 
effect of rs143383 in humans, with both systems confirming the a joint’s reliance upon 
sufficient levels of GDF5 (113). 
Egli et al. (2009) carried out a more comprehensive interrogation of the functionality 
of rs143383 with the identification of a candidate trans-acting factor, deformed epidermal 
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autoregulatory factor-1 (DEAF1), which binds differentially to the two alleles of the SNP (54).  
They found that AEI of GDF5 was occurring in a joint-wide capacity and that rs143383 was not 
the only cis-acting factor effecting GDF5 expression, with another SNP in the 5ʹ UTR, rs143384, 
also having an effect on the expression of the gene.  Their luciferase reporter assays showed 
that a down regulation of the T-allele of rs143383 only occurred when in the presence of the T-
allele of rs143384.  Egli et al. also found that a SNP in the 3ʹ UTR, rs56366915, had an 
independent and partly additive effect upon GDF5 allelic imbalance. 
1.9 Collagen fibrillogenesis 
 Callagens are the most abundant proteins in the body, coded for by more than 30 
genes, they are responsible for providing the structural components of the tissues of the body 
(114).  These collagen structures can be both fibrils such as types I, II and III or sheets like type 
IV (115, 116).  Collagens contain a specific amino acid sequence of Glycine – X –Y with X usually 
being a proline residue every three residues and every seventh Y being a hyroxyproline (115).  
Type II collagen is the most abundant of the collagens found in articular cartilage and is 
synthesised within chondrocytes as a procollagen trimer, with large N- and C-propeptides at 
their termini.  The procollagen is secreted from the cell and undergoes propeptide cleavage 
and the trimers are then assembled into large collagen fibrils via covalent lysyl oxidase cross-
linking at their telopeptide regions (Figure 1.6) (117).  Type XI collagen is also a cartilage 
specific fibrillar collagen but it does not form its own fibrils, instead it associates with type II 
collagen molecules to create heterotrimers. 
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Figure 1.6 Collagen fibrillogenesis.  Procollagen trimers are synthesised and excreated from 
the cell where they undergo propeptide cleavage.  The trimers are then arranged into long 
fibrils where they a covalently bonded together at their terminus between lysine and 
hydroylysine residues.  Figure adapted from (117). 
1.20 Collagen, type XI, alpha 1 
 When stage 1 of the arcOGEN GWAS was published (82), and following replication 
analysis, one of the associations uncovered was to the SNP rs2615977.  The T-allele of this T/G 
SNP associated with OA with a p-value of 1.2x10-5 and an odds ratio of 1.10 in hip OA of both 
males and females.  rs2615977 resides on chromosome 1p21 within intron 31 of COL11A1, a  
67 exon gene which codes for the α1 polypeptide chain of type XI collagen and is not in LD 
with any amino acid substitutions within the gene.  Type XI collagen is a heterotrimer 
comprised of an α1 type XI chain (COL11A1), an α2 type XI chain (COL11A2) and a post-
translationally modified α1 type II chain (COL2A1) (85).  Although found in low abundance 
within the cartilage extracellular matrix, type XI collagen is a structurally important 
component.  It is believed that the globular nature of the amino terminal domain of the α1(XI) 
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chain, preventing its incorporation into the collagen fibrils along with the rest of the type XI 
molecule, is responsible for controlling the diameter of the overall collagen fibrils within the 
ECM (118).  Chondrodysplasia in mouse (cho/+) is caused by a frame-shift mutation within 
Col11a1, producing a truncated α1(XI) chain, with an inability to regulate correct collagen fibril 
thickness, and as a result cho/+ mice have thicker fibrils than wild-type mice (119). This 
highlights the critical role type XI collagen plays in the organisation of the supramolecular 
architecture of cartilage collagen (83). These haploinsufficient cho/+ mice develop OA-like 
changes in both their knee and temporomandibular joints, yet show no other skeletal 
abnormalities (120).  The result of the reduced expression of type XI collagen within the cho/+ 
mouse is that the type II collagen network is altered whereby there is a higher proportion of 
pericellular type II collagen than in wild type cartilage.  This in turn increases the levels of both 
discoidin domain receptor 2 (Ddr2) and matrix metalloproteinase 13 (Mmp13), which lead to 
cartilage degradation (120). 
  Type XI mutations, including those in COL11A1, typically affecting highly conserved 
glycine residues preventing the correct formation of the heterotrimer, are found in certain 
forms of Stickler syndrome, a rare and Mendelian disorder of severe OA that presents during 
adolescence (84, 85).  Patients with Stickler syndrome also have abnormalities with their spine, 
including a narrowing of the intervertebral disc, further highlighting type XI collagen’s critical 
role (83). 
In this thesis I report on genetic and functional analyses that I have performed on 
COL11A1 and GDF5. 
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Chapter 2: Allelic expression of COL11A1 in human 
articular cartilage 
2.1 Introduction 
 In late 2007, Mio et al. reported that a common non-synonymous SNP, rs1676486, 
found in exon 62 of COL11A1, was associated with lumbar disc herniation (LDH) in a Japanese 
population (83).  LDH and OA are both characterised by age-associated, loss of function and 
degradation of cartilage.  However, OA is categorised as degradation of hyaline, articular 
cartilage whereas LDH is categorised as degradation of type I collagen containing 
fibrocartilage.  rs1676486 is a C-T transition which codes for a proline (hydrophobic, non-polar) 
to serine (polar) substitution.  The T-allele of rs1676486, with an allele frequency of 25% in the 
Japanese population, was shown to be elevated within LDH cases, and correlated with 
decreased stability of the COL11A1 transcript in vitro when compared to that of the more 
common C-allele.  A difference in allelic output or transcript stability can impact upon the total 
amount of transcript of a gene and is known as an allelic expression imbalance (AEI).  AEI can 
be caused by mRNA differences in transcription efficiencies or by differences in mRNA stability, 
with the end result being less mRNA able to be translated into protein.  Mio et al. concluded 
that rs1676486 has a quantitative effect upon COL11A1 transcript abundance, implying that a 
quantitative deficiency also exists of the α1 polypeptide of type XI collagen and it is this 
deficiency which is contributing towards LDH susceptibility. 
As more and more susceptibility loci are being uncovered by GWASs it is becoming 
apparent that common disease risk is increasingly being linked to alleles which influence gene 
expression via the modulation of transcription levels or transcript stability (121, 122).  A good 
example of such a disease susceptibility locus is rs1676486 for LDH, affecting transcript levels 
in a tissue relevant to that disease.  It is key that investigations into the effects of susceptibility 
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alleles are carried out using RNA extracted from not just organs that exhibit the disease 
phenotype but specifically from tissues exhibiting the phenotype and ideally at the time of 
disease development, as AEI may not only be spatial but also temporal (122, 123).  
 With this knowledge, I hypothesised that the OA association to COL11A1 reported by 
the arcOGEN study, marked by rs2615977, may be mediated by the modulation of COL11A1 
expression in articular cartilage.  Additionally, I hypothesised that the AEI reported by Mio et 
al. in LDH, marked by rs1676486, may also be observed in OA, again in articular cartilage. 
2.2 Aims of this study 
The aims of this study were to firstly test whether the OA association to COL11A1 
reported by the arcOGEN study, marked by rs2615977, is mediated by the modulation of 
COL11A1 expression in articular cartilage, and secondly to test whether the AEI reported by 
Mio et al. in LDH, marked by rs1676486, may also be observed in OA, again in articular 
cartilage.  In order to test these hypotheses I used two approaches; firstly to quantitatively 
measure overall COL11A1 expression in articular cartilage and stratify by genotype at the two 
SNPs, and secondly to test for AEI within COLL11A1 using assays which can both discriminate 
and quantify the mRNA levels of each allele of a SNP within the transcript of the target gene. 
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2.3 Materials and methods 
2.3.1 Patients, tissues and nucleic acid extraction 
 Macroscopically normal articular cartilage tissue located distal to the OA lesion was 
dissected from individuals undergoing elective joint replacement for OA of the hip (total hip 
replacement, THR) or of the knee (total knee replacement, TKR), as described extensively 
previously (53, 93).  The Newcastle and North Tyneside research ethics committee granted 
ethical approval for the collection (REC reference number 09/H0906/72) and informed consent 
was obtained from each donor.  On the day of operation, tissue samples were snap frozen and 
ground to a powder using a Resch mixermill 200 (Retsch Limited, UK) under liquid nitrogen to 
prevent RNA degradation.  Genomic DNA and RNA were extracted from ground tissue using an 
EZNA DNA/RNA Isolation Kit (Omega bio-tek, R6731-02).  Nucleic acids were then quantified 
using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, USA).  Tissue 
grinding and nucleic acid extraction for all tissue samples was carried out exclusively by Emma 
Raine, a colleague working within my supervisor, Professor Loughlin’s, research group. 
2.3.2 DNA genotyping COL11A1 SNPs 
Genomic DNA isolated during the nucleic extraction from articular cartilage was used 
to genotype three SNPs within COL11A1: the OA associated non-transcript SNP rs2615977, 
located within intron 31; the LDH associated SNP rs1676486, located within exon 62; and SNP 
rs9659030, located within the 3ʹ UTR.  rs9659030 was tested for AEI due to the absence of any 
transcript SNPs in high LD (r2 ≥ 0.8) with the OA associated SNP, rs2615977.  Heterozygosity 
was determined by PCR-restriction fragment length polymorphism (RFLP) analysis.  In order to 
genotype both rs2615977 and rs9659030 PCR was performed using a forward primer 
containing a single base change allowing the creation of a restriction enzyme site in the 
presence of one allele but not in the presence of the other allele, along with a reverse primer 
which was also specific to the genomic sequence.  In order to genotype rs1676486 no base 
36 
 
changes were needed to be made to the primers as the SNP naturally altered a restriction 
enzyme site.  A 15 μl PCR contained 50 ng DNA, along with 7.5 μM of forward and 7.5 μM of 
reverse primer, 1.5 μl of 10X PCR buffer (50 mM KCl, 10 mM Tris-HCl pH 8.3), 2 mM MgCl2, 0.2 
mM dNTPs, 0.08 units of AmpliTaq Gold DNA polymerase (Applied Biosystems) and the total 
volume was brought up to 15 μl using H2O.  Thermocycling conditions to genotype both 
rs2615977 and rs1676486 were an initial denaturation at 94oC for 10 minutes, followed by 35 
cycles of 94oC for 30 seconds, annealing at 64oC for 30 seconds, and a polymerase extension at 
72oC for 30 seconds, with a final extension step at 72oC for 10 minutes.  Thermocycling 
conditions to genotype rs9659030 were an initial denaturation at 94oC for 10 minutes, 
followed by 35 cycles of 94oC for 30 seconds, annealing at 55oC for 30 seconds, and a 
polymerase extension at 72oC for 30 seconds, with a final extension step at 72oC for 10 
minutes.  A 5 μl digestion mixture was added to each PCR to create a 20 μl reaction mixture.  
Five units of restriction enzyme were added along with 2 μl of the appropriate 10X NEB Buffer 
and 2.5 μl of H2O.  The PCR and digestion mixture was then incubated at 37
oC for 3 hours 
followed by a 20 minute heat inactivation at 60oC.  Primer sequences, PCR conditions and the 
enzymes used are listed in Table 2.1.  Digestion products were electrophoresed through a 3% 
(weight/volume) agarose gel containing ethidium bromide, and genotypes were scored after 
UV visualisation.   
2.3.3 Reverse transcriptase (RT) polymerase chain reaction  (RT-PCR) 
RNA was stored in diethylpyrocarbonate (DEPC)-treated H2O (Invitrogen) at a 
concentration of 250 ng/μl. RT-PCR was carried out using the SuperScript First-Strand 
Synthesis System (Invitrogen).  Initially 4ul of RNA in DEPC-treated H2O was mixed with 1 μl of 
random primers (50 ng/μl), 1 μl of 10 mM dNTP mix (10 mM each: dATP; dCTP; dGTP; dTTP), 
and 2 μl of DEPC-treated H2O.  This reaction mix was then incubated at 65
oC for 5 minutes 
followed by incubation on ice for at least 1 minute.  Following this, 4 μl of 5X Reaction buffer 
(250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2), 4 μl of 25 mM MgCl2, 2 μl of 0.1 M DTT 
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and 1 μl of RNaseOUT inhibitor (40 units/μl) were added and incubated at 25oC for 1 minute.  
Then 50 units of SuperScript II RT enzyme was added to the reaction mixture and mixed via 
pipetting.  The 20 μl total reaction mix was incubated at 25oC for 10 minutes, 42oC for 50 
minutes and finally 70oC for 15 minutes.  Following the incubation cycle, 2 units of RNase H 
(New England Biolabs, 5 units/μl) were added and the reaction mixture was incubated at 37oC 
for 20 minutes.  The newly synthesised cDNA was then stored at -20oC until required. 
2.3.4 Quantitative real-time PCR  
PrimeTime Mini qPCR Assays (Table 2.2) were purchased from Integrated DNA 
Technologies (IDT; Iowa, USA) and overall expression of COL11A1 was measured relative to the 
housekeeping genes HPRT1, GAPDH and 18S using an ABI PRISM 7900HT Sequence Detection 
System following the manufacturer’s protocol (Applied Biosystems).  Three replicates for each 
patient cDNA sample were carried out per gene, creating a total of 9 housekeeper cycle 
threshold (Ct) values.  A mean housekeeper Ct value was calculated and used as a control 
against COL11A1 expression using the 2-∆Ct method.  Mann-Whitney U and Kruskal-Wallis tests 
were performed to test whether genotype at rs2615977 and genotype at rs1676486 correlated 
with COL11A1 expression. 
2.3.3 Allelic expression imbalance analysis  
Allelic expression imbalance was assessed using the transcript SNPs rs1676486 and 
rs9659030 and quantitative real time PCR genotyping assays.  These assays are standard real 
time assays except that they employ a probe (FAM or VIC labelled) specific to each of the two 
alleles of a SNP.  Readymade TaqMan genotyping assays for rs9659030 and rs1676486 for use 
with genomic DNA were purchased from Applied Biosystems.  A custom made assay was 
required to PCR cDNA for rs1676486 as the SNP is only 5 bp from the exon 62/intron 62 
boundary.  Real time PCR was carried out according to the manufacturer’s instructions.  In 
brief, 4 l of cDNA (corresponding to 200 ng of patient tissue RNA) or 20 ng of DNA (also 
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extracted from the tissue) was added to 5 l of TaqMan Universal Master Mix II no UNG 
(Applied Biosystems) and 0.25 l of 40 x TaqMan assay in a 10 l reaction.  The samples were 
then amplified on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems), 
under the following cycle conditions: 50°C for 2 minutes, 95°C for 10 minutes and 40 cycles of 
92°C for 15 seconds and 60°C for 1 minute.  The reactions were performed in five replicates.  
The allelic ratios were calculated using the formula (2^-FAM Ct)/ (2^-VIC Ct). 
For each assay, the ratios between the amounts of each allele in every sample were 
calculated for genomic DNA and cDNA.  For each sample the average allelic ratio for genomic 
DNA, which represents the 1:1 ratio, was then used to normalise the cDNA ratio to generate a 
corrected allelic ratio.  To determine if there was an overall difference in expression between 
alleles for a particular tissue across all patients the mean allelic ratios for the patient cDNAs 
were compared to the mean allelic ratios for the patient genomic DNAs using a 2-tailed Mann-
Whitney exact test.  
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Table 2.1 Table of primers and PCR conditions along with restriction enzymes used for genotyping SNPs by RFLP analysis. 
SNP 
 Sequence (5'-3') PCR Conditions 
Enzyme 
rs2615977 Forward primer  GTTTTAAAACATCCCCAGATAATTATCATATTCACTG 2 mM MgCl2 BsrI 
  Reverse primer GTAACTAACCTGCACGTTGT 64oC annealing temp. 
 
rs1676486 Forward primer GCATTTTGTAGGGTCCTCAAGGC 2 mM MgCl2 BsaI 
  Reverse primer ACTTTGCTATGGTAGCCCTAGC 64oC annealing temp. 
 
rs9659030 Forward primer GACCTACCTAATTGCTAAATGAATAACATATGGTGGACTGTTATTAACAG 2 mM MgCl2 TspRI 
  Reverse primer ACTGTTCCAGTGAAATCTGG 55oC annealing temp. 
 
 
Table 2.2 Table of the PrimeTime Mini qPCR Assays used for quantitative PCR analysis of COL11A1 
Gene Primer 1 (5'-3') Primer 2 (5'-3') Probe 
COL11A1 TTCTCCACGCTGATTGCTAC TTGGTGTTGAGGTTGGGAG 56-FAM/TTAACATCGCTGACGGGAAGTGGC/36-TAMSp 
HPRT1 TGCTGAGGATTTGGAAAGGG ACAGAGGGCTACAATGTGATG 56-FAM/AGGACTGAACGTCTTGCTCGAGATG/36-TAMSp 
GAPDH GGCCATCCACAGTCTTCTG CAGCCTCAAGATCATCAGCAA 56-FAM/ATGACCACA/ZEN/GTCCATGCCATCACT/31ABkFQ 
18S CGAATGGCTCATTAAATCAGTTATGG TATTAGCTCTAGAATTACCACAGTTATCC 56-FAM/TCCTTTGGTCGCTCGCTCCTCTCCC/TAMRA 
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2.4 Results 
2.4.1 Genotyping of OA patients at rs1676486, rs2615977 and 
rs9659030 
 DNA extracted from patient articular cartilage was used to genotype the three SNPs by 
RFLP analysis.  Genotyping of rs1676486 resulted in an uncut 753 bp C-allele fragment and two 
564 bp and 189 bp cut T-allele fragments (Figure 2.1, A).  Of the 78 patients tested, 48 were 
CC, 29 were CT and one was TT at rs1676486 (Table 2.3).  Genotyping of rs2615977 resulted in 
an uncut 360 bp T-allele and two 324 bp and 36 bp cut G-allele fragments (Figure 2.1, B).  Of 
the 78 patients tested, 40 were TT, 32 were TG and six were GG at rs1676486 (Table 2.3).  
Genotyping of rs9659030 resulted in an uncut 256 bp A-allele and two 206 bp and 50 bp cut G-
allele fragments (Figure 2.1, C).  Of the 78 patients tested, 34 were AA, 39 were TG and five 
were GG at rs1676486 (Table 2.3). 
2.4.2 COL11A1 expression in articular cartilage stratified by genotype at 
associated SNPs 
 Using cDNA synthesised from articular cartilage RNA I was able to measure the level of 
COL11A1 expression using quantitative real-time PCR.  This data was then stratified by 
genotype at the OA associated locus, rs2615977 and by genotype at the LDH associated locus, 
rs1676486 (Figure 2.2).  Due to rs1676486 having a MAF of only 20% (T-allele), and 
homozygous TT individuals being limited to only 1.8% of the HapMap CEU population, I only 
encountered one homozygous TT individual.  Due to the low incidence of these individuals I 
decided to stratify by carriers (TT and CT individuals) and non-carriers (CC individuals) of the 
LDH associated T-allele.  Stratification yielded no significant correlation (p<0.05) between the 
level of COL11A1 expression and genotype at either rs2615977 or rs1676486.  Additionally I 
stratified these data further by those patients who had undergone TKR and those who had 
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undergone THR, but again there was no correlation between COL11A1 expression levels and 
genotype at either rs2615977 or rs1676486 (Figure 2.3). 
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Figure 2.1 Restriction fragment length polymorphism analysis of SNPs within COL11A1. Agarose gel images using 100 bp ladder of: (A) rs1676486 genotyping, 
BsaI digestion produces an uncut C-allele band of 753 bp and two cut T-allele bands of 564 bp and 189 bp in length. (B) rs2615977 genotyping, BsrI digestion 
produces an uncut T-allele band of 360 bp and two cut G-allele bands of 324 bp and 36 bp in length. (C) rs9659030 genotyping, TspRI digestion produces an uncut 
A-allele band of 256 bp and two cut G-allele bands of 206 bp and 50 bp in length. 
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Table 2.3 Table of patient characteristics and their genotype at rs2615977, rs1676486 and 
rs9659030. F, female; M, male, K, knee, H, hip. 
 
Patient  Sex Age at surgery 
(years) 
Joint replaced 
at surgery 
Genotype 
rs2615977 rs1676486 rs9659030 
1 F 75 H TT CT AG 
2 F 67 K TT CC AA 
3 M 69 K TT CT AG 
4 F 77 H TG CC AG 
5 F 73 K TT CC AA 
6 M 71 K TT CT AG 
7 F 73 K GG CC AA 
8 F 51 H TT CT AG 
9 F 60 K GG CC AG 
10 F 67 K TT CT AG 
11 M 62 K TT CT AG 
12 M 50 K TG CC AA 
13 M 67 K TT CT AG 
14 F 76 H TT CC AA 
15 F 71 K TG CC AG 
16 F 67 H TT CC AA 
17 F 70 H TT CC AA 
18 F 60 H TG CC AA 
19 M 80 K TG CC AG 
20 F 81 K TG CC AG 
21 M 76 K TG CT AA 
22 F 55 K TT CT AA 
23 M 57 K TT CT AA 
24 M 57 H TT CT AG 
25 M 69 K TG CT GG 
26 F 67 K TT CC AA 
27 F 69 K GG CC AA 
28 M 57 K GG CC AG 
29 F 60 K TG CC AA 
30 F 66 K TT CC AA 
31 M 63 K TT CT AG 
32 M 77 K TT CC AA 
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33 M 82 K TT CT AA 
34 F 78 K TT CC AA 
35 M 82 K TG CT AG 
36 M 46 K TT CC AA 
37 M 56 K TT CT AG 
38 F 54 K TT TT GG 
39 M 71 K TT CT AG 
40 F 58 H TT CC AA 
41 F 69 H TG CT GG 
42 F 64 K TT CT AA 
43 M 63 K TG CC AA 
44 F 71 H TG CC AG 
45 M 70 K TG CT AG 
46 M 67 K TT CT AG 
47 M 86 K TT CT AA 
48 F 67 K TT CC AA 
49 M 71 K TG CC AA 
50 F 46 K TT CC AA 
51 F 62 K TT CC AA 
52 F 58 K TG CC AA 
53 M 69 K TG CC AG 
54 M 59 K TT CT AG 
55 M 64 K TT CT GG 
56 F 81 K GG CC AG 
57 F 80 K TT CT AG 
58 F 64 K TG CC AA 
59 F 78 K TG CC AG 
60 F 61 K TT CT AG 
61 F 80 K TG CT GG 
62 F 80 K TT CC AA 
63 F 59 K TG CT AG 
64 F 71 H TT CT AG 
65 M 74 K GG CC AG 
66 F 74 H TT CC AG 
67 M 72 K TG CC AG 
68 M 72 K TT CC AA 
69 M 68 H TG CC AA 
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70 F 72 H TG CC AA 
71 M 68 K TG CC AA 
72 M 75 K TG CC AG 
73 F 82 H TG CC AG 
74 F 78 K TG CC AG 
75 M 72 K TG CC AG 
76 F 59 K TG CC AG 
77 F 71 H TG CC AG 
78 M 69 K TG CC AG 
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Figure 2.2 Columnar scatter plots of the quantitative expression of COL11A1 in cartilage 
cDNA stratified by genotype at A) the OA associated SNP rs2615977 and B) the LDH 
associated SNP rs1676486. Due to the low frequency of TT homozygotes at rs1676486 the 
analysis in B) was between CC homozygotes and T-allele carriers (CT and TT combined) at this 
SNP. n is the number of patients studied for each group. The horizontal lines in each plot 
represent the mean and the standard error of the mean. P-values were calculated using a 
Kruskal-Wallis test for A) and a Mann-Whitney U test for B). 
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Figure 2.3 Columnar scatter plots of the quantitative expression of COL11A1 in OA cartilage 
cDNA stratified by A) genotype at the LDH associated SNP rs1676486 in knee cases, B) 
genotype at the LDH associated SNP rs1676486 in hip cases, C) genotype at the OA 
associated SNP rs2615977 in knee cases, and D) genotype at the OA associated SNP 
rs2615977 in hip cases. Due to the low frequency of TT homozygotes at rs1676486 the analysis 
in A) and B) was between CC homozygotes and T-allele carriers (CT and TT combined) at this 
SNP. Due to the absence in the hip strata of GG homozygotes at rs2615977 the analysis in D) 
was between TT homozygotes and TG heterozygotes at this SNP. n is the number of patients 
studied for each group. The horizontal lines in each plot represent the mean and the standard 
error of the mean. P-values were calculated using a Mann-Whitney U test for A), B) and D) and 
a Kruskal-Wallis test for C). 
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2.4.3 Allelic Expression Imbalance in COL11A1 
 The technique used in section 3.4.1 did not yield a correlation between COL11A1 
expression and genotype at either SNP.  However, as both Figures 2.2 and 2.3 show, there is a 
large variation in expression between individuals of the same genotype.  For example, the 
expression of COL11A1 can vary by more than 200 fold between individuals of the same 
genotype at the targeted SNPs. This indicates that the technique used is vulnerable to natural 
fluctuation in gene expression which impinges upon the sensitivity and accuracy of the assay 
(124), potentially creating false negatives which I believe is happening in this instance and 
measuring gene expression and stratifying by genotype is therefore unable to accurately 
reflect any imbalances in expression at the allelic level.  Instead, one can test directly for AEI by 
using transcript SNPs to measure the cDNA output from each allele within each heterozygous 
patient.  By only using heterozygotes and testing each allele’s output against the other, one 
can overcome inter-individual fluctuations in overall gene expression.  Additionally, by using 
genomic DNA as a control to provide a 1:1 ratio one is able to normalise the cDNA allelic ratio 
and overcome any allele specific assay amplification differences. 
 The LDH associated SNP, rs1676486, is a transcript SNP and therefore can be subjected 
to direct AEI analysis.  However, rs26715977 is within intron 31 of COL11A1 and therefore 
cannot be used to detect an AEI.  Using public databases I was unable to identify any SNPs with 
an LD of 0.8 or greater with rs26715977, and so opted to use a transcript SNP with a high 
heterozygosity.  By doing this I ensured that I could utilise as many of our patients for the 
analysis as possible, focusing on individuals who were compound heterozygotes at rs26715977 
and the transcript SNP that was chosen, rs9659030.  The heterozygosity of rs9659030 is 31% in 
the European (HapMap CEU) population.  rs9659030 is not in LD with rs2615977 (pair wise 
r2=0.08), but by testing compound heterozygotes for AEI I was able to use the two alleles of 
rs9659030 to differentiate between the two alleles of rs2615977.  Due to there being no LD 
between the two SNPs it is not possible to determine the phase between the two SNPs, but 
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should rs2615977 drive, or correlate with a SNP that drives AEI, then one would expect a high 
proportion of the compound heterozygotes to show either a positive or negative deviation 
from an allelic expression ratio of 1:1. 
2.4.3.1 rs1676486 
 I tested for AEI on a total of 22 OA patients who were heterozygous at the LDH 
associated SNP rs1676486.  All 22 patients exhibited a significant (p<0.05) decrease in 
expression of the disease associated T-allele relative to that of the C-allele.  The mean allelic 
ratio of these 22 patients was 0.36 (p<0.0001) (Figure 2.4 and Table 2.4), meaning that there is 
only 0.36 molecules of T-allele cDNA for every one molecule of C-allele cDNA.  This AEI in 
articular cartilage echoes the findings of the original LDH study where the T-allele was shown 
to exhibit reduced stability (83). 
 
Figure 2.4 Allelic expression analysis in cartilage samples from OA patients assessed using 
the LDH associated SNP rs1676486. The genotypes of the patients at rs1676486, at the OA 
associated SNP rs2615977 and at the 3ʹUTR SNP rs9659030 are shown. P-values were 
calculated by comparing the cDNA allelic ratio to the DNA allelic ratio using a Mann-Whitney U 
test. ** denotes p < 0.01.  
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Table 2.4 Table of the allelic ratios for the patients analysed for AEI at rs9659030 and 
rs1676486. Allelic ratios are shown ± the standard error of the mean. P-values were calculated 
using a Mann Whitney U test. P-values < 0.01 are highlighted in bold. Experiments to assess 
AEI on patient samples at rs9659030 denoted with a * were carried out by Emma Raine. 
 
rs9659030   rs1676486 
Patient Allelic ratio (A/G) P value   Patient Allelic ratio (C/T) P value 
1* 1.16 ± 0.16 0.42  
 
1 0.36 ± 0.01 <0.01 
3* 0.98 ± 0.2 1.00 
 
3 0.31 ± 0.01 <0.01 
4* 1.08 ± 0.08 0.84 
 
6 0.43 ± 0.08 <0.01 
8* 1.09 ± 0.11 0.55 
 
8 0.35 ± 0.02 <0.01 
9* 0.94 ± 0.1 1.00 
 
10 0.24 ± 0.02 <0.01 
10* 0.8 ± 0.06 0.1 
 
11 0.38 ± 0.02 <0.01 
11* 0.66 ±  0.03 <0.01 
 
13 0.29 ± 0.01 <0.01 
13* 0.81 ± 0.07 0.06 
 
21 0.42 ± 0.01 <0.01 
15* 0.94 ± 0.12 0.69 
 
22 0.48 ± 0.02 <0.01 
19* 1.16 ± 0.05 0.06 
 
23 0.64 ± 0.02 <0.01 
20* 0.81 ± 0.02 <0.01 
 
24 0.33 ± 0.02 <0.01 
24* 0.83 ± 0.08 0.22 
 
25 0.29 ± 0.01 <0.01 
28* 0.92 ± 0.05 0.55 
 
31 0.33 ± 0.01 <0.01 
31* 0.75 ± 0.05 0.15 
 
33 0.48 ± 0.04 <0.01 
35* 1.35 ± 0.6 0.33 
 
35 0.24 ± 0.03 <0.01 
37* 0.69 ± 0.03 <0.01 
 
37 0.29 ± 0.01 <0.01 
39* 0.66 ± 0.04 <0.01 
 
39 0.22 ± 0.01 <0.01 
45* 1.2 ± 0.16 0.69 
 
41 0.22 ± 0.01 <0.01 
46* 1.06 ± 0.1 0.69 
 
42 0.44 ± 0.03 <0.01 
72* 1.06 ± 0.12 0.73 
 
45 0.34 ± 0.03 <0.01 
73* 0.96 ± 0.18 0.57 
 
46 0.35 ± 0.02 <0.01 
74* 0.90 ± 0.04   1.00    47 0.47 ± 0.02 <0.01 
75* 0.98 ± 0.04  1.00 
    76* 0.99 ± 0.21   0.79 
    77* 0.93 ± 0.14  0.69 
    78* 0.72 ± 0.08  0.55 
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2.4.3.2 rs9659030 
 I tested for AEI on a total of 26 OA patients who were heterozygous at rs9659030 
(Figure 2.5 and Table 2.4).  Of these 26 patients, 13 were compound heterozygotes at 
rs2615977 and rs9659030 but only one of these 13 patients exhibited a significant imbalance 
in allelic expression (Patient 20), demonstrating that the two alleles of the OA associated SNP 
rs2615977 do not show any correlation with an expression imbalance of COL11A1.  Three 
additional patients exhibited a significant AEI (patients 13, 37 and 39 in Figure 2.5) who, as 
mentioned, were not heterozygous at rs2615977 but they were all heterozygous at rs1676486 
– the LDH associated SNP – and it is most likely this which is driving the imbalance observed. 
 
 
Figure 2.5 Allelic expression analysis in cartilage samples from OA patients assessed using 
the 3′UTR SNP rs9659030. The genotypes of the patients at rs9659030, at the OA associated 
SNP rs2615977 and at the LDH associated SNP rs1676486 are shown. P-values were calculated 
by comparing the cDNA allelic ratio to the DNA allelic ratio using a Mann-Whitney U test. ** 
denotes p < 0.01.  
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However, it is to be noted that nine patients who are compound heterozygous for 
rs1676486 and rs9659030 did not exhibit a significant AEI when allelic expression was 
measured with rs9659030 (patients 1, 3, 8, 10, 11, 24, 31, 46 and 76 in Figure 2.5).  Based on 
the AEI data that I had obtained for rs1676486 (Section 2.4.3.1) I had expected all patients who 
were heterozygous for this SNP to demonstrate AEI, even when the AEI was measured using a 
SNP other than rs1676486.  Eight of these nine patients had undergone AEI testing at 
rs1676486 in Section 2.4.3.1, and exhibited a significant AEI (patients 1, 3, 8, 10, 11, 24, 31, and 
46 in Figure 2.4).  Mio et al. 2007 postulated that the COL11A1 transcript is subjected to 
differential degradation, and hence a variable stability, dictated by genotype (83).  A 
differential allelic degradation could affect the AEI observed depending upon where on the 
transcript the AEI was being measured.  In order to investigate this further I used the AEI data 
from the 22 patients tested using rs1676486 and plotted their allelic ratios stratified by their 
genotype at the 3ʹ UTR SNP rs9659030 (Figure 2.6).  When this data was assessed using a 
Kruskal–Wallis one-way analysis of variance test, it was apparent that genotype at the 
rs9659030 correlated with the degree of AEI observed at rs1676486, with the G-allele of 
rs9659030 correlating with a greater magnitude of AEI at  rs1676486 (p=0.001). 
2.4.4 Genetic association of rs1676486 and OA 
 Having confirmed rs1676486 as exhibiting AEI in articular OA cartilage I tested whether 
this SNP was associated with OA.  Using the arcOGEN GWAS dataset (80) it was revealed that 
the SNP showed minimal evidence of an association with OA (Table 2.5), with a comparison of 
7 410 cases and 11 009 controls producing a p-value of 0.012.  As in the LDH study, the T-allele 
of rs1676486 showed an elevation in cases versus controls (frequency of 0.201 vs 0.1905) with 
an odd ratio of 1.069 (95% confidence interval of 1.015-1.127). 
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Figure 2.6 Columnar scatter plot of the allelic ratios for AEI analysis of rs1676486 stratified by 
genotype at the 3′UTR SNP rs9659030. An allelic ratio of 0 represents no difference between 
the two alleles. A negative allelic ratio value represents increased expression of the C-allele. n 
is the number of patients analysed for each group. The p-value was calculated using a Kruskal-
Wallis test.  
 
 
 
 
Table 2.5 Association analysis of rs1676486 with OA using the arcOGEN data. 
 
 
Stratum Number 
of cases 
Number of 
controls 
T-allele frequency P-value Odds ratio 
(95% confidence intervals) Cases Controls 
All cases 7410 11009 0.201 0.1905 0.012 1.069 (1.015-1.127) 
Hip cases 3912 11009 0.201 0.1905 0.043 1.069 (1.002-1.141) 
Knee cases 4144 11009 0.2035 0.1905 0.010 1.086 (1.02-1.157) 
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2.5 Discussion 
 Decreased expression of type XI collagen in Col11A1 haploinsufficient mice (cho/+) can 
lead to an OA-like phenotype in the joints of these mice due to the altered collagen structure 
of the articular cartilage and subsequent increase in Mmp13 expression (120).  A key 
mechanism of OA susceptibility in humans has been shown to be that of allelic expression 
imbalance, with the 5ʹ UTR SNP rs143383 of GDF5 being a prime example whereby the disease 
associated T-allele confers a reduced level of expression relative to that of the C-allele in 
articular cartilage and all other tissues of the synovial joint (54).  Following investigations such 
as this, I hypothesised that the OA association to COL11A1 marked by rs2615977, as reported 
by the arcOGEN GWAS (82), was due to AEI acting upon COL11A1 in OA articular cartilage.  
Additionally, following an investigation into LDH, it was apparent that COL11A1 expression can 
be subjected to AEI in intervertebral disc (83) marked by rs1676486 and I was keen to test 
whether this imbalance is present within OA cartilage.  Should this prove to be the case, I also 
wanted to see if genotype at this SNP associates with OA as it does with LDH.  Following our 
AEI analysis I did not see a correlation between the arcOGEN GWAS OA associated SNP 
rs2615977 and AEI within COL11A1.  However, my analysis of the LDH associated SNP 
rs1676486 did yield a definite correlation between genotype and AEI within COL11A1.  Like in 
LDH, it is the T-allele of rs1676486 which corresponds to reduced expression of the gene, 
however when tested for an association with OA the SNP yielded only a very weak association 
with the disease.  This result stems from a GWAS of over 480 000 SNPs and as a result the very 
modest p-value does not support rs1676486 as a locus conferring an OA susceptibility, despite 
it conferring an imbalance in allelic output.   
From this study it can be concluded that while COL11A1 exhibits AEI in OA cartilage it 
is not a risk factor for the progression of OA, unlike LDH.  There are clearly differing 
mechanistic effects within human articular cartilage and human disc cartilage, whereby an AEI 
in COL11A1 can be tolerated in the former but not in the latter.  The fact that we see AEI in 
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COL11A1 mediated by rs1676486 in OA cartilage as it occurs in LDH cartilage implies that the 
same trans-acting factors are at work in both tissue types.  When Mio and colleagues 
investigated the effect of rs1676486 on LDH, they quantified the level of COL11A1 expression 
in both intervertebral disc and articular cartilage.  They found COL11A1 expression to be 
almost 5 times greater in intervertebral disc than in articular cartilage, which could provide an 
explanation as to why AEI mediated by rs1676486 is not a risk factor for OA, if the ratio of 
imbalance is the same in both tissues then the actual disparity in the number of allelic 
molecules would be greater within intervertebral disc. 
The association of OA marked by rs2615977 is obviously acting in a different manner 
than affecting the level of COL11A1 expression in mature cartilage, as our AEI analysis of the 
SNP suggests.  It is possible that rs2615977 marks an association to a polymorphism which 
impinges upon COL11A1 expression at a time point not investigated here.  Our OA cartilage 
samples were from patients with end stage OA electing for total joint replacement.  For this 
reason one cannot rule out the possibility that rs2615977 may induce AEI of COL11A1 during 
skeletogenesis or in adolescent tissues before OA is present, affecting the structural integrity 
of the cartilage as it is laid down or early on in life, initiating the long term progression of OA.  
However, testing this theory by examining cartilage at these time points is obviously very 
challenging due to their unavailability.  One avenue of investigation would be to take 
mesenchymal stem cells from the bone marrow of patients undergoing total joint replacement 
and culturing these cells while differentiating them into chondrocytes.  During this 
differentiation, at various time points RNA could be extracted and tested for AEI. 
It should be noted that in nine patients that were compound heterozygotes for 
rs1676486 and rs9659030, to detect no AEI at rs9659030 when AEI was observed when 
measuring at rs1676486 was surprising.  It is fair to assume that should AEI exist then it would 
be detectable using any SNP as the marker.  However, as Mio et al. postulated, rs1676486 
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alters the stability of the mRNA transcript (83).  The data suggests that there is variation in the 
rate of RNA degradation across the transcript length and that the AEI values obtained could be 
in part dependent upon the physical position of the SNP used to measure AEI within the 
transcript, and rs9659030 was located in the 3ʹ UTR only approximately 360 nucleotides from 
the end of the transcript. 
The mRNA molecules being translated within the cytoplasm of a cell are protected 
from degradation by a 5ʹ cap and a polyadenylated 3ʹ tail (125).  The polyadenylated tail is 
reduced with each cycle of translation, upon the removal of the poly(A) tail the mRNA can be 
decapped by the DCP1-DCP2 complex.  This process then allows for the mRNA to be degraded 
5ʹ-3ʹ by XRN1/XRN2 or by the exosome complex which degrades in a 3ʹ-5ʹ direction.  The 
presence of AU-rich elements within mRNAs bind proteins which aid the removal of the 
poly(A) tail, which in turn initiates decapping and the degradation by the exosome complex.  
As rs9659030 is located closer to the end of the transcript than rs1676486, if mRNA 
degradation is causing AEI at rs1676486 then it suggests that decapping and subsequent 5ʹ-3ʹ 
degrading of the mRNA transcript is affecting the AEI measured.  With rs9659030 being closer 
to the 3ʹ end of the transcript it would remain longer before being subjected to 5ʹ-3ʹ 
degradation. 
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Chapter 3: Deep Sequencing of GDF5 reveals the 
absence of rare variants 
3.1 Introduction 
 The hypothesis that common diseases are caused by common variants (126–129) has 
been at the forefront of thinking in case-control association studies for over a decade.  This 
hypothesis originally dictated that a common polymorphism had a minor allele frequency 
(MAF) of ≥1%, however in practice researchers often omit SNPs with MAFs of <5% (98).  The 
International HapMap Project (68) is a key resource for improving case-control studies, but 
currently concentrates on SNPs with MAFs of ≥5%.  Rare SNPs are often overlooked during 
case-control studies due to the reduced statistical power when cohorts are of limited size and 
also because common SNPs can significantly contribute to disease prevalence even if their 
effect on disease risk is modest.  While case-control association studies have yielded many 
polymorphisms that affect a person’s risk to common diseases, this dominance of common 
variants in research has deterred genotyping companies from including rare SNPs in coding 
and regulatory elements into their genotyping panels (98).   
 As mentioned previously, there are many factors that contribute to the development 
of OA including BMI, age, sex and genetic susceptibility. The genetic heritability of OA is 
estimated to be between 39-65% for the hand or knee, 58% for the hip and 63-79% for the 
spine (9).  However, few loci have achieved a genome-wide significance (p ≤ 5x10-8) of 
association in Europeans, GDF5 being one such loci.  These loci have small effect sizes and by 
no means account for the overall heritability attributed to OA.   
Gorlov et al. (2008) suggests that within the rare SNPs category lie slightly deleterious 
SNPs, SNPs which are subjected to weak purifying selection.  They also hypothesised that 
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slightly deleterious SNPs in genes implicated in disease pathways are mainly responsible for 
the inter-individual variation in susceptibility to complex disease.  This may be due “to the 
summation of the effects of a series of low frequency dominantly and independently acting 
variants of a variety of different genes, each conferring a moderate but readily detectable 
increase in relative risk” (99).  These SNPs have lower MAFs than common variants (which 
have MAFs of 1% or more), but they have higher MAFs than clearly deleterious SNPs (which 
have MAFs of 0.1% or less).  Slightly deleterious SNPs are in large numbers in the human 
genome, with the rare allele disrupting gene function and dramatically increasing 
susceptibility.  However, their actions are not strong enough to be eradicated from the 
population (98, 99).  The same can be said of course for slightly advantageous SNPs, where 
their actions are not strong enough to become fixed within a population.  OA is of course 
characteristically a late onset disease, when reproduction has been completed and so risk 
alleles are not affected by natural selection purely on their basis of disease risk.  It has been 
estimated that within the global population there should be on average at least two to three 
slightly deleterious SNPs per gene in the human genome (98), which leads to the idea that the 
discovery of these rare variants can radically improve the understanding of common complex 
disease susceptibility.  Such SNPs can be retained in the population by random genetic drift or 
population bottlenecks, however, as such SNPs are likely to be rather novel, evolutionarily 
speaking, then they are likely to be highly population specific (98, 99).  A strong criticism of the 
notion that slightly deleterious rare SNPs are responsible for common diseases is that their 
prevalence does not in any way reflect that of the disease in question (98).  This argument can 
be countered in that the slightly deleterious SNPs may be rare, but on the whole such SNPs are 
very common throughout the genome, particularly if the Gorlov et al.’s prediction of there 
being two to three rare variants within each gene of the genome is correct.  Conversely to this, 
rare variants may be slightly protective rather than deleterious, and such variants would have 
MAFs that were elevated in controls rather than cases (130). 
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The detection of rare causal variants is not possible using common tagSNPs in a GWAS 
as the weak correlations between the rare and common SNPs leave the study low-powered 
(97).  Instead the discovery of rare variants must be achieved by the re-sequencing of 
candidate genes in a cohort of both cases and controls.  If variants are slightly deleterious then 
they should be elevated in cases, where as if they are protective they should be elevated in 
controls.  For this reason it is important to re-sequence both groups, and not re-sequence 
cases and then merely genotype controls (97). 
As mentioned previously GDF5 harbours a common SNP, rs143383, who’s T-allele has 
been shown to associate with OA.  This association signal has been replicated in both Japanese 
(52) and European (55) populations.  This makes GDF5 a good candidate for re-sequencing to 
look for rare variants which could account for some of the missing heritability in OA.  One such 
example of this approach in another disease is that of the resequencing of interferon induced 
with helicase C domain 1 (IFIH1), a gene located within a genetic region shown by GWAS to be 
associated with type 1 diabetes (130).  In this study, four rare variants were discovered with 
MAFs ranging from 0.46-1.1% in patients with type 1 diabetes.  These MAFs were all elevated 
in controls.  The variants all associated with disease; with the rare alleles consistently 
protecting against type 1 diabetes, and the common allele carried by the majority of the 
population predisposing the carrier to type 1 diabetes. 
3.2 Aims of this study 
 The aim of this study is to interrogate the genetic architecture of this important OA 
locus in both OA cases and symptom free controls.  This was to be achieved by resequencing 
GDF5, including its promoter, UTRs and open reading frame in 502 OA and 460 controls, 
looking for novel variants and cataloguing the allele frequencies of common known 
polymorphisms. 
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3.3 Materials and methods 
3.3.1 Cases and controls 
There were a total of 502 cases (383 females and 119 males; 220 knee cases and 282 
hip) and 460 controls (184 females and 276 males). These cases were ascertained using the 
criteria of signs and symptoms of OA sufficiently severe to require joint replacement surgery.  
The radiological stage of the disease was a Kellgren and Lawrence grade of 2 or more in all 
cases with over 90% beng grade 3 or 4.  Inflammatory arthritis (rheumatoid, polyarthritic or 
autoimmune disease) was excluded, as was post-traumatic or post-septic arthritis.  The cases 
had an age range of 56-85 years.  The controls had no signs or symptoms of arthritis or joint 
disease (pain, swelling, tenderness or restriction of movement) and had an age range of 55-89 
years.  Ethical approvals for the use of the DNAs in OA genetic studies was obtained from the 
Oxfordshire Clinical Research Ethics Committee (COREC reference 541). 
3.3.2 Sequence analysis of GDF5 
DNA was extracted from peripheral blood samples using guanidine hydrochloride by 
members of my supervisor’s research group prior to my undertaking of this study.  Deep 
sequencing of GDF5 was carried out by resequencing the 962 cases and controls (1 924 
chromosomes) using six PCR amplicons.  Genomic DNA was first amplified by PCR in a 15 μl 
reaction containing 50 ng DNA, along with 7.5 μM of forward and 7.5 μM of reverse primer, 
1.5 μl of 10X PCR buffer (50 mM KCl, 10 mM Tris-HCl pH 8.3), 1 or 2 mM MgCl2 (depending 
upon primer pairs used), 0.2 mM dNTPs, 0.08 units of AmpliTaq Gold DNA polymerase (Applied 
Biosystems) and the total volume was brought up to 15 μl using H2O.  For amplicons 1, 2 and 4-
6 specific M13 phage DNA sequence was included to the 5ʹ end of the forward and reverse 
primers.  Incorporating these M13 sequences into the amplicons allowed for the same 
sequencing primers and the same sequencing reaction conditions to be used when amplicons 
1, 2 and 4-6 were sequenced.  This was found not to be of benefit for amplicon 3, which was 
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sequenced without the addition of the M13 sequences to the PCR primers.  For amplicon 4 the 
use of PCR primers at a concentration of 0.75 μM together with the addition of 25% betaine 
(Sigma Aldrich) to the PCR reaction was needed to generate an intense PCR product.  
Thermocycling conditions were 94oC for 4 minutes, followed by a denaturation step of 94oC for 
30 seconds, a specific annealing temperature step for 30 seconds, an extension step of 72oC 
for 1 minute, cycled 35-40 times.  Table 3.1 lists the sequences of the PCR primers, the 
annealing temperatures and MgCl2 concentrations used in the PCRs, and the length of the 
amplified products.   After amplification and prior to the sequencing chemistry reaction, 10 μl 
of PCR product was incubated with 2.4 units of Shrimp Alkaline Phosphatase (SAP) (Fisher 
Scientific UK), 12 units of Exonuclease I (EXO) (New England Biolabs) and 1.4 μl of 10X 
Exonuclease I buffer (New England Biolabs) for 15 minutes at 37oC followed by another 15 
minute incubation at 80oC.  The sequencing chemistry reaction was performed with the BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).  6 μl of the SAP/EXO treated PCR 
product was added to 0.5 μl of BigDye premix v3.1, 2 μl of 5X BigDye v3.1 Sequencing Buffer, 
1.2 μl of H2O and 30 μM of M13 reverse primer (amplicons 1,2, 5 and 6), or 30 μM of Amp 3 7F 
forward primer for amplicon 3 (Table 3.1).  Amplicon 4 contained 240 μM M13 reverse primer.  
This reaction mixture was incubated for 25 cycles of 96oC for 10 seconds, 50oC for 5 seconds, 
and 60oC for 4 minutes with temperature ramping at 1oC/second.   
To precipitate the 10 μl of sequencing products, 10 μl of H2O were added along with 
60 μl of 100% ethanol and 0.1 μl of Pellet Paint Non-Fluorescent Co-Precipitant (Novagen) with 
the mixture then incubated for 30 minutes at room temperature and in the dark.  After the 
incubation, the products were centrifuged at room temperature at 1 600 g for 45 minutes 
followed by the removal of the supernatant via an inversion of the sample and brief centrifuge 
ramping up to 50 g.  To each pellet, 70 μl of 70% (volume/volume) ethanol was added and this 
mixture was again centrifuged at 1,600 g, this time for 15 minutes.  After removal of the 
supernatant, the pellet was resuspended in 10 μl of Hi-Di formamide (Applied Biosystems) and 
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10 μl of H2O.  These products were then separated by electrophoresis through a 36 cm 
capillary array with POP-7 polymer (Applied Biosystems) at 55oC using an Applied Biosystems 
3130xl Genetic Analyzer.  These data were then analysed with the Sequencing Analysis and 
Seqscape software (Applied Biosystems). 
3.3.3 Verification of novel variants 
In order to verify the novel variants discovered, new sequencing primers were 
designed and each relevant patient was re-sequenced in the opposite strand to the strand that 
was sequenced when the variant was discovered.  The primers used along with their PCR 
conditions are listed in Table 3.2.  In addition to re-sequencing, a restriction fragment length 
polymorphism (RFLP) assay was designed to further confirm the existence of a variant 
discovered in amplicon 1.  An elongated forward primer with a single base change (underlined) 
was synthesised in order to force a HinfI restriction site (5ʹ-
AAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGCGATT-3ʹ).  This primer was 
used in conjunction with a standard reverse primer (5ʹ-CCGGGTGTGTGTTTGTATCCAG-3ʹ).  PCR 
was carried out as described in Section 3.3.2, using an annealing temperature of 64oC and a 
MgCl2 concentration of 2 mM.  The HinfI restriction site of GANTC allows HinfI to cut the 
wildtype C-allele producing two fragments of 190 bp and 50 bp in length, where as a mutant 
allele would remain uncut with a single 240 bp undigested band (Figure 3.1).  Five units of HinfI 
were added to a 15 µl PCR in addition to 2 µl of 10X Buffer 2 (New England Biolabs) and the 
reaction made up to 20 µl with H2O.  This digestion mix was then incubated at 37
oC for 3 hours 
and then electrophoresed on a 3% (weight/volume) agarose gel. 
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TGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAAGTATTTTC 
ACTGGAAAGGATTCAAAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGC 
GATTCTTCCTTCTTGGAAAAATCCCTCAGCCTTATACAAGCCTCCTTCAAGCCCTCAGTC 
AGTTGTGCAGGAGAAAGGGGGCGGTTGGCTTTCTCCTTTCAAGAACGAGTTATTTTCAGC 
TGCTGACTGGAGACGGTGCACGTCTGGATACGAGAGCATTTCCACTATGGGACTGGATAC 
AAACACACACCCGGCAGACTTCAAGAGTCTCAGACTGAGGAGAAAGCCTTTCCTTCTGCT 
GCTACTGCTGCTGCCGCTGCTTTTGAAAGTCCACTCCTTTCATGGTTTTTCCTGCCAAAC 
CAGAGGCACCTTTGCTGCTGCCGCTGTTCTCTTTGGTGTCATTCAGCGGCTGGCCAGAGG 
ATGAGACTCCCCAAACTCCTCACTTTCTTGCTTTGGTACCTGGCTTGGCTGGACCTGGAA 
 
TGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAAGTATTTTC 
ACTGGAAAGGATTCAAAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGC 
GATTATTCCTTCTTGGAAAAATCCCTCAGCCTTATACAAGCCTCCTTCAAGCCCTCAGTC 
AGTTGTGCAGGAGAAAGGGGGCGGTTGGCTTTCTCCTTTCAAGAACGAGTTATTTTCAGC 
TGCTGACTGGAGACGGTGCACGTCTGGATACGAGAGCATTTCCACTATGGGACTGGATAC 
AAACACACACCCGGCAGACTTCAAGAGTCTCAGACTGAGGAGAAAGCCTTTCCTTCTGCT 
GCTACTGCTGCTGCCGCTGCTTTTGAAAGTCCACTCCTTTCATGGTTTTTCCTGCCAAAC 
CAGAGGCACCTTTGCTGCTGCCGCTGTTCTCTTTGGTGTCATTCAGCGGCTGGCCAGAGG 
ATGAGACTCCCCAAACTCCTCACTTTCTTGCTTTGGTACCTGGCTTGGCTGGACCTGGAA 
 
Figure 3.1 HinfI RFLP assay.  Top) GDF5 proximal promoter containing the wildtype C-allele of 
the -41 bp variant (C – large bolded) and immediate 5ʹ sequence (highlighted orange).  
Forward RFLP primer (highlighted green) with forced base change (red and underlined G) and 
reverse primer (highlighted blue).  The black box indicates a positive site for HinfI digestion.  
Below) As above, but variant A-allele of the -41 bp variant (A- large bolded). No HinfI digestion 
site is present. 
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Table 3.1 Primer sequences and PCR conditions used .  Underlined bases denote GDF5 specific sections of each primer.  Also listed are the sequences of the M13 
primers used in the sequencing reactions of amplicons 1, 2 and 4-6. 
 
 
 
    MgCl2 Annealing  Number of  Amplicon 
Amplicon Primer name Primer Sequence (5' - 3') Concentration Temperature Cycles Length 
1 Amp 1 1F TGTAAAACGACGGCCAGTATTTTCACTGGAAAGGATTC 
1 mM 66oC 35 513   Amp 1 1R CAGGAAACAGCTATGACCAGGGGCACCCAACACAGTGC 
2 Amp 2 3F TGTAAAACGACGGCCAGTACACCCGGCAGACTTCAAGAG 
1 mM 70oC 35 540   Amp 2 3R CAGGAAACAGCTATGACCGACAGATCCTGCTTTTGGGGG 
3 Amp 3 7F GCCCGGAACGTCTTCAGGCCAG 
1 mM 64oC 35 551   Amp 3 7R TGCCAGGGCTTTGAAAGCCCCT 
4 Amp 4 2F TGTAAAACGACGGCCAGTTCGAAGTGACTGGCTCCCTTG 
2 mM 56oC 40 712   Amp 4 3R CAGGAAACAGCTATGACCTGGAAAGCCTCGTACTCAAGG 
5 Amp 5 1F TGTAAAACGACGGCCAGTCTGGCCAGGACGATAAGACC 
2 mM 68oC 35 679   Amp 5 2R CAGGAAACAGCTATGACCGAGTCTGTCTCCCTGGACCTG 
6 Amp 6 2F TGTAAAACGACGGCCAGTTTCCTGCACTCCTGGAATCAC 
2 mM 66oC 35 630   Amp 6 1R CAGGAAACAGCTATGACCGATAGGGCTCTGAAAACTGAG 
              
  M13-F   TGTAAAACGACGGCCAGT N/A 50oC 25   
  M13-R CAGGAAACAGCTATGACC N/A 50oC 25   
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Table 3.2 Primer sequences and PCR conditions used for variant verification.  Underlined bases denote GDF5 specific sections of each primer. 
 
   
MgCl2 Annealing Number of   
Variant 
 
Primer Sequence (5' - 3') Concentration Temperature Cycles   
1 
 
TGTAAAACGACGGCCAGTGATTTTTCTGAGCACCTGCAG 
1 mM 62oC 35 
   
CAGGAAACAGCTATGACCGCAGTAGCAGCAGAAGGAAAG 
2, 3 
 
TGTAAAACGACGGCCAGTCACTCCTTTCATGGTTTTTCC 
2mM 60oC 35 
   
TGTAGCCTGCCTTGTTTGGG 
4, 5 
 
TGTAAAACGACGGCCAGTTCGAAGTGACTGGCTCCCTTG 
3 mM 59oC 35 
25% 
  
CAGGAAACAGCTATGACCAGAACAGGTCCCGTTTCTTGGTG Betaine 
6 
 
TGTAAAACGACGGCCAGTAAGGCACTGCATGTCAACTTC 
2 mM 66oC 35 
   
CAGGAAACAGCTATGACCGAGTCTGTCTCCCTGGACCTG 
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3.3.3 Online prediction databases 
 In order to assess the implications of a variant discovered within the promoter of GDF5, 
two online prediction databases were used; Promo 3.0 (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) and TESS: Transcription Element Search 
System (http://www.cbil.upenn.edu/cgi-bin/tess/tess).  To assess the implications of a non-
synonymous variant, PolyPhen (http://genetics.bwh.harvard.edu/pph2/) was used, which gave a 
prediction on the effect of the variant on protein function ranging from benign to seriously 
damaging. 
3.3.4 Protein modelling 
 To model and mutate a non-synonymous variant I used a program called Coot (131) in 
collaboration with Professor Rick Lewis of the Institute of Cell and Molecular Biosciences at 
Newcastle University.  The images from this modelling were created using the program PyMOL 
(pymol.sourceforge.net/). 
3.4 Results 
In order to cover both exons of GDF5, as well as the proximal promoter and the 
exon/intron boundaries, six PCR amplicons were designed.  These six PCR amplicons covered 
111 bp of the proximal promoter, the whole 2 383 bp transcript including both 5ʹ and 3ʹ UTRs as 
well as 76 bp of intronic sequence following exon one, 60 bp of intronic sequence before exon 
two and 114 bp of intergenic sequence following exon 2.  These amplicons varied both in length 
and ease of amplification, with the shortest being 513 bp and the largest being 712 bp (Figures 
3.2 and 3.3). 
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  ATTCCGTTTCCAATTCCTGAGTTCAGGTTTGTAAAAGATTTTTCTGAGCACCTGCAGGCC 
  TGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAAGTATTTTC   
Amp1 1F ACTGGAAAGGATTCAAAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGC 
  CATTCTTCCTTCTTGGAAAAATCCCTCAGCCTTATACAAGCCTCCTTCAAGCCCTCAGTC 
  AGTTGTGCAGGAGAAAGGGGGCGGTTGGCTTTCTCCTTTCAAGAACGAGTTATTTTCAGC 
  TGCTGACTGGAGACGGTGCACGTCTGGATACGAGAGCATTTCCACTATGGGACTGGATAC 
  AAACACACACCCGGCAGACTTCAAGAGTCTCAGACTGAGGAGAAAGCCTTTCCTTCTGCT  Amp2 3F 
  GCTACTGCTGCTGCCGCTGCTTTTGAAAGTCCACTCCTTTCATGGTTTTTCCTGCCAAAC 
  CAGAGGCACCTTTGCTGCTGCCGCTGTTCTCTTTGGTGTCATTCAGCGGCTGGCCAGAGG 
  ATGAGACTCCCCAAACTCCTCACTTTCTTGCTTTGGTACCTGGCTTGGCTGGACCTGGAA 
EXON 1 TTCATCTGCACTGTGTTGGGTGCCCCTGACTTGGGCCAGAGACCCCAGGGGACCAGGCCA  Amp1 1R 
  GGATTGGCCAAAGCAGAGGCCAAGGAGAGGCCCCCCCTGGCCCGGAACGTCTTCAGGCCA  Amp3 7F 
  GGGGGTCACAGCTATGGTGGGGGGGCCACCAATGCCAATGCCAGGGCAAAGGGAGGCACC 
  GGGCAGACAGGAGGCCTGACACAGCCCAAGAAGGATGAACCCAAAAAGCTGCCCCCCAGA 
  CCGGGCGGCCCTGAACCCAAGCCAGGACACCCTCCCCAAACAAGGCAGGCTACAGCCCGG 
  ACTGTGACCCCAAAAGGACAGCTTCCCGGAGGCAAGGCACCCCCAAAAGCAGGATCTGTC  Amp2 3R 
  CCCAGCTCCTTCCTGCTGAAGAAGGCCAGGGAGCCCGGGCCCCCACGAGAGCCCAAGGAG 
  CCGTTTCGCCCACCCCCCATCACACCCCACGAGTACATGCTCTCGCTGTACAGGACGCTG 
  TCCGATGCTGACAGAAAGGGAGGCAACAGCAGCGTGAAGTTGGAGGCTGGCCTGGCCAAC 
  ACCATCACCAGCTTTATTGACAAAGGGCAAGGTGAGGGGGCGGGGTGGCAGGGGCACGGC 
  TCAGAGGGAGGGGCATCTGCATGAATGGAGGGGCTTTCAAAGCCCTGGCACTGCCCTGGT  Amp3 7R 
  GGGAGACACTGTGTGCATCTGGCCCGGGGTGGGTGTCTGGGGACACTGACACATATCTCA 
  CACATAGCAGATCCTAGGCTGCCCACACATCAGGGCTGGAGGGCACCTAGGAAGCACCAG 
 
  CAGAATGGGGCAGAGGTGAAAGAAAGCTCTCTGGACGGGGAGAGAGCTGGGGCCTTCCCC 
  CGCAGCCTCGAAGTGACTGGCTCCCTTGGTGAGGTTGCAGGGAATGACTTCTGGGTGTTC  Amp4 2F 
  TCTCTAGATGACCGAGGTCCCGTGGTCAGGAAGCAGAGGTACGTGTTTGACATTAGTGCC 
  CTGGAGAAGGATGGGCTGCTGGGGGCCGAGCTGCGGATCTTGCGGAAGAAGCCCTCGGAC 
  ACGGCCAAGCCAGCGGCCCCCGGAGGCGGGCGGGCTGCCCAGCTGAAGCTGTCCAGCTGC 
  CCCAGCGGCCGGCAGCCGGCCTCCTTGCTGGATGTGCGCTCCGTGCCAGGCCTGGACGGA 
  TCTGGCTGGGAGGTGTTCGACATCTGGAAGCTCTTCCGAAACTTTAAGAACTCGGCCCAG 
  CTGTGCCTGGAGCTGGAGGCCTGGGAACGGGGCAGGGCCGTGGACCTCCGTGGCCTGGGC 
  TTCGACCGCGCCGCCCGGCAGGTCCACGAGAAGGCCCTGTTCCTGGTGTTTGGCCGCACC 
  AAGAAACGGGACCTGTTCTTTAATGAGATTAAGGCCCGCTCTGGCCAGGACGATAAGACC  Amp5 1F 
  GTGTATGAGTACCTGTTCAGCCAGCGGCGAAAACGGCGGGCCCCACTGGCCACTCGCCAG 
  GGCAAGCGACCCAGCAAGAACCTTAAGGCTCGCTGCAGTCGGAAGGCACTGCATGTCAAC 
  TTCAAGGACATGGGCTGGGACGACTGGATCATCGCACCCCTTGAGTACGAGGCTTTCCAC  Amp4 3R 
EXON 2 TGCGAGGGGCTGTGCGAGTTCCCATTGCGCTCCCACCTGGAGCCCACGAATCATGCAGTC 
  ATCCAGACCCTGATGAACTCCATGGACCCCGAGTCCACACCACCCACCTGCTGTGTGCCC 
  ACGCGGCTGAGTCCCATCAGCATCCTCTTCATTGACTCTGCCAACAACGTGGTGTATAAG 
  CAGTATGAGGACATGGTCGTGGAGTCGTGTGGCTGCAGGTAGCAGCACTGGCCCTCTGTC 
  TTCCTGGGTGGCACATCCCAAGAGCCCCTTCCTGCACTCCTGGAATCACAGAGGGGTCAG  Amp6 2F 
  GAAGCTGTGGCAGGAGCATCTACACAGCTTGGGTGAAAGGGGATTCCAATAAGCTTGCTC 
  GCTCTCTGAGTGTGACTTGGGCTAAAGGCCCCCTTTTATCCACAAGTTCCCCTGGCTGAG 
  GATTGCTGCCCGTCTGCTGATGTGACCAGTGGCAGGCACAGGTCCAGGGAGACAGACTCT  Amp5 2R 
  GAATGGGACTGAGTCCCAGGAAACAGTGCTTTCCGATGAGACTCAGCCCACCATTTCTCC 
  TCACCTGGGCCTTCTCAGCCTCTGGACTCTCCTAAGCACCTCTCAGGAGAGCCACAGGTG 
  CCACTGCCTCCTCAAATCACATTTGTGCCTGGTGACTTCCTGTCCCTGGGACAGTTGAGA 
  AGCTGACTGGGCAAGAGTGGGAGAGAAGAGGAGAGGGCTTGGATAGAGTTGAGGAGTGTG 
  AGGCTGTTAGACTGTTAGATTTAAATGTATATTGATGAGATAAAAAGCAAAACTGTGCCT 
  AAAACTGTGGCAAATTTCTTGTTTACTCCAGGGGACCCAGTGACCCCTTGAAGAATTACT 
  GACCCAGGGCAGGGAGGTGGGTTGCTTCATGTATAAACTCAGTTTTCAGAGCCCTATCCC  Amp6 1R 
 
Figure 3.2 GDF5 Sequencing amplicons.  All six sequencing amplicons are shown with each 
colour depicting a primer pair. Green shows amplicon 1 primers, blue shows amplicon 2 
primers, violet shows amplicon 3 primers all of which cover the 5ʹ UTR and exon 1 (upper 
highlighted section) and its flanking sequence.  The ATG start codon is shown in black.  In 
exon 2 and the 3ʹ UTR (lower highlighted section), pink shows amplicon 4 primers, yellow 
shows amplicon 5 primers and red shows amplicon 6 primers.  The TAG stop codon is shown 
in black. 
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Figure 3.3 Sequenced areas of GDF5 and amplicon locations.  Schematic showing the areas of GDF5 covered by each amplicon.  Arrows depict the direction the 
sequence was generated, relative to transcription. 
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3.4.1 Amplicon 1 
Amplicon 1, once amplified and sequenced, produced an average read length of 354 
bp.  Successful sequencing data was generated from 458 OA cases and 418 controls (1 752 
chromosomes).  In addition to common catalogued SNPs, a novel variant was discovered in a 
female control individual from this cohort (Figure 3.4, Panel A).  This mutation, a C to A 
transversion, resides 41 bp upstream of the transcription start site of GDF5.  According to the 
online database PROMO, this -41 bp variant lies within several possible trans-acting factor 
binding sites, including YY1, UCRBP, SOX9, SEF-4, VDR and abaA (Figure 3.5).  A RFLP assay 
(Figure 3.4, Panel D) and resequencing in the reverse direction using new primers that reside 
distal to the original amplicon 1 PCR primers, were used to confirm the mutation (Figure 3.4, 
Panel B).  An unrelated control individual was also sequenced to demonstrate the wildtype 
sequence (Figure 3.4, Panel C). 
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Figure 3.4 The -41 bp mutation identified in a female control individual (variant 1).  (A) 
Electropherogram showing two alleles, A and C, following sequencing of amplicon 1 in the 
female control. Sequence is shown along the top along with a bar height corresponding to the 
confidence in which the Sequencing Analysis program calls each base.  Blue corresponds to the 
greatest confidence, yellow is low confidence and red is zero confidence.  (B) 
Electropherogram showing the same double peak when the individual was resequenced using 
a new primer pair. (C) Electropherogram showing only a single allele present in an unrelated 
individual when sequenced using the same conditions as in B.  (D) Agarose gel image of an 
RFLP assay along with a 100 bp ladder, carried out when DNA from the individual carrying the 
variant (three replicates, lanes 1-3) and four unrelated individuals (lanes 4-7) were PCR 
amplified and then digested with HinfI restriction enzyme, which cuts only when the C allele is 
present (lane 8 is a PCR blank). 
 
1 2 3 4 5 6 7 8 
100 bp 
200 bp 
300 bp 
B A 
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A/C A/C 
C 
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TGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAAGTATTTTC 
ACTGGAAAGGATTCAAAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGC 
CATTCTTCCTTCTTGGAAAAATCCCTCAGCCTTATACAAGCCTCCTTCAAGCCCTCAGTC 
AGTTGTGCAGGAGAAAGGGGGCGGTTGGCTTTCTCCTTTCAAGAACGAGTTATTTTCAGC 
TGCTGACTGGAGACGGTGCACGTCTGGATACGAGAGCATTTCCACTATGGGACTGGATAC 
AAACACACACCCGGCAGACTTCAAGAGTCTCAGACTGAGGAGAAAGCCTTTCCTTCTGCT 
 
CGCCATTCTTCCTT  CGCCATTCTTCCTT 
  CCATTTT - YY1   GGATCCTGTCG – SOX9 
CGCCATTATTCCTT  CGCCATTATTCCTT 
 
CGCCATTCTTCCTT  CGCCATTCTTCCTT 
CGCCATTCT – UCRBP         CATTCTT – SEF-4 
CGCCATTATTCCTT  CGCCATTATTCCTT 
 
CGCCATTCTTCCTT  CGCCATTCTTCCTT 
   CATTCTTCC – VDR     CATTCT – abaA 
CGCCATTATTCCTT  CGCCATTATTCCTT 
 
Figure 3.5 Predicted binding trans-factors.  Top) GDF5 proximal promoter sequence (non-
highlighted) and initial 5ʹ UTR sequence (highlighted) with the -41 bp wildtype allele 
highlighted green.  Below) -41 bp wildtype allele (geeen), variant (blue) and immediate 
sequence surrounding site shown next to predicted binding trans-acting factors and their 
consensus sequences, as given from the PROMO transcription factor binding prediction 
database. 
 
3.4.2 Amplicon 2 
Amplicon 2 produced an average read length of 457 bp, including a degree of overlap 
with amplicon 1.  Successful sequencing data was generated from 491 OA cases and 425 
controls (1 832 chromosomes).  From these individuals, two mutations were discovered.  One 
was a G to A transition within the coding region of exon 1 in a female OA patient (Figure 3.6, 
Panel A).  This transition is synonymous.  This mutation was verified by resequencing of the 
region with new primers (Figure 3.6, Panel B).  The second mutation was also found in the 
coding region of exon 1, in a male OA patient.  This mutation, a G to A transition (Figure 3.7, 
Panel A), is predicted to cause an amino acid substitution at position 81 of the GDF5 protein.  
The wild type glycine residue is neutral and non-polar whereas the substitution would be to an 
arginine residue which is polar and positively charged. The glycine residue is highly conserved 
in mammals (Figure 3.8).  The variant was also verified using the new primers.  This non-
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synonymous mutation was however predicted to be benign by the PolyPhen protein prediction 
database. 
 
 
Figure 3.6 The exon 1 synonymous mutation identified in a female OA patient (variant 2).  (A) 
Electropherogram showing two alleles, A and G, following sequencing of amplicon in the 
female OA patient. Sequence is shown along the top along with a bar height corresponding to 
the confidence in which the Sequencing Analysis program calls each base.  Blue corresponds to 
the greatest confidence, yellow is low confidence and red is zero confidence.  (B) 
Electropherogram showing the same double peak when the individual was resequenced using 
a new primer pair. (C) Electropherogram showing only a single wildtype allele, G, present in an 
unrelated individual when sequenced using the same conditions as in B. 
A B 
C 
A/G 
A/G 
G 
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Figure 3.7 The exon 1 non-synonymous mutation identified in a male OA patient (variant 3).  
(A) Electropherogram showing two the alleles, A and G, following sequencing of amplicon 2 in 
the male OA patient. Sequence is shown along the top along with a bar height corresponding 
to the confidence in which the Sequencing Analysis program calls each base.  Blue corresponds 
to the greatest confidence, yellow is low confidence and red is zero confidence.  (B) 
Electropherogram showing the same double peak when the individual was resequenced using 
a new primer pair. (C) Electropherogram showing only the single wildtype allele, G, present in 
unrelated individual when sequenced using the same conditions as in B. 
  
A B 
C 
A/G 
A/G 
G 
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Human           GGHSYGGGATNANARAKGGTGQTGGLTQPKKDEPKKLPPRPGGPEPKPGHPPQTRQATAR 120 
Gorilla         GGHSYGGGATNANARAKGGTGQTGGLTQPRKDEPKKLPPRPGGPEPKPGHPPQTRQATAR 120 
Chimpanzee      GGHSYGGGATNANARAKGGTGQKGGLTQPKKDEPKKLPPRPGGPEPKPGHPPQTRQTTAR 120 
Orangutan       GGHSYGGGAANANARAKGGTGQTGGLTQPKKDEPKKLSPRPGGPEPKPGHPPQTRQATAR 120 
Macaque         GGHSYGGGA--ANARAKGGTGHTGGLTQPKKDEPKKLPPRPGGPEPKPGHPPQTRQATAR 118 
Dog             GGHSYGGGA--ANARAKGGTGQTGGLTQPKKDEPKKLPPRPGSPEPKPGHPTQTRQAAPR 118 
Mouse           GGHIYGVGA--TNARAKGSSGQ----TQAKKDEPRKMPPRSGGPETKPGPSSQTRQAAAR 114 
Zebra fish      ------------------------------------------------------------ 
Xenopus         RTGILGHGVGLQKGRSKVPLVQSRIFLSKNEDIKKQAASRAN-PHVKTGN-AENRQSGEK 115 
                *********:**:*:*:**:**********:**********.:***************** 
Figure 3.8 Amino acid sequence alignments.  (A) The amino acid sequence alignment proximal 
to the non-synonymous mutation identified in exon 1 of an OA patient (Variant 3).  The 
wildtype amino acid residue is highlighted in blue, and shows that in mammals the glycine 
residue is highly conserved.  This mutation was predicted to be benign. 
 
3.4.3 Amplicon 3 
Amplicon 3, produced an average read length of 441 bp, including a 24 bp overlap with 
amplicon 2.  Successful sequencing data was generated for a total of 442 OA cases and 332 
controls (1 548 chromosomes).  No novel mutations were discovered. 
3.4.4 Amplicon 4 
Amplicon 4, which covered the 5ʹ end of the second exon of GDF5, produced an 
average read length of 546 bp.  Successful sequencing data was generated for 474 OA cases 
and 389 controls (1 726 chromosomes).  From the sequencing of these individuals two novel 
mutations were discovered (Figures 3.9 and 3.10, Panels A), both of which are synonymous C 
to T transitions with the first found in a male control individual and the second in a female 
control individual.  Both mutations were verified by resequencing each using new primers. 
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Figure 3.9 The exon 2 synonymous mutation identified in a male control individual (variant 
4).  (A) Electropherogram showing two alleles, C and T, following sequencing of amplicon 4 in 
the male control. Sequence is shown along the top along with a bar height corresponding to 
the confidence in which the Sequencing Analysis program calls each base.  Blue corresponds to 
the greatest confidence, yellow is low confidence and red is zero confidence.  (B) 
Electropherogram showing the same double peak when the individual was resequenced using 
a new primer pair. (C) Electropherogram showing only the single wildtype allele, C, present in 
an unrelated individual when sequenced using the same conditions as in B. 
  
A B 
C 
C/T 
C/T 
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Figure 3.10 The exon 2 synonymous mutation identified in a female control individual 
(variant 5).  (A) Electropherogram showing two alleles, C and T, following sequencing of 
amplicon 4 in the female control. Sequence is shown along the top along with a bar height 
corresponding to the confidence in which the Sequencing Analysis program calls each base.  
Blue corresponds to the greatest confidence, yellow is low confidence and red is zero 
confidence.  (B) Electropherogram showing the same double peak when the individual was 
resequenced using a new primer pair. (C) Electropherogram showing only the single wildtype 
allele, C, present in an independent control individual when sequenced using the same 
conditions as in B. 
  
A B 
C 
C/T 
C/T 
C 
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3.4.5 Amplicon 5 
Amplicon 5 covered the intermediate section of exon 2 producing an average 
sequencing read length of 454 bp which overlapped with amplicons 4 and 6.  Successful 
sequencing data was generated for 495 OA cases and 436 controls (1 862 chromosomes).  
From these individuals, one mutation was detected in a control individual (Figure 3.11, Panel 
A).  This mutation is predicted to result in a non-synonymous amino acid substitution and was 
validated by resequencing it using new primers (Figure 3.11, Panel B).  The C to G transversion 
results in a non-polar, neutral, highly conserved (Figure 3.12) threonine residue being 
substituted by a non-polar but positively charged arginine residue at position 469.  This amino 
acid substitution is predicted to be “possibly damaging” by PolyPhen. When GDF5 was 
modelled using the program Coot, Thr469 was shown to be interacting with a serine residue at 
position 115.  It was also apparent that the threonine rotamer is most likely to be the standard 
rotamer for this side chain as seen in 49% of all threonine conformations (131).  After in silico 
mutating of Thr469 to an arginine, which has a much longer side chain, it was apparent that 
the serine interaction is lost and the integration of this amino acid side chain becomes much 
more complex, with the suggested rotamer only observed in 9% of all arginine rotamers, and 
with another 32 possible rotamers suggested all with less frequency.  The mutant Arg469 side 
chain becomes too close to Leu441 and Arg501 to allow for a wildtype protein folding due to 
the large collection of positive charge (Figure 3.13).  In the GDF5 dimer the threonine 469s are 
only 10 Å apart, this is too small a distance to accommodate the arginine side chain coupled 
with its positive charge along with that of arginine 501. 
78 
 
 
 
Figure 3.11 The exon 2 non-synonymous mutation identified in a female control individual 
(variant 6).  (A) Electropherogram showing two alleles, C and G, following sequencing of 
amplicon 5 in the female control. Sequence is shown along the top along with a bar height 
corresponding to the confidence in which the Sequencing Analysis program calls each base.  
Blue corresponds to the greatest confidence, yellow is low confidence and red is zero 
confidence.  (B) Electropherogram showing the same double peak when the individual was 
resequenced using a new primer pair. (C) Electropherogram showing only the single wildtype 
allele, C, present in an independent control individual when sequenced using the same 
conditions as in B. 
  
A B 
C 
C/G 
C/G 
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Human           IIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISIL 477 
Gorilla         IIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISIL 477 
Chimpanzee      IIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISIL 477 
Orangutan       IIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISIL 477 
Macaque         IIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISIL 475 
Dog             IIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISIL 475 
Mouse           IIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISIL 471 
Zebra fish      IIAPLEYEAFHCDGVCDFPIRSHLEPTNHAIIQTLMNSMDPRSTPPTCCVPTRLSPISIL 233 
Xenopus         IIAPLEYEAYHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPETTPPTCCVPTRLSPISIL 472 
                *********:**:*:*:**:**********:**********.:***************** 
 
Figure 3.12 Amino acid sequence alignments.  The amino acid sequence alignment proximal 
to the non-synonymous mutation identified in exon 2 of a female control individual (variant 6).  
This threonine residue (highlighted in red) is highly conserved across many species, not just 
mammals.  The mutation to an arginine residue is predicted to be possibly damaging. 
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Figure 3.13 Protein model of a single GDF5 molecule.  Left, shows the 3D structure of a single GDF5 molecule with both threonine 469 (shown in 
green) and arginine 469 (shown in yellow) as well as the C- and N-termini.  Right, shows the area surrounding position 469 more clearly.  Wildtype 
amino acids are shown with green carbons, whereas the variant Arg469’s carbons are coloured yellow.  Blue depicts nitrogen atoms and red depicts 
oxygen atoms.  As shown the extended sidechain of the variant Arg469 brings it into close proximity with both Arg501 and Leu441, both of which 
carry a positive charge. 
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3.4.6 Amplicon 6 
Amplicon 6 covered the 3ʹ end of exon 2 producing an average read length of 528 bp 
with some overlap with amplicon 5.  Successful sequencing data was generated for 489 OA 
cases and 410 controls (1 798 chromosomes).  No novel mutations were discovered. 
3.4.7 Novel variants 
 Overall, six novel variants were identified, all extremely rare (Figure 3.14, Figure 3.15 
and Table 3.3).  Each variant was detected in a single individual, two in cases and four in 
controls, with each individual being heterozygote for the variant allele that they carry.  Variant 
1, discovered in a female control had a MAF of 0.0006 (MAF = number of variant alleles dived 
by the total number of chromosomes, ie. 1/1 752 for variant 1). Variant 2, discovered in a 
female case with knee OA and variant 3, discovered in a male case with knee OA both had 
MAFs of 0.0005.  Variants 4, discovered in a male control, and 5, discovered in a female 
control, both had MAFs of 0.0006.  Variant 6, discovered in a female control had a MAF of 
0.0005.  
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Figure 3.14 Locations of novel and known variants within GDF5.  Schematic diagram depicting the locations of the six novel variants (top) found by deep 
sequencing and the seven previously known variants (bottom) within GDF5. 
 
Table 3.3 Characteristics of each of the six novel mutations discovered within GDF5 and its proximal promoter. Numbers correspond with mutation location in 
relation to Figure 3.14 
 
Variant Individual Wild-type allele Mutant allele Location Predicted effect 
1 Control C A Promoter Alteration of a possible trans-factor binding site 
2 Case G A Exon 1 Synonymous, Gly67Gly 
3 Case G A Exon 1 Non-synonymous, Gly81Arg 
4 Control C T Exon 2 Synonymous, Gly285Gly 
5 Control C T Exon 2 Synonymous, Asp287Asp 
6 Control C G Exon 2 Non-synonymous, Thr469Arg 
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ATTCCGTTTCCAATTCCTGAGTTCAGGTTTGTAAAAGATTTTTCTGAGCACCTGCAGGCC 
TGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAAGTATTTTC 
ACTGGAAAGGATTCAAAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGC 
CATTMTTCCTTCTTGGAAAAATCCCTCAGCCTTATACAAGCCTCCTTCAAGCCCTCAGTC 
AGTTGTGCAGGAGAAAGGGGGCGGTYGGCTTTCTCCTTTCAAGAACGAGTTATTTTCAGC 
TGCTGACTGGAGACGGTGCACGTCTGGATACGAGAGCATTTCCACTATGGGACTGGATAC 
AAACACACACCCGGCAGACTTCAAGAGTCTCAGACTGAGGAGAAARCCTTTCCTTCTGCT 
GCTACTGCTGCTGCCGCTGCTTTTGAAAGTCCACTCCTTTCATGGTTTTTCCTGCCAAAC 
CAGAGGCACCTTYGCTGCTGCCGCTGTTCTCTTTGGTGTCATTCAGCGGCTGGCCAGAGG 
ATGAGACTCCCCAAACTCCTCACTTTCTTGCTTTGGTACCTGGCTTGGCTGGACCTGGAA 
TTCATCTGCACTGTGTTGGGTGCCCCTGACTTGGGCCAGAGACCCCAGGGGACCAGGCCA 
GGATTGGCCAAAGCAGAGGCCAAGGAGAGGCCCCCCCTGGCCCGGAACGTCTTCAGGCCA Bd-C 
GGGGGTCACAGCTATGGTGGRGGGGCCACCAATGCCAATGCCAGGGCAAAGGGAGGCACC 
RGGCAGACAGGAGGCCTGACACAGCCCAAGAAGGATGAACCCAAAAAGCTGCCCCCCAGA 
CCGGGCGGCCCTGAACCCAAGCCAGGACACCCTCCCCAAACAAGGCAGGCTACAGCCCGG 
ACTGTGACCCCAAAAGGACAGCTTCCCGGAGGCAAGGCACCCCCAAAAGCAGGATCTGTC 
CCCAGCTCCTTCCTGCTGAAGAAGGCCAGGGAGCCCGGGCCCCCACGAGAGCCCAAGGAG 
CCGTTTCGCCCACCCCCCATCACACCCCACGAGTACYTGCTCTCGCTGTACAGGACGCTG Bd-C 
TCCGATGCTGACAGAAAGGGAGGCAACAGCAGCGTGAAGTTGGAGGCTGGCCTGGCCAAC 
ACCATCACCAGCTTTATTGACAAAGGGCAAGGTGAGGGGGCGGGGTGGCAGGGGCACGGC 
TCAGAGGGAGGGGCATCTGCATGAATGGAGGGGCTTTCAAAGCCCTGGCACTGCCCTGGT 
GGGAGACACTGTGTGCATCTGGCCCGGGGTGGGTGTCTGGGGACACTGACACATATCTCA 
 
CAGAATGGGGCAGAGGTGAAAGAAAGCTCTCTGGACGGGGAGAGAGCTGGGGCCTTCCCC 
CGCAGCCTCGAAGTGACTGGCTCCCTTGGTGAGGTTGCAGGGAATGACTTCTGGGTGTTC 
TCTCTAGATGACCGAGGTCCCGTGGTCAGGAAGCAGAGGTACGTGTTTGACATTAGTGCC 
CTGGAGAAGGATGGGCTGCTGGGGGCCGAGCTGCGGATCTTGCGGAAGAAGCCCTCGGAC 
ACGGCCAAGCCAGCGGCCCCCGGAGGCGGGCGGGCTGCCCAGCTGAAGCTGTCCAGCTGC 
CCCAGCGGCCGGCAGCCGGCCTCCTTGCTGGATGTGCGCTCCGTGCCAGGYCTGGAYGGA 
TCTGGCTGGGAGGTGTTCGACATCTGGAAGCTCTTCRGAAACTTTAAGAACTCGGCCCAG CGT 
CTGTGCCTGGAGCTGGAGGCCTGGGAACGGGGCAGGGCCGTGGACCTCCGTGGCCTGGGC 
TTCGACCGCGCCGCCCGGCAGGTCCACGAGAAGGCCCTGTTCCTGGTGTTTGGCCGCACC 
AAGAAACGGGACCTGTTCTTTAATGAGATTAAGGCCCGCTCTGGCCAGGACGATAAGACC 
GTGTATGAGTACCTGTTCAGCCAGCGGCGAAAACGGCGGGCCCCACTGGCCACTCGCCAG 
GGCAAGCGACCCAGCAAGAACCTTAAGGCTCGCTYCAGTCGGAAGGCACTGCATGTCAAC CGT 
TTCAAGGACATGGGCTGGGACGACTGGATCATCGCACCCCTTGAGTACGAGGCTTTCCAC 
TGCGAGGGGCTGTGCGAGTTCCCATTGCGCTCCCACCRGGAGCCCACGAATCATGCAGTC Bd-A2 
ATCCAGACCCTGATGAACTCCATGGACCCCGAGTCCACACCACCCACCTGCTGTGTGCCC 
ASGCGGCTGAGTCCCATCAGCATCCTCTTCATTGACTCTGCCAACAACGTGGTGTAMAAG Bd-C 
CAGTATGAGGACATGGTCGTGGAGTCGTGTGGCTGCAGGTAGCAGCACTGGCCCTCTGTC 
TTCCTGGGTGGCACATCCCAAGAGCCCCTTCCTGCACTCCTGGAATCACAGAGGGGTCAG 
GAAGCTGTGGCAGGAGCATCTACACAGCTTGGGTGAAAGGGGATTCCAATAAGCTTGCTC 
GCTCTCTGAGTGTGACTTGGGCTAAAGGCCCCCTTTTATCCACAAGTTCCCCTGGCTGAG 
GATTGCTGCCCGTCTGCTGATGTGACCAGTGGCAGGCACAGGTCCAGGGAGACAGACTCT 
GAATGGGACTGAGTCCCAGGAAACAGTGCTTTCCGATGAGACTCAGCCCACCATTTCTCC 
TCACCTGGGCCTTCTCKGCCTCTGGACTCTCCTAAGCACCTCTCAGGAGAGCCACAGGTG 
CCACTGCCTCCTCAAATCACATTTGTGCCTGGTGACTTCCTGTCCCRGGGACAGTTGAGA 
AGCTGACTGGGCAAGAGTGGGAGAGAAGAGGAGAGGGCTTGGATAGAGTTGAGGAGTGTG 
AGGCTGTTAGACTGTTAGATTTAAATGTATATTGATGAGATAAAAAGCAAAACTGTGCCT 
AAAACTGTGGCAAATTTCTTGTTTACTCCAGGGGACCCAGTGACCCCTTGAAGAATTACT 
GACCCAGGGCAGGGAGGTGGGTTGCTTCATGTATAAACTCAGTTTTCAGAGCCCTATCCC 
R= A/G Y= C/T M= A/C K= G/T S= G/C W= A/T 
 
Figure 3.15 Variants within GDF5. GDF5 sequence with variants recorded (novel variants in 
blue and common, known variants in green).  Variants in red are disease causing; Brachytactyly 
type-C (Bd-C), chondrodysplasia Grebe Type (CGT) and Brachytactyly type A2 (Bd-A2) were not 
found. ATG translation start site and TAG stop codon are underlined.  The yellow bases mark 
the location of cleavage site. 
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3.4.8 Known variants 
GDF5 is 4.9 kb in length from its transcription start site to termination site and 
contains one intron between two exons coding for a 510 amino acid protein.  In addition to the 
six novel variants that I have discovered here, I also identified seven common variants that 
were previously known to exist in the gene: rs143383, rs73094730, rs143384, rs224331, 
rs224330, rs73611720 and rs56366915 (Figures 3.14 and 3.15).  The resequencing data gave 
rise to over 15 000 genotypes in the OA cases and controls.  I therefore tested each SNP for 
association to OA by case-control analysis, using a χ2 test.  I examined both genotpic and allelic 
association.  None of the known variants identified demonstrated association to OA (P < 0.05), 
with association analysis performed unstratified and stratified by sex and by joint (Tables 3.4-
3.10).  This is not particularly surprising since it is known that large sample sizes are required to 
generate robust association to common SNPs, such as rs143383 (55–57), and by comparison 
our sample size is small and underpowered. 
There are several other GDF5 SNPs listed in the public SNP database dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) but these either lack frequency data or have so 
far been shown to be polymorphic only in non-European samples. These are rs34534075, 
rs61754581, rs28936397, rs76603468, rs61754580, rs28936683, rs17853055, rs5841206, 
rs6120942 and rs79051206. I did not detect these variants despite the coverage in my 
sequence analysis of the relevant parts of GDF5 that are purported to harbour these SNPs and 
I can conclude therefore that they are not polymorphic in Europeans, at least not in the large 
sample that I have studied. 
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Table 3.4 Genotype and allele frequencies of rs143383, along with χ2 p values. 
 
Group 
 Genotype   Allele  
 P value  P value 
 (CC) (CT) (TT)   (C) (T) 
All cases Count 64 199 195 0.53 
  
327 589 0.42 
(n =458) Frequency (%) 14.0 43.4 42.6 35.7 64.3 
All controls Count 59 196 163 
  
314 522 
(n = 418) Frequency (%) 15.3 45.3 39.4 38.0 62.0 
Female cases Count 47 148 144 0.675   242 436 0.465 
(n=339) Frequency (%) 13.9 43.6 42.5 
 
  35.7 64.3 
  
Female controls Count 25 81 67   131 215 
(n =173) Frequency (%) 14.5 46.8 38.7   37.9 62.1 
Male cases Count 17 51 51 0.752   85 153 0.668 
(n =119) Frequency (%) 14.2 42.9 42.9    35.7 64.3   
Male controls Count 34 115 96    183 307   
(n =245) Frequency (%) 13.9 46.9 39.2     37.3 62.7   
All knees Count 22 90 78 
0.678 
  134 246 
0.442 (n = 190) Frequency (%) 11.6 47.4 41.0   35.3 64.7 
All hips Count 43 116 123 
0.32 
  202 362 
0.507 (n = 282) Frequency (%) 15.3 41.1 43.6   35.8 64.2 
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Table 3.5 Genotype and allele frequencies of SNP 224, along with χ 2 p values. 
 
Group 
 Genotype   Allele  
 P value  P value 
 (AA) (GA) (GG)   (A) (G) 
All cases Count 0 20 486 0.43 
  
20 992 0.43 
(n = 506) Frequency (%) 0 4.0 96.0 2.0 98.0 
All controls Count 0 21 396 
  
21 813 
(n = 417) Frequency (%) 0 5.0 95.0 3.0 97.0 
Female cases Count 0 17 370 0.55   17 757 0.56 
(n= 387) Frequency (%) 0 4.0 96.0 
 
  2.0 98.0 
  
Female controls Count 0 10 171   10 352 
(n = 181) Frequency (%) 0 5.5 94.5   2.8 97.2 
Male cases Count 0 3 116 0.33   3 235 0.33 
(n = 119) Frequency (%) 0 2.5 97.5    1.3 98.7   
Male controls Count 0 11 225    11 461   
(n = 236) Frequency (%) 0 4.7 95.3     2.3 97.7   
All knees Count 0 11 209 
1 
  11 429 
1 (n = 220) Frequency (%) 0 5.0 95.0   2.5 97.5 
All hips Count 0 13 291 
0.63 
  13 595 
0.64 (n = 304) Frequency (%) 0 4.3 95.7   2.1 97.9 
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Table 3.6 Genotype and allele frequencies of rs143384, along with χ 2 p values. 
 
Group 
 Genotype   Allele  
 P value  P value 
 (CC) (CT) (TT)   (C) (T) 
All cases Count 78 224 189 0.6   380 602 0.53 
(n = 491) Frequency (%) 15.9 45.6 38.5   38.7 61.3 
All controls Count 67 207 151   341 509 
(n = 425) Frequency (%) 14.8 45.8 33.4   40.1 59.9 
Female cases Count 62 174 150 0.54   298 474 0.473 
(n= 386) Frequency (%) 16.1 45.0 38.7 
 
  38.6 61.4 
  
Female controls Count 28 87 60   143 207 
(n= 175) Frequency (%) 16.0 49.7 34.3   40.9 59.1 
Male cases Count 16 50 39 0.99   82 128 0.89 
(n = 105) Frequency (%) 15.2 47.6 37.1 
 
  39.0 61.0 
  
Male controls Count 39 120 91   198 302 
(n = 250) Frequency (%) 15.6 48.0 36.4   39.6 60.4 
All knees Count 32 104 85 
0.75 
  168 274 
0.46 (n = 221) Frequency (%) 14.5 47.1 38.4   38.0 62.0 
All hips Count 47 130 111 
0.63 
  224 352 
0.64 (n = 288) Frequency (%) 16.3 45.1 38.6   38.9 61.1 
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Table 3.7 Genotype and allele frequencies of rs224331, along with χ 2 p values. 
 
 
Group 
 Genotype   Allele  
 P value  P value 
 (TT) (TG) (GG)   (T) (G) 
All cases Count 218 191 61 0.67 
  
627 313 0.77 
(n = 470) Frequency (%) 46.4 40.6 13.0 66.7 33.3 
All controls Count 171 169 47 
  
511 263 
(n = 387) Frequency (%) 44.2 43.7 12.1 66.0 34.0 
Female cases Count 163 145 45 0.56   471 235 0.41 
(n= 353) Frequency (%) 40.2 41.1 12.7 
 
  66.7 33.3 
  
Female controls Count 63 70 20   196 110 
(n = 153) Frequency (%) 41.2 45.8 13.0   64.1 35.9 
Male cases Count 55 46 16 0.79   156 78 0.86 
(n = 117) Frequency (%) 47.0 39.3 13.7    66.7 33.3   
Male controls Count 108 99 27    315 153   
(n = 234) Frequency (%) 46.2 42.3 11.5     67.3 32.7   
All knees Count 91 77 21 
0.67 
  259 119 
0.4 (n = 189) Frequency (%) 48.2 40.7 11.1   68.5 31.5 
All hips Count 134 121 41 
0.69 
  389 203 
0.77 (n = 296) Frequency (%) 45.2 40.9 13.9   65.7 34.3 
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Table 3.8 Genotype and allele frequencies of rs224330, along with χ 2 p values. 
 
 
Group 
 Genotype   Allele  
 P value  P value 
 (AA) (AG) (GG)   (A) (G) 
All cases Count 2 39 433 0.63 
  
43 905 0.77 
(n = 474) Frequency (%) 0.4 8.2 91.4 4.5 95.5 
All controls Count 3 27 359 
  
33 745 
(n = 389) Frequency (%) 0.8 6.9 92.3 4.2 95.8 
Female cases Count 1 30 325 0.24   32 680 0.85 
(n= 356) Frequency (%) 0.3 8.4 91.3 
 
  4.5 95.5 
  
Female controls Count 2 9 143   13 295 
(n = 154) Frequency (%) 1.3 5.8 92.9   4.2 95.8 
Male cases Count 1 9 108 0.88   11 225 0.8 
(n = 118) Frequency (%) 0.8 7.6 91.6    4.7 95.3   
Male controls Count 1 18 216    20 450   
(n = 235) Frequency (%) 0.4 7.7 91.9     4.3 95.7   
All knees Count 2 17 172 
0.66 
  21 361 
0.34 (n = 191) Frequency (%) 1.1 8.9 90.0   5.5 94.5 
All hips Count 0 24 274 
0.27 
  24 572 
0.84 (n = 298) Frequency (%) 0 8.1 91.9   4.0 96.0 
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Table 3.9 Genotype and allele frequencies of SNP 4715, along with χ 2 p values. 
 
 
Group 
 Genotype   Allele  
 P value  P value 
 (CC) (CA) (AA)   (C) (A) 
All cases Count 2 44 443 0.95 
  
48 930 0.84 
(n = 489) Frequency (%) 0.4 9.0 90.6 4.9 95.1 
All controls Count 2 38 370 
  
42 778 
(n = 410) Frequency (%) 0.5 9.3 90.2 5.1 94.9 
Female cases Count 1 32 339 0.86   34 710 0.82 
(n= 372) Frequency (%) 0.3 8.6 91.1 
 
  4.4 95.6 
  
Female controls Count 1 15 158   17 331 
(n = 174) Frequency (%) 0.6 8.6 90.8   4.9 95.1 
Male cases Count 1 12 104 0.87   14 220 0.71 
(n = 117) Frequency (%) 0.9 10.2 88.9 
 
  6.0 94.0 
  
Male controls Count 1 23 212   25 447 
(n = 236) Frequency (%) 0.5 9.7 89.8   5.3 94.7 
All knees Count 2 21 201 
0.99 
  25 423 
0.73 (n = 224) Frequency (%) 0.9 9.4 89.7   5.6 94.4 
All hips Count 0 24 257 
0.88 
  24 538 
0.47 (n = 281) Frequency (%) 0 8.5 91.5   4.3 95.7 
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Table 3.10 Genotype and allele frequencies of rs56366915, along with χ 2 p values. 
 
 
Group 
 Genotype   Allele  
 P value  P value 
 (CC) (CT) (TT)  (C) (T) 
All cases Count 1 42 442 0.5 
 
44 926 0.56 
(n = 485) Frequency (%) 0.2 8.7 91.1 4.5 95.5 
All controls Count 3 36 370 
 
42 776 
(n = 409) Frequency (%) 0.7 8.8 90.5 5.1 94.9 
Female cases Count 0 30 340 0.12  30 710 0.3 
(n= 370) Frequency (%) 0 8.1 91.9 
 
 4.1 95.9 
 
Female controls Count 2 15 157  19 329 
(n = 174) Frequency (%) 1.1 8.7 90.2  5.6 94.4 
Male cases Count 1 12 102 0.79  14 216 0.51 
(n = 115) Frequency (%) 0.9 10.4 88.7 
 
 6.1 93.9 
 
Male controls Count 1 21 213  23 447 
(n = 235) Frequency (%) 0.4 8.9 90.7  4.9 95.1 
All knees Count 1 20 200 
0.91 
 22 420 
0.9 (n = 221) Frequency (%) 0.5 9.0 90.5  5.0 95.0 
All hips Count 0 23 257 
0.69 
 23 537 
0.38 (n = 280) Frequency (%) 0 8.2 91.8   4.1 95.9 
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3.4.9 Absence of any rare variants 
 Overall, my sequencing of GDF5 did not detect any rare variants, that is variants with a 
MAF in the region of 0.001–0.025 (i.e., 0.1–2.5%). Instead, variants were either extremely rare 
(MAFs ≤ 0.0006, i.e., ≤0.06%, n = 6) or common (MAFs > 0.025, i.e., 2.5%, n = 7), as 
represented in Figure 3.16. 
 
Figure 3.16 The number of variants within GDF5 displayed according to their MAFs.  Graph 
showing that variants within GDF5 are either very rare (MAFs ≤0.0006) or common (MAFs 
≥0.025). 
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3.5 Discussion 
 Current literature is increasingly suggesting that loci harbouring alleles with major 
disease susceptibility risk to a certain trait are also likely to contain other alleles with varying 
influence upon that same trait (132).  GDF5 contains a common functional 5ʹ UTR SNP, 
rs143383, whereby the under expressing T-allele has robustly been associated to OA in both 
European and Asian populations (52, 53, 55–57).  Furthermore, the allelic imbalance observed 
at rs143383 has been shown to be modulated by genotype at a neighbouring SNP, rs143384 
(54).  Additionally, Egli et al. also demonstrated that another common SNP in the 3ʹ UTR, 
rs56366915, is able to influence the allelic output of GDF5 but completely independent of 
genotype at rs143383 (54).  GDF5 therefore exhibits its potential to be influenced by genetic 
polymorphism within it, by both an interacting polymorphism and independent polymorphism.  
These three mentioned polymorphisms are all common, with high MAFs.  In this study I set out 
to assess the genetic architecture of GDF5 to evaluate whether this gene harbours any other 
variants which may also be functional and that could impact upon OA aetiology.  At present 
this is the first example of a deep-sequencing analysis of an OA susceptibility locus. 
 I set out to sequence GDF5 in both cases and controls from the UK population with the 
hypothesis that by focusing on cases and controls rather than random individuals from the 
general population I would increase the chances of discovering penetrant risk or protective 
mutations.  I demonstrated the accuracy of my sequencing by detecting all of the known 
variants from dbSNP that reside within the sections of the gene that I covered.  By virtue of 
detecting six extremely rare novel variants present in only single individuals from over 1 800 
chromosomes, I also validated the sensitivity of my study. 
 Of these six extremely rare variants, three are potentially functional; variant 1, which is 
located in the proximal promoter of GDF5 and is within predicted transcription factor binding 
sites, variant 3, which is located in exon 1 and is predicted to code for the substitution of a 
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highly conserved glycine residue and variant 6, which is located in exon 2 and is predicted to 
code for the substitution of a highly conserved threonine residue.  However, as these variants 
are extremely rare, occurring each in single individuals only, they can’t be having any effect at 
a population level on OA susceptibility.  Should these variants be functional then it is possible 
that they have an effect at the individual or family level.  It is known that penetrant deleterious 
mutations of GDF5 can cause Mendelian phenotypes.  For example, brachydactyly types A2 
and C, characterized by malformation of the phalanges can be caused by mutation within 
GDF5, although these mutations typically involve or are proximal to highly conserved cysteine 
residues which are involved in both monomer formation and dimerization of GDF5 (133).  The 
ethics used to collect the OA cases and controls used in this thesis does not allow us to 
retrospectively contact the individuals.  It is therefore not possible for us to assess whether the 
two individuals harbouring the amino-acid substitution mutations have any overt skeletal 
abnormalities that could be the result of the mutations.  Variant 3, Gly81Arg, occurs within the 
immature form of GDF5 and this makes it difficult to assess the effect this mutation would 
have on GDF5 through modelling and functional protein studies as the crystal structure of the 
immature form of GDF5 has not been determined, although the PolyPhen database predicts 
this amino acid substitution to be benign.  This variant does not reside anywhere near to any 
previously known disease causing variants within the gene.  Polyphen predicts that variant 6, 
Thr469Arg, could be potentially damaging.  As this mutation resides within the mature, 
cleaved form of GDF5, more scope is offered up for potential investigation.  The crystal 
structure is known for this protein form making in silico modelling possible.  It was found that 
the introduction of an arginine side chain to this area of GDF5 would probably impact on the 
folding of the whole protein due to the size and charge of the arginine side chain.  Also assays 
assessing GDF5 activity have been performed in chicken micromass cultures (100) providing a 
potential further avenue for interrogation of Thr469Arg and its effect upon protein activity. 
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 The absence of rare alleles could be due to the biological importance of GDF5, 
whereby new mutation within the gene cannot be tolerated unless it is benign. One other 
plausible explanation for this situation is that the study population has undergone some form 
of evolutionary or population bottleneck.  A population bottleneck is a sudden reduction in 
population size, and with it reduced heterozygosity within that population (134, 135).  During a 
population bottleneck, MAFs and genetic diversity are severely affected by random genetic 
drift (136).  Rare alleles can be wiped out altogether and common alleles can be reduced to 
very rare alleles, all depending upon which individuals survive the bottleneck.  It is possible 
that the current genetic architecture of GDF5 is reflective of a bottleneck imparted upon the 
population, whereby the seven common polymorphisms that were confirmed in my study 
made it through the bottleneck with all other potential GDF5 alleles lost.  The six very rare 
novel variants that I discovered may be the result of mutation that has occurred after the 
bottleneck, as the population is expanding once again and greater heterogeneity is developing.  
It is believed that, in the last 10 000 years, the global population has exploded from a few 
million to the estimated 7 billion that it is today.  Such an explosion allows for rare variants 
within sub-populations due to mutation, which can exact upon complex disease (137).  The 
bottleneck hypothesis may be supported by recent findings that both rs143383 and rs143384 
have undergone positive selection within the East Asian population (138).  In this study it was 
shown that the T-allele of rs143383 – which is associated with OA – along with the T-allele of 
rs143384 – which has been shown to modulate the effect of rs143383 of GDF5 expression (54) 
– are both associated with height and that there has been a positive selection on these alleles.  
The ages of these alleles are around 12 000 years old, a time which saw an increase in early 
agriculture, a decline in the average body mass of humans, as well as the spread of infectious 
disease.  By growing and rearing one’s own food rather than hunting and foraging, the 
necessity for a large and high energy dependant body mass becomes reduced (138).  Lower 
expression of GDF5 confers with shorter limb growth (139), aiding the reduction in body mass.  
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It is likely that the onset of a typically high-age related disease like OA would rarely come into 
play as a negative selection pressure during this time period. 
 In summary, the deep sequencing of the transcript and promoter sequence of GDF5 
has revealed that this gene harbours both extremely rare variants and also common 
polymorphism but there is an absence of mutation of intermediate frequency.  This study was 
further expanded by the collaboration of another research group from Santiago de 
Compostela, Spain who sequenced the open reading frame of GDF5 in a cohort of Spanish and 
Greek individuals, and thus allowing the study to incorporate both Northern and Southern 
Europeans (140).  The research group in Spain only detected common variants, finding no 
novel variants, either unique to that cohort or the same as the extremely rare variants found in 
the UK population. 
Of the six extremely rare variants found, the promoter variant (variant 1) and the non-
synonymous variant (variant 6) appear to have the greatest potential to impart a functional 
effect upon GDF5 expression or GDF5 activity, respectively.  However, none of those six 
variants can be having any effect on OA susceptibility at a population level.  Due to the size of 
and coverage of this study it is unlikely that there is any other mutation within GDF5 within the 
population tested. 
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Chapter 4: A rare variant in the promoter of the 
OA-associated locus GDF5 is functional and reveals 
a site that can be manipulated to modulate gene 
expression 
4.1 Introduction 
As previously mentioned, rs143383 is a common polymorphism in Asians and 
Europeans, with a minor allele frequency (MAF) >20%. During the recent frenetic activity into 
the genetic dissection of polygenic traits it has become apparent that common alleles 
individually contribute only modestly to trait variance (132) and that rare variants of greater 
individual impact could account for some of the missing heritability that is a current 
conundrum in the field (99).  As such I was keen to assess whether GDF5 harbored rare 
variants that could influence OA susceptibility by either acting as independent risk factors or 
by potentially modulating the influence of rs143383, akin to rs143384.  I therefore performed 
a deep sequence analysis of GDF5, on >1900 European individuals, and focused the sequencing 
on the proximal regulatory elements of the gene (promoter, UTRs, intron/exon boundaries) 
and on the protein coding sequence. This revealed an absence of rare GDF5 variants, with the 
gene harboring either known common variants, with MAFs ≥2.5%, or very rare novel variants, 
with MAFs ≤0.006% as described in Chapter 3 (140).  In total, the study uncovered six novel 
mutations; five within the protein coding sequence of GDF5 and one in the proximal promoter, 
41 base pairs upstream of the transcription start site.  I was particularly intrigued by the -41 bp 
variant, which is a C/A transversion that is located in a conserved sequence of GDF5; as 
mentioned in Chapter 3, a search of databases of transcription factor binding sites predicted 
that the novel A-allele is likely to impact on the binding of trans-acting regulators of gene 
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transcription.  If the -41 bp variant does highlight a genuine regulatory domain of GDF5 then 
this could offer us with a DNA site that could be exploited to manipulate the expression of the 
gene and therefore potentially alleviate the detrimental effect that the T-allele of rs143383 
has on GDF5 expression and therefore on OA risk. 
4.2 Aims of this study 
The aim of this study is to assess whether the novel -41 bp variant which I discovered 
in the promoter of GDF5 is functional.  If it is, I plan to use EMSAs in order to identify possible 
trans-acting factors which bind to this locus. 
4.3 Materials and methods 
4.3.1 Molecular haplotyping and construction of GDF5-pGL3 basic 
luciferase reporter plasmids 
We investigated the -41 bp variant in combination with rs143383 and rs143384. The 
physical order of the three polymorphisms is -41 bp-rs143383-rs143384 (Figure 4.1).  To 
generate constructs for use in the GDF5 promoter/5ʹ UTR luciferase reporter gene assays, a 
403bp fragment of genomic DNA corresponding to the GDF5 proximal promoter and part of 
the 5ʹUTR (-97 to +305 with respect to the transcriptional start site of GDF5) and encompassing 
the three polymorphisms was PCR amplified using gene specific primers (underlined) 
containing either a MluI (forward primer 5ʹ-ACTCAACGCGTGGATTCAAAACTAGGGG-3ʹ; MluI 
site marked in bold) or a BglII (reverse primer 5ʹ-GCACAAGATCTAGCCGCTGAATGACACCAAAG-
3ʹ; BglII site marked in bold) restriction site at the 5ʹ end of the primer.  PCR was carried out as 
described in Chapter 2.3.2 with thermocycling conditions of an initial denaturation at 94oC for 
14 minutes, followed by 37 cycles of 94oC for 30 seconds, annealing at 70oC for 30 seconds, 
and extension at 72oC for 45 seconds, with a final extension at 72oC for 5 minutes.  After 
amplification, the PCR product was purified and eluted in 30 µl of water using the QIAquick 
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PCR purification kit following the manufacturer’s instructions (Qiagen).  After PCR purification, 
double digestion of the PCR products was achieved with 15 units of MluI and 15 units of BglII 
restriction enzymes (NEB), in the presence of 10X NEB Buffer 3 (50 mM Tris-HCl, 10 mM MgCl2, 
100 mM NaCl and 1 mM DTT, pH 7.9) incubated for 3 hours at 37oC, followed by heat 
inactivation at 80oC for 20 minutes.  Following digestion the product was again purified using 
the QIAquick PCR purification kit (QIAGEN). 
 
 
-165 TGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAAGTATTTTC 
-105 ACTGGAAAGGATTCAAAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGC 
-45  CATTMTTCCTTCTTGGAAAAATCCCTCAGCCTTATACAAGCCTCCTTCAAGCCCTCAGTC  -41 bp  C/A 
  16 AGTTGTGCAGGAGAAAGGGGGCGGTYGGCTTTCTCCTTTCAAGAACGAGTTATTTTCAGC rs143383 C/T 
  76 TGCTGACTGGAGACGGTGCACGTCTGGATACGAGAGCATTTCCACTATGGGACTGGATAC 
 136 AAACACACACCCGGCAGACTTCAAGAGTCTCAGACTGAGGAGAAAGCCTTTCCTTCTGCT 
 196 GCTACTGCTGCTGCCGCTGCTTTTGAAAGTCCACTCCTTTCATGGTTTTTCCTGCCAAAC 
 256 CAGAGGCACCTTYGCTGCTGCCGCTGTTCTCTTTGGTGTCATTCAGCGGCTGGCCAGAGG rs143384 C/T 
 316 ATGAGACTCCCCAAACTCCTCACTTTCTTGCTTTGGTACCTGGCTTGGCTGGACCTGGAA 
 376 TTCATCTGCACTGTGTTGGGTGCCCCTGACTTGGGCCAGAGACCCCAGGGGACCAGGCCA 
 436 GGATTGGCCAAAGCAGAGGCCAAGGAGAGGCCCCCCCTGGCCCGGAACGTCTTCAGGCCA 
 496 GGGGGTCACAGCTATGGTGGGGGGGCCACCAATGCCAATGCCAGGGCAAAGGGAGGCACC 
 556 GGGCAGACAGGAGGCCTGACACAGCCCAAGAAGGATGAACCCAAAAAGCTGCCCCCCAGA 
 616 CCGGGCGGCCCTGAACCCAAGCCAGGACACCCTCCCCAAACAAGGCAGGCTACAGCCCGG 
 676 ACTGTGACCCCAAAAGGACAGCTTCCCGGAGGCAAGGCACCCCCAAAAGCAGGATCTGTC 
 736 CCCAGCTCCTTCCTGCTGAAGAAGGCCAGGGAGCCCGGGCCCCCACGAGAGCCCAAGGAG 
 796 CCGTTTCGCCCACCCCCCATCACACCCCACGAGTACATGCTCTCGCTGTACAGGACGCTG 
 856 TCCGATGCTGACAGAAAGGGAGGCAACAGCAGCGTGAAGTTGGAGGCTGGCCTGGCCAAC 
 916 ACCATCACCAGCTTTATTGACAAAGGGCAAGGTGAGGGGGCGGGGTGGCAGGGGCACGGC 
 
Figure 4.1 Exon 1 (highlighted) and flanking intronic sequence of GDF5.  -41 bp, rs143383 and 
rs143384 are shown in blue.  Numbering is relative to the transcription start site. 
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In preparation for cloning, 10 µg of pGL3-Basic luciferase reporter vector (Promega) 
was double digested with BglII and MluI restriction enzymes as described above.  The digested 
vector was treated with 5 units of Antarctic Phosphatase (New England Biolabs) and then 
purified using the QIAquick gel extraction kit (Qiagen) following the manufacturer’s 
instructions and eluted in water.  The digested and purified PCR product was then cloned into 
the MluI/BglII sites of the purified pGL3-Basic vector using a 5:1 ratio of PCR fragment to 
plasmid and 400 units of T4 ligase (New England Biolabs), incubated at 16oC overnight to 
create the GDF5 promoter/5ʹ UTR-Luciferase construct (Figure 4.2).  Plasmid DNA was 
transformed into MACH 1 E. coli bacterial cells (Invitrogen) following manufacturers guidelines.   
Following incubation, 50-100  l of transformed cells were spread out onto agar plates 
containing 100 µg/ml of ampicillin (Sigma Aldrich).  These plates were then incubated upside 
down at 37oC overnight to allow colonies to grow. 
Colonies were picked from the bacterial culture plates and grown overnight at 37oC at 
200 rpm in 3.5 ml of LB broth (Sigma Aldrich) containing 100 µg/ml of ampicillin (Sigma 
Aldrich).  Glycerol stocks were made by adding 200 µl of bacterial culture to 200 µl of glycerol 
(Sigma Aldrich), stocks were then stored at -80oC.  Each culture was mini-prepped by 
centrifuging 1.4 ml of bacterial culture in a 1.5 ml centrifuge tube (Griener Bio) at 8 200 rpm 
for 3 minutes to pellet the bacteria.  Following the aspiration of the supernatant, the bacterial 
pellet was re-suspended in 100 µl of P1 + RNaseA solution (Qiagen).  Following re-suspension, 
200 µl of P2 solution (Qiagen) was added and the tubes were inverted to mix and left to 
incubate at room temperature for 2 minutes.  After incubation, 150 µl of P3 solution (Qiagen) 
was added, mixed and then centrifuged for 5 minutes at 13 000 rpm.  The supernatant was 
then removed and added to 1 ml of 100% ethanol.  The ethanol/supernatant mix was then 
stored at -80oC for at least 15 minutes.  Following storage at -80oC the tubes were centrifuged 
for 10 minutes at 13 000 rpm at room temperature to pellet the DNA.  All of the supernatant 
was then removed and the DNA pellet was air-dried for 10-15 minutes until all ethanol had 
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evaporated.  Each pellet was then re-suspended in 30 µl of DEPC water (Invitrogen) and stored 
at -20oC.  These individual plasmid clones were sequenced via Sanger capillary sequencing as 
described in Chapter 3.3.2, by Genome Enterprises, Norwich, UK using the primer pGL3basic R 
5ʹ-ACCAGGGCGTATCTCTTCAT-3ʹ. 
 
 
Figure 4.2 Vector map of the pGL3-Basic Vector with the 403 bp GDF5 insert, containing the 
proximal promoter and 305 bp of the 5′ UTR.  The insert was cloned into the vector’s multiple 
cloning site using the enzymes MluI and BglII.  Image adapted from 
http://vesuvias.files.wordpress.com/2009/06/plasmidvector.png 
 
The starting input DNA for this cloning strategy came from the individual in whom the -
41 bp variant had been originally detected (140), as described in Chapter 3.  This individual was 
heterozygous for -41 bp and heterozygous for both rs143383 and rs143384.   Following 
successful cloning and sequencing, it was discovered that this individual carried a -41 bp (A) - 
rs143383 (C) - rs143384 (C) haplotype (in future known as the A-C-C haplotype) and a -41 bp 
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(C) - rs143383 (T) - rs143384 (T) haplotype (in future known as the C-T-T haplotype).  The non-
naturally occurring A-T-T and C-C-C haplotypes were generated using the Agilent Quickchange 
II site directed mutagenesis kit (Agilent). To generate A-T-T I used the C-T-T clone and the 
forward primer 5ʹ-CAGCATTACGCCATTATTCCTTCTTGGAAA and the reverse primer 5ʹ-
TTTCCAAGAAGGAATAATGGCGTAATGCTG-3ʹ.  To generate C-C-C I used the A-C-C clone and the 
forward primer 5ʹ-CAGCATTACGCCATTCTTCCTTCTTGGAAA-3ʹ and the reverse primer 5ʹ-
TTTCCAAGAAGGAAGAATGGCGTAATGCTG-3ʹ. The reaction mix contained 50 ng of plasmid, 125 
ng of forward primer, 125 ng of reverse primer, 0.01 mM dNTP mix, 10X reaction buffer, 2.5 
units of Pfu Ultra high fidelity DNA polymerase (Agilent) in a total volume of 50 µl.  
Thermocycling conditions were denaturing at 95oC for 30 seconds followed by 18 cycles of 
denaturing at 95oC for 30 seconds, annealing at 50oC for 1 minute and extension at 68oC for 7 
minutes.  Following thermocycling the reaction was placed on ice for 2 minutes to cool to 
below 37oC.   
Following mutagenesis, methylated and hemimethylated DNA was digested by the 
addition of 10 units of DpnI (Agilent).  Reactions were mixed and briefly centrifuged for 1 
minute before incubation at 37oC for 1 hour.   The transformation of these mutated plasmids, 
along with the control plasmid, was carried out following the manufacturer’s instructions 
(Agilent).  Colonies were picked and cultured as described above, and miniprepped in the same 
manner along with glycerol stocks being made.  Clones were again sent for sequencing by 
Genome Enterprises Ltd, Norwich, UK. 
4.3.2 Maxiprep of the four haplotypes of the GDF5 promoter/5ʹ UTR 
Luciferase reporter plasmids 
In order to obtain large quantities of pure plasmid DNA, 10 µl of glycerol stock was 
thawed and initially cultured in 5 ml of LB containing 100 ng/µl of ampicillin at 37oC and 200 
rpm for 3 hours.  This culture was then transferred to a conical flask containing 250 ml of LB 
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containing 100 ng/µl of ampicillin, and incubated overnight at 37oC and 200 rpm.  Cultures 
were then centrifuged at 6000 g for 15 minutes at 4oC in a 50 ml centrifuge tube (Nalgene).  
Bacterial pellets were then re-suspended in 10 ml of P1 + RNaseA solution (Qiagen).  Following 
re-suspension, 10 ml of P2 solution (Qiagen) was added and the solution was vigorously mixed 
manually and incubated at room temperature for 5 minutes.  After incubation, 10 ml of ice 
cold P3 solution (Qiagen) was added and again the solution was vigorously mixed manually 
before being incubated on ice for 20 minutes.  Lysates were then centrifuged at 20 000 g for 
30 minutes at 4oC.  The supernatant was then transferred to a fresh tube and centrifuged 
under the same conditions for a further 15 minutes.  Following the equilibration of a QIAGEN-
tip500 gravity column with 10 ml of Buffer QBT (Qiagen), the supernatant was applied to the 
column and allowed to run through by gravity into a waste receptacle.  The column was then 
washed with two 30 ml volumes of Buffer QC, and then eluted with 15 ml of Buffer QF into a 
fresh centrifuge tube.  DNA was precipitated by adding 10.5 ml of isopropanol which was 
mixed and centrifuged at 15 000 g for 30 minutes at 4oC.  The supernatant was aspirated and 
the pellet air dried.  The DNA pellet was then re-suspended in 500 µl of de-ionized H2O.  Two 
and half times volume of 100% ethanol was then added to the re-suspended DNA, and after 
mixing was stored at -80oC for at least 30 minutes.  This precipitant was centrifuged at 13 000 
rpm in a desktop centrifuge for 10 minutes.  The supernatant was aspirated and pellets were 
air dried for 5-10 minutes before being re-suspended in 300 µl of H2O and quantified using a 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). 
4.3.3 Cell Culture 
 Three human cell lines were cultured for transfection experiments; the SW1353 
chondrosarcoma cell line, the MG63 osteosarcoma cell line and the CH8 articular chondrocyte 
cell line.  The SW1353 cell line was cultured in a T75 or T162 cell culture flask (Corstar) in 
Dulbecco's Modified Eagle’s Medium: Nutrient Mixture F-12 (DMEM/F12) (GIBCO), containing 
5% foetal bovine serum (FBS), 10 ml of 2X Penicillin:Streptomycin mix (Sigma Aldrich) and 2 
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mM of glutamine (Sigma Aldrich).  The MG63 cell line was cultured in a T75 or T162 cell culture 
flask in Dulbecco's Modified Eagle’s Medium (DMEM) (GIBCO), containing 5% foetal bovine 
serum (FBS), 1X Penicillin:Streptomycin mix (Sigma Aldrich) and 2 mM of glutamine (Sigma 
Aldrich).  The CH8 cell line was cultured in a T75 flask coated with 0.4 mg/ml of rat tail Collagen 
Type I (BD Biosciences).  Collagen coating was achieved by making 100 mg/ml of rat tail 
Collagen Type I in Dulbecco’s Phosphate Buffered Solution (Lonza) and adding this to a T75 
flask until the flask surface was completely covered.  The coated flask was then incubated at 
37oC for one hour, and subsequently washed twice with PBS.  The CH8 cell line was cultured on 
this collagen surface in DMEM containing 10% FBS and 1X Penicillin:Streptomycin mix.  Cells 
were allowed to grow until 70% confluencey before being passaged and reseeded. 
4.3.4 Transfection of cell lines 
 Cells were seeded in 300 µl of media at a density of 17 500 cells per well in a 48 well 
cell culture plate (Costar).  Cells were treated with trypsin and placed in fresh media and then 
pelleted by centrifugation at room temperature at 400 g for 5 minutes. They were then 
resuspended in media and counted using a Rosenthal haemocytometer.  The seeded cells were 
then cultured for 24 hours with respect to MG63 cells and 48 hours with respect to SW1353 
and CH8 cells.  After this period of culture the cells in each well were transfected using a 
transfection mixture consisting of 500 ng of pGL3 plasmid DNA and 15 ng of pTK-RL Renilla 
plasmid in 28.35 µl of a 0.9 M NaCl solution.  This mixture was then mixed and pelleted and 
then 1.65 µl of Exgen 500 Transfection reagent (Fermentas) was added before being mixed 
again for 10 seconds.  This mixture was then incubated at room temperature for 10 minutes.  
During this incubation, cells were aspirated prior to the 30 µl of transfection mixture being 
added directly to the cells.  Following this, 270 µl of appropriate fresh media was added per 
well and cultured for a further 24 hours prior to cell lysis. 
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4.3.5 Cell Lysis and Luciferase Activity Reading 
  Twenty-four hours after transfection cells were lysed and their protein extracted.  The 
48 well cell culture plates had their media aspirated and the wells were then washed twice in 
37oC PBS.  Following this washing process, 65 µl of 1X Passive Lysis Buffer (Promega) was 
added to each well.  The plate was then incubated for 20 minutes on a platform rocker, and 
then frozen to -20oC.  In order to read the luciferase activity from the cell lysate, the plate was 
thawed again on a platform rocker.  Once thawed, 20 µl of lysate was added to a luminometer 
plate, which was loaded onto a Microlumat Plus LB96V luminometer.  To each 20 µl of lysate 
sample, 50 µl of Luciferase Activating Reagent II (LAR II, Promega) was added.  The plate was 
then read, using a 1 second measurement and the WinGlow software.  Following this reading, 
50 µl of Stop & Glo (Promega) was added to each sample to measure the Renilla activity; the 
measurement was carried out using the same exposure time.  This measurement of Renilla 
activity is used as a transfection efficiency control. Six biological repeats were measured once 
each on the machine.  The whole experiment was repeated three times, producing a total of 
18 data readings for each condition.  Statistical analysis was then carried out by performing a 
student’s t-test. 
4.3.6 Identification of candidate trans-acting factors 
I used two in silico prediction programs to identify candidate trans-acting factors which 
could be binding at the -41 bp site.  The two programs I used were both internet based; Promo 
3.0 (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) (141) and 
TESS: Transcription Element Search System (http://www.cbil.upenn.edu/cgi-bin/tess/tess).  
4.3.7 Nuclear protein extraction 
Twenty million SW1353 or MG63 cells were plated on to 500cm2 cell culture dishes 
(Corstar). After 24 hours, culture medium was removed and cells were washed in ice-cold PBS.  
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The PBS was then removed and cells were scraped, using an 18 cm cell lifter, into 5 ml of fresh 
PBS and centrifuged for 30 seconds at 10 000 g at 4°C.  Cells were then re-suspended in 1ml of 
hypotonic buffer (10 mM HEPES, pH 7.6, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 10 mM NaF, 1 
mM Na3VO4, 0.1% Tergitol (volume/volume), 1x complete protease inhibitor cocktail tablet per 
50 ml solution (Roche)) and incubated on ice for 15 minutes.  Cells were re-pelleted as 
described in Chapter 4.3.4 and the supernatant containing cytosolic proteins was collected, 
snap-frozen on dry ice, and stored at -80°C.  In order to fractionate the nuclei, the pellet was 
re-suspended in ice-cold hypotonic buffer supplemented with 0.25 M sucrose.  Again, cells 
were centrifuged and the pellet was re-suspended in 1.5 ml high salt buffer (20 mM HEPES, pH 
7.9, 420 mM NaCl, 20% glycerol (volume/volume), 1 mM DTT, 10 mM NaF, 1 mM Na3VO4, 1x 
complete protease inhibitor cocktail tablet per 50 ml of buffer).  Following a 30 minute 
incubation on ice, the cells were centrifuged for the final time at 10 000 g for 2 minutes at 4°C 
and the supernatant containing nuclear protein was transferred to a new 1.5 ml tube and 
stored at -80°C.  
4.3.8 Electrophoretic mobility shift assay (EMSA) 
Fluorescently labeled (5ʹDY682) oligonucleotides (Eurofins MWG Operon) were re-
suspended in H20 (Sigma) to a concentration of 100 pmol/µl.  To create double-stranded 
probes a pair of complimentary oligonucleotides were heated to 95oC in an EMSA annealing 
buffer (100 mM Tris HCl, 500 mM NaCl, 10 mM EDTA).  Following this incubation, the reaction 
was allowed to cool to room temperature for 2-3 hours.  A native 2.3% acrylamide gel 
(weight/volume) (3.2 µl polyacrylamide, 2.6 µl 5X TBE, 19.1 µl diH2O, 88 µl of ammonium 
persulfate (APS) and 25 µl  of TEMED) was prepared the day before the reaction and left to set 
at 4°C overnight.  The gel was pre-run at 100 V for 30 minutes and at 4oC in 0.5x TBE buffer 
prior to the loading of samples in order to remove any traces of APS, to equilibriate ions within 
the running buffer and to ensure constant gel temperature.  Following initial optimisation of 
binding conditions, the Odyssey Infrared EMSA reaction mixture consisted of 2 µl of 10X 
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binding buffer, 2 µl of 25 mM DTT, 1 µg of PolyIC, 1 µl of 1% NP40, 200 fmol of double 
stranded oligonucleotide, 5 µg of nuclear protein extract brought up to 20 µl with H2O. An 
additional 1 µl of unlabeled competitor oligonucleotide was added to the competitor reaction.  
These reaction mixes were incubated at room temperature for 20 minutes in the dark.  When 
using unlabeled competitor oligonucleotides, these were added prior to the addition of the 
fluorescently labeled oligonucleotides.  10X Orange Loading dye (Li-Cor Biosciences) was then 
added (1x final concentration) and samples were loaded onto the gel.  Electrophoresis was 
performed at 100 V at 4°C in the dark for approximately 4 hours, or until the dye front had 
reached the end of the gel.  Visualisation of the EMSA gel was carried out using an Odyssey 
Infrared Imager (Li-Cor).  When carrying out supershift EMSAs, 2 µg of antibody (YY1 antibody 
YY1(C-20) cat number sc-281X, raised in rabbit) (Transcruz, Santa Cruz) was added in place of 
the unlabelled competitor oligonucleotides.  Table 4.1 lists the nucleotide sequences of the 
two -41 bp probes and of the competitor oligonucleotides used. 
 
Table 4.1 Nucleotide sequences of the -41 bp probes and of the competitor oligonucleotides 
used in the EMSA experiments.  
 
Probe/Competitor Sequence (5'-3') 
-41 bp C-allele probe GCATTACGCCATTCTTCCTTCTTGGAA 
-41 bp A-allele probe GCATTACGCCATTATTCCTTCTTGGAA 
abaA Competitor AATTGGACCCATTCTTTAGTACGTAGCA 
GRLF Competitor AATTGGACCCATTCTTCCTTCTGTAGCA 
SOX9 Competitor AATTGGACGGATCCTGTCGTACGTAGCA 
SEF4 Competitor AATTGGACCCATTCTTTAGTACGTAGCA 
UCRBP Competitor AATTGGCGCCATTCTTTAGTACGTAGCA 
VDR Competitor AATTGGACCCATTCTTCCGTACGTAGCA 
YY1 Competitor AATTGGACCCATTTTTTAGTACGTAGCA 
 
4.3 Results 
4.3.1 Molecular haplotyping of the -41 bp patient 
 The -41 bp variant was discovered in an individual who was heterozygous at this site 
and also at rs143383 and rs143384.  Cloning and sequencing of this person’s DNA revealed 
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that the haplotypes that the individual carried were A-C-C (-41 bp (A) - rs143383 (C) - rs143384 
(C)) and C-T-T (-41 bp (C) - rs143383 (T) - rs143384 (T)).  I therefore investigated the effect of 
the -41 bp variant within the context of these natural haplotypes and in the context of the 
alternative A-T-T and C-C-C haplotypes. 
4.3.2 Luciferase assays 
 Of the three cell lines which I transfected, one cell line – CH8 – was unable to be 
efficiently transfected.  Luciferase readings from the transfection of this cell line were never 
over the background reading, indicating transfection had not occurred.  This result was 
consistent for all 5 vectors over 4 repeated experiments, with 6 replicates in each. 
In the comparison of A-C-C with C-T-T it was apparent that A-C-C drove greater 
luciferase expression than C-T-T, with a 30% difference (p = 4.0 x10-5) seen in MG63 and a 20% 
difference (p = 2.5x10-5) seen in SW1353 (Figures 4.3 and 4.4).  As noted in Chapter 1.8, it is 
already known that the T-allele of rs143383, when in combination with the T-allele of 
rs143384, results in reduced expression.  As such, the greater expression seen here for the A-
C-C haplotype could reflect the functionality of rs143383 and rs143384 rather than any 
functionality of the -41 bp variant.  This dilemma could be resolved by studying the alternative 
haplotypes, A-T-T and C-C-C.  When the A-T-T haplotype was compared to the C-T-T haplotype, 
A-T-T drove greater expression, with a 21% difference (p = 0.00073) seen in MG63 and a 10% 
difference (p = 0.044) seen in SW1353.  Furthermore, when the C-C-C haplotype was compared 
to the A-C-C haplotype, C-C-C resulted in reduced expression, with a 17% difference (p = 
0.0072) observed in MG63 and a 25% difference (p = 5.0 x 10-7) observed in SW1353.  This data 
clearly demonstrates that the -41 bp variant is itself functional and that the A-allele discovered 
in the original deep-sequencing experiments mediates increased gene expression, in the two 
cell lines that I tested.   
109 
 
A 
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Figure 4.3 Results of luciferase (LUC) reporter assays of GDF5 promoter/5'UTR constructs in 
the osteogenic MG63 cell line (A) and the chondrogenic SW1353 cell line (B). A schematic 
drawing of the promoter/5'UTR construct is shown at the top left of each panel and highlights 
the relative positions of the -41 bp, rs143383 and rs143384 polymorphisms. Data are the fold 
expression in relation to the control empty pGL3 vector, and are shown as the mean and 
standard error (SE) from 3 independent experiments, each performed with 6 biological 
repeats.  P-values were calculated using a student’s t-test. 
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Relative Light Units 
  
Relative Light Units 
 
ACC CTT ATT CCC 
  
ACC CTT ATT CCC 
MG63 7.45 5.23 6.60 6.16 
 
SW1353 6.86 5.50 6.12 5.17 
           % difference CTT ATT CCC 
  
% difference CTT ATT CCC 
 ACC 30 11 17 
  
ACC 20 11 25 
 CTT - 21 15 
  
CTT - 10 6 
 ATT - - 7 
  
ATT - - 16 
  
 
Figure 4.4 The relative mean light unit outputs from each plasmid following renilla correction 
(top) and the percentage differences in expression between each (bottom), in MG63 (left) 
and SW1353 (right) cells. 
  
What was particularly striking about the luciferase data was the discovery that 
introducing a -41 bp A-allele onto a rs143383-rs143384 T-T haplotype reverses the capacity of 
this T-T haplotype to mediate reduced expression.  This is apparent when one compares the 
relative expressions seen between the C-C-C and the A-T-T haplotypes; in both cell lines the A-
T-T expression is greater despite it harboring the T-alleles of both rs143383 and rs143384.  
4.3.3 Electrophoretic mobility shift assays 
Having established that the -41 bp variant is functional I went on to use EMSAs to 
characterize trans-acting factors that bind to this site. I investigated both alleles of -41bp and 
nuclear extracts from MG63 and SW1353 cells. The -41 bp variant resides within a sequence of 
GDF5 that is conserved amongst mammals (Figure 4.5). Using the online prediction databases 
TESS and Promo 3.0, I identified several transcription factors whose consensus sequences 
indicated a potential binding relationship with the sequence encompassing -41 bp and in which 
this binding is predicted to be influenced by the C/A change (Figure 3.5, Section 3.4.1). I tested 
the ability of YY1, UCRBP (a synonym of YY1 but with a different registered consensus 
sequence), SOX9, abaA, SEF4, VDR, and GRLF to out-compete the binding to the C-allele and 
the A-allele probes, using the competitor oligonucleotides listed in Table 4.1.  I firstly tried two 
concentrations of each competitor – 10x and 50x – and saw possible band intensity changes in 
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YY1, abaA, UCRBP1 and SOX9 using MG63 nuclear extract (Figure 4.6A).  I repeated the 
negative results using SW1353 nuclear extract and again saw no band intensity changes (Figure 
4.6B).  By titrating concentrations of the competitor from 5x to 50x probe concentration I was 
able to determine if the affinity for transcription factor binding differed between the two 
alleles. I did not detect any consistent band intensity depletion when using abaA, GRLF, SEF4, 
SOX9 or VDR competitors. I did however detect band intensity depletion for YY1 and its 
synonym UCRBP in both MG63 and SW1353, and that in each case the site-specific band 
produced by fluorescent probe binding was diminished by a lower concentration of YY1 
consensus sequence probe when testing the C-allele compared to the A-allele (Figures 4.7-
4.10). This indicates that YY1 binds to this locus and that binding is stronger to the A-allele 
than the C-allele.  
 
 
Homo sapiens -41 bp C TGGAGCACACAGGCAGCATTACGCCATTCTTCCTTCTTGGAAAAATCCC 49 
Homo sapiens -41 bp A TGGAGCACACAGGCAGCATTACGCCATTATTCCTTCTTGGAAAAATCCC 49 
Pan troglodytes       TGGAGCACACAGGCAGCATTACGCCATTCTTCCTTCTTGGAAAAATCCC 49 
Equus caballus        TGGAGCACACAGGCAGCATTACGCCATTCTTCCTTCTTGGAAAAATCCC 49 
Mus musculus          TGGAGCGCACAGGCAGCATTACGCCATTCTTCCTTCTTGGAAAAATCCC 49 
 
Figure 4.5 Nucleotide alignment of the -41bp variant site. The wild type C-allele is shown in 
red and the mutant A-allele is shown in blue. The homologous sequences of Pan troglodytes 
(common chimpanzee), Equus caballus (horse) and Mus musculus (house mouse) are also 
shown. 
 
  I next carried out an antibody supershift EMSA for both MG63 and SW1353 and this 
confirmed that YY1 does bind to the -41 bp locus (Figure 4.11).  Although I didn’t observe a 
supershift of the YY1 specific band, I did observe that the YY1 specific band disappeared when 
antibody was added to the C-allele, and certainly diminished when added to the stronger 
affinity A-allele.  It is possible that the antibody is binding directly over the site of the 
fluorescently tagged oligonucleotide and that is why I see a band disappearance/diminishment 
rather than a shift. 
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Figure 4.6 EMSA performed on MG63 nuclear extract (A) and SW1353 nuclear extract (B), 
using increasing concentrations of transcription factor binding consensus sequence 
unlabeled probes.  Initial two concentration (10x and 50x) EMSAs carried out using unlabeled 
probes to test for their suitability to out compete the site specific band (denoted by arrows). A) 
shows that YY1, abaA, UCRBP and SOX9 may be possible candidates when using MG63 nuclear 
extract. B) shows those negative results repeated with SW1353 nuclear extract but again they 
still show no out competition of any bands. 
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Figure 4.7 EMSA performed on MG63 nuclear extract (A) and SW1353 nuclear extract (B), 
using increasing concentrations of YY1 consensus sequence unlabeled probe.  Both EMSAs 
show that the site specific band (denoted by the arrows) produced by nuclear 
protein/fluorescent probe binding can be diminished by a lower concentration of YY1 
consensus sequence probe when testing the wildtype C-allele compared to the mutant A-
allele.  This indicates that YY1 is a strong candidate for binding to this locus and that binding is 
stronger to the A-allele than the C-allele. 
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Figure 4.8 EMSA performed on MG63 nuclear extract (A) and SW1353 nuclear extract (B), 
using increasing concentrations of UCRBP consensus sequence unlabeled probe.  Both EMSAs 
show that the site specific band (denoted by the arrows) produced by nuclear 
protein/fluorescent probe binding can be diminished by a lower concentration of UCRBP 
consensus sequence probe when testing the wildtype C-allele compared to the mutant A-
allele.  URCBP is an synonym of YY1 but with a different registered consensus sequence. This 
verifies YY1 as a strong candidate for binding to this locus and that again binding is stronger to 
the A-allele than the C-allele. 
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Figure 4.9 EMSA performed on MG63 nuclear extract (A) and SW1353 nuclear extract (B), 
using increasing concentrations of abaA consensus sequence unlabeled probe.  Both EMSAs 
show that the site specific band (denoted by the arrows) produced by nuclear 
protein/fluorescent probe binding cannot be diminished by varying the concentration of a 
abaA unlabeled probe. 
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Figure 4.10 EMSA performed on MG63 nuclear extract (A) and SW1353 nuclear extract (B), 
using increasing concentrations of SOX9 consensus sequence unlabeled probe.  Both EMSAs 
show that the site specific band (denoted by the arrows) produced by nuclear 
protein/fluorescent probe binding cannot be diminished by varying the concentration of a 
SOX9 unlabeled probe. 
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Figure 4.11 Antibody supershift EMSA of (A) MG63 nuclear extract and (B) SW1353 nuclear 
extract. The addition of the YY1 antibody clearly shows a reduction in the intensity of the site 
specific band (denoted by the arrows) when compared to when either no antibody (empty) or 
a non-targeting (control) antibody was added. In the case of the C allele the band is completely 
diminished. A shift in the band is not observed as I hypothesize the antibody is binding directly 
over the fluorescently tagged oligonucleotide. 
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4.4 Discussion 
Using a range of techniques I have demonstrated that the -41 bp variant discovered by 
my deep-sequencing analysis of GDF5 (Chapter 3) is functional, with the novel A-allele 
mediating increased gene expression.  One of the particularly exciting outcomes of my 
luciferase assays was the discovery that this allele is able to compensate for the reduced 
expression that is mediated by the OA-associated T-allele of rs143383.  This result clearly 
demonstrates that the activity of an OA susceptibility allele is highly context specific and that 
negative effects on gene expression mediated by cis-acting regulatory sites are potentially 
modifiable by targeting other cis sites within the gene.   
 Although previously implicated in binding to the promoter of GDF5 (142), I have 
identified YY1 as a trans-acting factor that differentially binds to the C and A alleles of the -41 
bp variant, with more avid binding to the A allele.  YY1 (Yin Yang 1) is a widely expressed zinc-
finger nuclear protein that is conserved between species and which can act as a transcriptional 
repressor or activator, depending on cellular context (143).  It has roles in cellular proliferation, 
differentiation and apoptosis, with yy1 knockout mice having in utero lethality (144).  YY1 
expression has been associated with the development of malignant phenotypes of human 
cancers, along with tumour progression, including metastasis and also in tumour survival (145).  
However, due to its ability to act as a repressor and as an activator, its role in tumor 
progression is controversial as YY1 plays a key role in both cell proliferation and apoptosis.  As 
far as I am aware the protein has not so far been implicated in OA pathogenesis.  Its discovery 
as a differential regulator of GDF5 expression now opens up the possibility that it can be 
exploited to modulate the expression of this important OA susceptibility locus. 
 When I carried out the deep-sequencing of GDF5 which I described in Chapter 3, my 
primary goal was to assess whether this gene harbored other, novel, polymorphisms that could 
directly contribute to OA genetic susceptibility at a population level; by definition, such 
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polymorphisms would need to be common in the population.  My experiment however only 
identified extremely rare variants, with MAFs ≤0.006% (Table 3.3).  My functional analysis of 
the -41 bp variant has demonstrated that despite its low frequency this mutation offers insight 
into the regulation of expression of GDF5 and provides us with a protein, YY1, that can be 
exploited to alleviate the OA risk coded for by this gene.  Deep sequencing therefore offers not 
only a means to identify novel susceptibility alleles but also a means to identify a mechanism 
to counteract the effects of those that are already known. 
 In order to further understand YY1’s role in the regulation of GDF5, I collaborated with 
another member of my research group, Catherine Syddall, who demonstrated that YY1 was 
expressed (mRNA and protein) in cartilage and also performed a knockdown of YY1 to assess 
what effect this had on GDF5 expression.  It was found that knock down of YY1 reduces the 
expression of GDF5, supporting my data.  This research has now been published under the title 
“A rare variant in the promoter of the OA-associated locus GDF5 is functional and reveals a site 
that can be manipulated to modulate gene expression” within the European Journal of Human 
Genetics (146). 
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Chapter 5: General Discussion  
 Osteoarthritis (OA) is the most common musculoskeletal disease, and in some 
populations up to 90% of the over 65s suffer from OA in one or more of their joints (2).  It is 
characterised by focal areas of loss of articular cartilage resulting in the deterioration of joint 
form and function.  In Europe an osteoarthritic joint is replaced once every 90 seconds, placing 
an enormous economic burden upon governments and heath care authorities (1).  Genetic 
analysis is a useful tool for uncovering biological factors important in healthy body function 
and in the initiation and progression of common diseases.  At present, OA research has yielded 
fewer robust genetic associations when compared to other common complex diseases such as 
type 1 diabetes or Crohn’s disease (96, 113).  The heterogeneity of OA has a large 
responsibility for situation.  OA is an end stage phenotype achieved from many different single 
starting points or indeed multiple starting points, stemming from multiple possible triggers 
(147).  Heterogeneity exists amongst genders, ethnicities, anatomical sites and this manifests 
observed differences in joint pathology even at end stage disease. 
The strategies employed in furthering genetic research into OA can be classified into 
two categories: the candidate gene approach and the genome-wide approach.  The former 
relies on a hypothesis leading to the candidate gene whereas the latter is hypothesis-free and 
agnostic of gene function.  Both strategies have yielded significant associations to disease and 
this thesis demonstrates research following each strategy. 
Genome-wide association scans (GWASs) compare the frequencies of SNPs within a 
cohort of affected individuals and a cohort of people either free of disease or representative of 
the normal population as a whole.  By exploiting linkage disequilibrium (LD) we are able to 
cover the whole genome by genotyping only a fraction of the total number of SNPs present 
within the human genome.  The consequence of this is that any SNP providing an association 
signal is not necessarily the SNP that is causal with regard to disease.  A GWAS carried out in 
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Rotterdam reported a locus on chromosome 7q22 with an association to knee and/or hand OA 
(75).  This locus contains a region of high LD which encapsulates six genes, none of which are 
obvious candidates for OA susceptibility: BCAP29 (encoding B cell receptor-associated protein 
29), COG5 (encoding component of oligomeric golgi complex 5), DUS4L (encoding 
dihydrouridine synthase four-like), GPR22 (encoding G protein-coupled receptor 22), HBP1 
(encoding HMG-box transcription factor 1) and PRKAR2B (encoding protein kinase-cAMP-
dependant-regulatory-type II-β).  A further investigation failed to find GPR22 expressed 
anywhere within the joint and went on to single out HBP1 as possessing an expression 
quantitative trait locus in carriers of the associated allele (77).  This demonstrates that 
functional studies are a crucial in order to understand the results from GWASs 
Following the inception of the arcOGEN Consortium and the subsequent publication of 
Stage 1 of its GWAS findings, one association signal was that of the T-allele of rs2615977, a G/T 
transversion, located within intron 31 of the type XI collagen α1 polypeptide encoding gene 
COL11A1 (82).  Unlike the Rotterdam GWAS and the 7q22 locus, an association to a collagen 
gene is a much more compelling candidate due to type XI collagen being such key components 
of the articular cartilage.  The suitable candidacy of COL11A1 is further reinforced due to the 
fact a Japanese group found a common non-synonymous SNP, rs1676486, within exon 62 of 
COL11A1, was associated with lumbar disc herniation (LDH) in a Japanese population (83).  
Both LDH and OA are characterised by age-associated, loss of function and degradation of 
cartilage. 
Chondrodysplasia in the mouse model (cho/+) is caused by a frame-shift mutation 
within Col11a1, producing a truncated α1(XI) chain, with an inability to regulate correct 
collagen fibril thickness, and as a result cho/+ mice have thicker fibrils than wild-type mice 
(119).  These haploinsufficient cho/+ mice develop OA-like changes in both their knee joints, 
yet show no other skeletal abnormalities (120).  The type II collagen network is altered 
whereby there is a higher proportion of pericellular type II collagen than in wild type cartilage.  
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This is a result of the reduced expression of type XI collagen within the cho/+ mouse which in 
turn increases the levels of both discoidin domain receptor 2 (Ddr2) and matrix 
metalloproteinase 13 (Mmp13), which lead to cartilage degradation (120).  In humans, type IX  
collagen mutations are found in certain forms of Stickler syndrome, a rare and Mendelian 
disorder of severe OA that presents during adolescence (84, 85). 
A key mechanism of OA susceptibility in humans has been shown to be that of allelic 
expression imbalance (AEI).  The T-allele of the 5ʹ UTR SNP rs143383 of GDF5 exhibits AEI and 
it is one of the most robust associations to OA we currently know of.  I therefore hypothesised 
that the OA association to COL11A1 marked by rs2615977, as reported by the arcOGEN GWAS 
(82), was due to AEI acting upon COL11A1 in OA articular cartilage.  Additionally, I was keen to 
test whether imbalance seen in LDH intervertebral disc cartilage is present within OA cartilage 
and should this prove to be the case, I also wanted to see if genotype at this SNP associates 
with OA as it does with LDH.   
Upon testing for AEI within COL11A1, I did not detect a correlation between genotype 
at the arcOGEN GWAS OA associated SNP rs2615977, and the level of expression of COL11A1.  
It should be pointed out that this study was carried out on OA cartilage samples from patients 
with end stage OA who elected for total joint replacement.  It is possible that rs2615977 marks 
an association to a polymorphism which impinges upon COL11A1 expression at a time-point 
during skeletogenesis or in adolescent tissues before OA is present, affecting the structural 
integrity of the cartilage as it is laid down or in early life, initiating the long term progression of 
OA as AEI may not only be spatial but also temporal (122, 123).  To further investigate this 
association will be complex as no transcript SNP was found within the gene that reflected a 
similar frequency or a high degree of LD.  If the association is marking a polymorphism which is 
exhibiting AEI during development or adolescence then it is obviously very difficult to test for 
this in vivo due to the inability to acquire tissue from such a time-point.  A possible direction to 
take this investigation further would be to extract mesenchymal stem cells from the bone 
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marrow of patients undergoing total joint replacement and culture these cells in vitro while 
differentiating them down the chondrocyte lineage.  During this differentiation, as the cells 
undergo phenotypic change, RNA could be extracted and tested for AEI.  It is also possible that 
rs2615977 is marking a specific haplotype rather than an individual polymorphism, assessing 
COL11A1 expression stratified by haplotypes could yield further results. 
I then wanted to test if AEI within COL11A1 marked by rs1676486 in the intervertebral 
disc of LDH patients by Mio et al. is also true of articular cartilage in OA patients.  I found this 
to be the case; I observed a reduction in the expression of the T-allele in articular cartilage, just 
as was seen in the intervertebral disc of LDH patients.  However upon testing the T-allele of 
rs1676486 for an association to OA susceptibility only a very modest significance was 
observed.  It can therefore be concluded that despite carriers of the T-allele of rs1676486 
exhibiting reduced expression of COL11A1, this does not make them susceptible to acquiring 
OA, unlike LDH.  There are clearly differing mechanistic effects between articular and 
intervertebral disc cartilages whereby a reduction in COL11A1 expression can be tolerated in 
articular cartilage but it leads to disease progression within intervertebral disc cartilage.  
However, due to seeing AEI in COL11A1 mediated by rs1676486 in both tissues, it implies that 
the same trans-acting factors are at work in both types of cartilages. 
Following my research into a locus highlighted by a GWAS, I then investigated a 
candidate gene, GDF5, which is a member of the TGFβ superfamily (110).  The TGFβ signalling 
pathway is involved in the homeostasis of all articular joint tissues and GDF5 itself participates 
in development, maintenance and repair of bone, cartilage, ligament and tendon via 
extracellular signalling (16).  This led Miyamoto and colleagues to genotype common 
polymorphisms in GDF5 in an Asian cohort of OA cases and controls.  This resulted in rs143383, 
a SNP in the 5ʹ UTR of the gene, to be associated with OA (52).  Replication in European 
cohorts have shown that this association has global significance to OA susceptibility (55–57), 
with functional studies indicating that rs143383 itself is influencing the susceptibility risk of OA 
124 
 
due to the disease associated T-allele mediating a reduction in GDF5 transcription, relative to 
the C-allele (52–54).   
Further investigations into the effects of common polymorphisms indicated that 
genotype at another 5’ UTR SNP within GDF5, rs143384, is able to modulate the AEI observed 
at rs143383, and it was also demonstrated that another SNP in the 3’ UTR, rs56366915, is able 
to subject GDF5 to further AEI, which is independent of genotype at both rs143383 and 
rs143384 (54).  These findings display GDF5’s potential to be influenced by genetic 
polymorphism within it, by both an interacting polymorphisms (in the case of rs143383 and 
rs143384) and independent polymorphism (in the case of rs56366915).  These three discussed 
polymorphisms are all common, with high minor allele frequencies (MAFs). 
I set out to further assess the genetic architecture of GDF5 to evaluate whether this 
important OA susceptibility locus harbours any more variants that may have lower MAFs than 
0.01, which could impact upon OA aetiology.  It has been demonstrated that loci harbouring 
alleles that confer disease susceptibility risk are also likely to contain other alleles able to 
influence the same trait (132).  Furthermore, studies have shown that rapid expansion of the 
human population, coupled with weak purifying selection has allowed for a plethora of rare, 
and population-specific variants, many of which are potentially deleterious (148, 149).  This is 
the first example of a deep-sequencing analysis of an OA susceptibility locus looking for the 
missing heritability of the disease. 
 Following the sequencing of GDF5, from a total of 1 800 chromosomes, only six novel 
variants were detected, all with very low MAFs (≤0.0006).  Of these six rare variants, three 
suggested that they had the potential to be functional.  One variant resides within the 
proximal promoter of the gene and two are non-synonymous base changes.  The first of the 
non-synonymous base changes lies within the immature form, or ‘pro-GDF5’, and as such this 
makes further studies such as modelling difficult as the crystal structure for GDF5 is currently 
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only available for the cleaved and therefore active, mature GDF5.  The PolyPhen database 
predicted that this glycine to arginine variant at position 81 would have a benign effect.  The 
second non-synonymous mutation, a threonine to arginine substitution at position 469 lies 
within the mature form of GDF5 and as such allowed me to model the change in silico.  The 
introduction of an arginine, with its positively charged and large side chain, would impact upon 
the folding of the protein, partly due to no common rotomer being able to be accommodated 
in to the wildtype polypeptide conformation of GDF5.  PolyPhen also predicted this amino acid 
change to be possibly damaging.  A group in Germany have a chicken micromass culture assay 
in which they are able to assess the activity of GDF5 as an extracellular signalling molecule 
(100), and I set up a collaboration with them to further investigate Thr469Arg but this 
experiment requires further optimisation due to measurement sensitivity issues.  The ethics 
used to collect the OA and control samples used in this thesis does not allow us to 
retrospectively contact the individuals.  It is therefore not possible for us to assess whether the 
two individuals harbouring the amino-acid substitutions have any overt skeletal abnormalities 
that could be the result of the mutations. 
 While I found six novel variants, they each existed in one individual only, meaning 
while they could be having an effect upon familial OA susceptibility, they are not acting at the 
population level.  It can therefore be concluded, in terms of population genetics, that I 
observed an absence of rare variants within GDF5.  This could be due to GDF5 being subjected 
to a population bottleneck in the past.  A population bottleneck is a sudden reduction in 
population size, and with it reduced heterozygosity within that population (134, 135) (Figure 
5.1).  During a population bottleneck, MAFs and genetic diversity are severely affected by 
random genetic drift (136).  It is possible that the current genetic architecture of GDF5 is 
reflective of a bottleneck imparted upon the population, whereby the seven common 
polymorphisms that were confirmed in my study made it through the bottleneck with all other 
potential GDF5 alleles lost.  The six very rare novel variants that I discovered may be the result 
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of mutation that has occurred after the bottleneck, as the population is expanding once again 
and greater heterogeneity is developing.  It is believed that, in the last 10 000 years, the global 
population has exploded from a few million to the estimated 7 billion that it is today.  Such an 
explosion allows for rare variants within sub-populations due to mutation, which can exact 
upon complex disease (137).  This hypothesis that GDF5 has been subjected to a bottleneck is 
supported by a recent study which found that T-alleles of both rs143383 and rs143384 are 
both associated with height and have undergone positive selection within the East Asian 
population (138).  As mentioned, the T-allele of rs143383 has been robustly associated with 
OA across both Asian and European populations and also shown to correlate with reduced 
expression of GDF5; the T-allele of rs143384 has been shown to modulate the further 
reduction in GDF5 expression.  Wu and colleagues postulate that the age of these two T-alleles 
correlates with a period in human history which saw an increase in early agriculture and a 
reduction of body mass as the need for a large hunter-gatherer, highly energy dependant 
body-type declined (138).  Further evidence for this reduction in body mass during this period 
is observed when looking at human brain size.  One of the best known and major 
characteristics of human evolution is the increase in brain size, and around 2.5 million years 
ago the human brain was approximately 750 ml (150).  If we jump to only 30 000 years ago this 
value had doubled with most of the brain volume expansion coming latterly at a rate of around 
70 ml per 100 000 years up until this 30 000 years ago mark (151).  However, it is less well 
known that in the remaining 30 000 years up until present day, the human brain has 
decreased, and at a substantial rate (152, 153).  In the last 10 000 years the brain size has 
dropped from 1 500 ml to 1 240 ml in a European female, this rate of decrease in 10 000 years 
is 36 times greater than the rate of increase over the previous 800 000 years, suggesting the 
presence of a strong selection pressure.  Brain size and body mass are closely linked in humans 
and the time when humans began hunting using projectile weapons and developing primitive 
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forms of agriculture coincides with reduced body mass (154) and the emergence of the 
rs143383 and rs143384 T-alleles. 
We know that reduced GDF5 expression confers shorter limb growth (139), which 
would produce a shorter stature and lower body mass, so the possession of these two lower 
GDF5-expressing T-alleles could help produce this advantageous phenotype.  It is reasonable 
to suggest that a characteristically high-age related disease like OA would be unlikely to exert a 
negative selection pressure during this time period and so any OA susceptibility would not 
manifest itself. 
 
Figure 5.1 Reduced heterogeneity due to a bottleneck.  Top) Four diploid copies of a gene, all 
carrying various mutant alleles of multiple loci (coloured circles).  Bottom) A selection pressure 
is applied whereby the carrying of the red and green mutant alleles is advantageous.  The 
frequencies of these two mutant alleles is greatly altered while some other mutant alleles are 
lost from the population all together (purple and grey) and others’ frequencies are reduced.  
Overall the population is less heterogeneous following the bottleneck. 
  
Fossil records indicate that a reduction in stature occurred in humans at around the 
same time as the arrival of the T-alleles of rs143383 and rs143384, which helps support the 
128 
 
hypothesis that GDF5 has passed through a bottleneck.  However, it can’t be said for certain 
that a positive selection pressure on these alleles caused a reduction in heterogeneity within 
GDF5.  In order to add more weight to this hypothesis it may be prudent to look at the ages of 
other alleles which have been associated with height.  Human height is a complex and 
polygenic trait, therefore one should see other alleles in other genes undergoing positive 
selection also at the same point in history. 
Collaborating with another research group from Santiago de Compostela, Spain – who 
sequenced the open reading frame of GDF5 in a cohort of Spanish and Greek individuals – 
allowed expansion of the study to incorporate both Northern and Southern Europeans.  This 
research was published in Osteoarthritis and Cartilage in 2011 (140).  The Spanish group 
detected the previously reported common GDF5 polymorphisms but detected no novel 
variants.  Of the six extremely rare variants I found in the UK population, the promoter variant 
(variant 1, Chapter 3.4.1) and the non-synonymous variant (variant 6, Chapter 3.4.5) appear to 
have the greatest potential to impart a functional effect upon GDF5 expression or GDF5 
activity, respectively.  It can be concluded that GDF5 possesses no rare variants that can 
impact at a population level; of course I cannot discount the possibility of rare variants existing 
within distal cis-acting sites such as enhancers or inducers, but there are currently no such 
sites known to be controlling GDF5.  It is reasonable to say that any additional OA susceptibility 
within GDF5 is due to either common polymorphism or epigenetics.  
 I investigated the effect that the -41 bp (C/A) variant could have upon GDF5 expression 
by firstly creating luciferase constructs of the two naturally occurring haplotypes when coupled 
with the alleles of rs143383 and rs143384.  I also created constructs containing two non-
naturally occurring haplotypes, so that I could circumvent the known functional effect of these 
two common polymorphisms (54).  My luciferase assays on both chondrogenic and oseotgenic 
human cell lines demonstrated that the novel A-allele of the -41 bp variant is functional and 
not only able to mediate increased expression of GDF5, but the increase is of such a degree 
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that it is able to reverse the capacity that the T-T rs143383-rs143384 haplotype has to mediate 
a reduction in expression of GDF5.  In both cell lines I observed that the A-T-T (-41 bp – 
rs143383 – rs143384) haplotype was able to drive expression to a greater degree than the C-C-
C haplotype despite the latter containing the two higher expressing C-alleles of both rs143383 
and rs143384.  This result clearly demonstrates that the activity of an OA susceptibility allele is 
highly context specific and that negative effects on gene expression mediated by cis-acting 
regulatory sites are potentially modifiable by targeting other cis sites within the gene. 
 I identified YY1 as a trans-acting factor which is able to bind differentially to the C- and 
A-alleles of the -41 bp variant, with an increased binding affinity for the novel A-allele.  YY1 is a 
widely expressed zinc-finger nuclear protein that is conserved between species and which can 
act as a transcriptional repressor or activator, depending on cellular context (143).  It has roles 
in cellular proliferation, differentiation and apoptosis, with Yy1 knockout mice having in utero 
lethality (144).  As its name suggests, Yin Yang 1 is able to perform conflicting functions and its 
expression has been associated with the development of malignant phenotypes of human 
cancers, along with tumour progression, including metastasis but also, conversely, in tumour 
survival (145).  To my knowledge, this protein has not been implicated in OA pathogenesis, and 
as a regulator of GDF5 expression there is a possibility that it can be exploited to modulate the 
expression of this OA susceptibility locus.  Due to YY1 being conserved between species it 
allows for the possibility of mouse models to be utilised in taking these findings further.  For 
instance, it would be interesting to place an additional Yy1 gene under the control of a 
chondrogenic specific promoter such as Sox9, so that there is an elevated level of Yy1 protein 
during chondrogensis.  This would be especially interesting in the haploinsufficient 
brachypodism (bp) mouse (Gdf5Bp-J/+), to see if an increase in Yy1 during chondrogenesis can 
protect the bp mouse from developing an OA phenotype when challenged. 
 In summary, this thesis has pursued research into both common variants in GWAS 
associated loci in the case of COL11A1, and rare variants in candidate gene studies in the case 
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of GDF5 to elucidate genetic factors which play a role in to the common, complex disease of 
OA.  I established that the arcOGEN GWAS association signal to rs2615977 is not due to AEI 
within COL11A1 within articular cartilage from end stage OA patients.  It is of course possible 
that the association signal to rs2615977 could have been a false positive from the GWAS.  I 
also found that the AEI within COL11A1 marked by rs1676486 in the intervertebral disc of LDH 
patients detected by Mio et al. (83) also exists in the articular cartilage in OA patients.  
However, this AEI does not prove to be a risk factor for OA.  By resequencing GDF5 in 962 
individuals, I carried out the first deep-sequencing of an OA susceptibility locus.  I discovered 
six novel variants but also discovered that there is an absence of rare variants with MAFs 
between 0.06% and 2.5%, suggesting that GDF5 has been subjected to a bottleneck in the past.  
I then carried out functional studies on a rare variant (-41 bp) I found in the proximal promoter 
of GDF5.  I found that the variant A-allele of this -41 bp locus is able to increase the expression 
of GDF5 to such an extent that it counteracts the effect of the OA associated T-allele of 
rs143383.  I established that this is due to the trans-acting factor YY1 having a greater binding 
affinity to this variant allele than that of the wildtype C-allele.  These findings expose a site for 
intervention and modulation of GDF5 expression to overcome a disease susceptibility allele.  In 
terms of the missing heritability of OA, this thesis has been unable to identify any loci that are 
contributing to the heritability of the disease on the population level.  The discovery of the -41 
bp variant, and the identification of a trans-acting factor which binds differentially to these 
two alleles may well be having an effect on the heritability of OA on a personal and familial 
level.   
In terms of genetic signals coming from GWASs and other genetic studies, with regards 
to OA there has been small effect sizes yielded.  Some argue that this could be due to low 
statistical power of these studies, and by greatly increasing the power then whole pathways 
could be identified.  In age-related macular degeneration five loci have been identified which 
accounts for 50% of the heritability of the disease, whereas research into Crohn’s disease has 
131 
 
accounted for approximately 20% of the heritability from 32 loci.  Genetic research into OA on 
the other hand has revealed only a handful of loci – such as GDF5, DIO2 and the 7q22 locus – 
all with small effect sizes.  We see a discordance of 40% for OA between MZ twins, as well as 
many other diseases and these discordant MZ twins have been shown to have differences in 
their DNA methylation profiles (155).  MMPs – shown to be elevated in expression in OA 
cartilage – have also found to have hypomethelated promoters which could be the cause of 
the disease associated alteration in expression (156).  Evidence such as this indicates that 
research into OA should not just be confined to common variants with small effect sizes; we 
must look for rarer variants which may have larger effect sizes and for epigenetic differences. 
Following this research I would suggest deep-sequencing of more OA susceptibility loci 
for rare variants.  It is likely that my failure to record any rare variants with MAFs capable of 
imparting an effect at a population level is due to the hypothesised bottleneck that GDF5 has 
been subjected to due to a positive selection pressure on the decreased height associated 
alleles of rs143383 and rs143384 (138).  Suitable candidates for deep-sequencing would be 
DIO2 which has been shown to exhibit AEI (67) or genes implicated in OA susceptibility from 
the publication of the final arcOGEN GWAS results such as CHRST11 (80). 
Should I carry out any of these mentioned deep-sequencing investigations I would not 
use the Sanger Sequencing method used in this thesis again.  Sequencing technologies are 
advancing all the time as well as becoming progressively cheaper.  From Sanger Sequencing 
there are now ‘next-generation’ sequencing methods, and even ‘next-next-generation’ 
sequencing methods.  Of the next-generation methods three methods have become widely 
used: Pyrosequencing, Illumina dye sequencing and SOLiD sequencing by Roche, Illumina and 
Life Technologies (formerly Applied Biosystems) respectively.   
Pyrosequencing uses single stranded template DNA along with DNA polymerases and 
enzymes including luciferase which fluoresce when a specific nucleotide base is incorporated 
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into the synthesising strand, one of the four bases are added in a specific order during each 
round of elongation.  Illumina dye sequencing involves the addition of adapter sequences 
being added to the ends of double stranded target DNA.  These adapters then bind to adapters 
on a slide and the DNA is replicated to produce local colonies of the same sequence.  The 
dNTPs are added and unincorporated bases washed off.  A laser is applied to the slide and the 
fluorescence given off corresponds to the base.  However, unlike Sanger Sequencing the 
application of the laser removes the 3ʹ terminator, allowing for the next round of base 
extensions to occur on the same molecule.  This cycles through until the whole molecule is 
sequenced.  The advantage of Illumina over other methods is that this method just uses a DNA 
polymerase and fluorescent bases, rather than a multitude of enzymes.  SOLiD sequencing 
requires the template DNA to be added to an adapter on an emulsion bead, then a primer of a 
specific length (n) binds to the adapter sequence, a ligase then adds fluorescent interrogation 
probes which contain two bases complementary to the target sequence plus multi-nonspecific 
binding sequence.  The probe is then cleaved to allow for identification of the first base of the 
probe.  Ligation and then cleavage of a new probe occurs and the sequence read grows until 
the end of the template is reached.  Following this, denaturation occurs from the template and 
a new primer of length n-1 is added and the whole cycle is repeated.  This results in each base 
of the template strand being read twice, increasing read accuracy.  Should I repeat the 
sequencing project on other genes I would use Pyrosequencing by Roche as it would allow long 
individual read lengths but many, many more reads per run, enabling me to go deeper in re-
sequencing, resulting in the ability to detect even rarer variants. 
Some large scale sequencing projects include ENCODE, the encyclopaedia of DNA 
elements which aims to identify and sequence all functional elements within the human 
genome and the 1 000 genomes project, which aimed to sequence the entire genomes of over 
1 000 people from across the world, highlighting population specific differences and giving 
allele frequencies.  All this data has since been added into the HapMap database.  While my 
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study was limited to only one gene rather than a whole genome, I sequenced with a greater 
depth than the 1 000 genome project has done for GDF5, as I sequenced over 1 800 
chromosomes at this locus.  Also my study was solely on Europeans, whereas the 1 000 
genomes project covers multiple populations, therefore reducing the population specific depth 
in which it goes to.  However, as I found out there are only very, very rare variants in GDF5 
with an absence of rare variants.  Had the 1 000 genomes project data for GDF5 been available 
at the start of my study, with sufficient depth in the European population, one would not have 
chosen GDF5 as the OA susceptibility locus to resequence as it would have been apparent that 
there were no rare mutations that still had a frequency high enough to have an effect at the 
population level.  Nonetheless, by carrying out my study I identified a site in the promoter of 
GDF5 that allows for the modulation of a trans-acting factor’s binding affinity, and thus the 
regulation of the gene’s expression.   
The HapMap database was invaluable for selecting candidate proxy SNPs to use for my 
AEI studies.  HapMap provides invaluable allele frequencies and LD values between SNPs. 
Further research into GDF5 should be concentrated upon common polymorphisms 
within the gene.  Egli and colleagues found that a SNP in the 3ʹ UTR of GDF5, rs56366915, is 
able to modulate gene expression, with the T-allele exhibiting lower expression than the C-
allele, an effect which is independent of the rs143383-rs143384 haplotype (54).  At present no 
cause for this AEI has been found.  It is possible that a microRNA is able to bind, or bind more 
strongly, to the T-allele of rs56366915 than it can to the C-allele, and thus reduces the 
expression of the T-allele.  Another possibility for the AEI observed at rs56366915 is that the 
SNP is modulating the stability of the GDF5 mRNA transcript.  An investigation into the half-life 
of GDF5 mRNA transcripts containing the two alleles of rs56366915 would be interesting. 
As mentioned earlier, in order to elucidate the cause of the arcOGEN association signal 
at rs2615977 one could extract mesenchymal stem cells from the bone marrow of patients 
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undergoing total joint replacement and culture these cells in vitro while differentiating them 
down the chondrocyte lineage.  During this differentiation, as the cells undergo phenotypic 
change, RNA could be extracted and tested for AEI. 
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